Document:

Exhibit 4.2

        
Exhibit 4.2

CERTIFICATE AS TO ACTIONS TAKEN BY OFFICER
OF SOUTHERN CALIFORNIA EDISON COMPANY
Adopted November 4, 2014

		
	RE:
	CREATION AND ISSUANCE OF ONE NEW SERIES 
OF FIRST AND REFUNDING MORTGAGE BONDS

WHEREAS, by a resolution adopted on December 12, 2013 entitled “Resolution Re:  Financing Authorizations,” the Board of Directors of this corporation delegated to the undersigned officer the authority to authorize and create an additional bonded indebtedness of this corporation to be represented by one new series of its First and Refunding Mortgage Bonds, Series 2014C (the “New Bonds”), and take all other actions necessary to create the New Bonds and cause the New Bonds to be issued, sold, and delivered;
NOW, THEREFORE, BE IT RESOLVED, that pursuant to the resolution and the Trust Indenture dated as of October 1, 1923, between this corporation and The Bank of New York Mellon Trust Company, N.A. (successor to Harris Trust and Savings Bank) and D. G. Donovan (successor to Pacific-Southwest Trust & Savings Bank), as Trustees, as amended and supplemented, including as supplemented or proposed to be supplemented by the One Hundred Thirty-Third Supplemental Indenture (the “Supplemental Indenture” and collectively, the “Trust Indenture”), the undersigned officer hereby executes and delivers this certificate and takes the actions set forth herein.
BE IT FURTHER RESOLVED, that the undersigned officer hereby authorizes and creates an authorized bonded indebtedness of this corporation in the initial aggregate principal amount of $100,000,000, which shall be an increase of, and in addition to, all presently existing 

authorized bonded indebtedness of this corporation, and which shall be represented by the New Bonds.
BE IT FURTHER RESOLVED, that the President or any Vice President and the Secretary or any Assistant Secretary of this corporation are authorized and directed, pursuant to the provisions of Section 1 of Article Two of the Trust Indenture, to sign and present to The Bank of New York Mellon Trust Company, N.A., as Trustee, a certificate stating that the authorized bonded indebtedness of this corporation has been so increased.
BE IT FURTHER RESOLVED, that each of the Chairman of the Board, the Chief Executive Officer, the President, the Senior Vice President and Chief Financial Officer, the Vice President and Treasurer, or any Assistant Treasurer, or any of them acting alone, is authorized and directed to execute and deliver the Supplemental Indenture, in such form as the officer acting may approve, such approval to be evidenced by the execution thereof, and to cause this corporation to perform all of its obligations under the Supplemental Indenture.
BE IT FURTHER RESOLVED, that, subject to the execution and delivery of the Supplemental Indenture, the New Bonds, to be issued under and secured by the Trust Indenture, are hereby created in the initial aggregate principal amount of $100,000,000, and the New Bonds are hereby designated as “First and Refunding Mortgage Bonds, Series 2014C, Due 2017”; the New Bonds shall be dated as of their date of issuance, shall mature on November 1, 2017, and shall bear interest from November 7, 2014, at the rate of 1.250% per annum on the principal amount thereof, payable semiannually on May 1 and November 1 of each year; the principal of and premium, if any, and interest on the New Bonds shall be payable at the offices of The Bank of New York Mellon Trust Company, N.A., in Chicago, Illinois, or at such other agency or agencies as may be designated by this corporation; all principal, premium, if any, and interest shall be 

2

payable in such coin or currency of the United States of America as at the time of payment shall be legal tender for public and private debts; the New Bonds shall be transferable only on the books of this corporation at the places designated above for the payment of the principal of and premium, if any, and interest on the New Bonds, or at such other agency or agencies as may be designated by this corporation; the New Bonds shall be redeemable, at the option of this corporation, in whole or in part, in the manner set forth in the form of definitive Series 2014C Bond set forth below; the New Bonds shall be issuable only as fully registered bonds, without coupons, in denominations of $1,000 and integral multiples of $1,000 in excess thereof; the definitive New Bonds shall be numbered from R-1 upward; and the definitive New Bonds, and the Certificate of Authentication to be endorsed upon each of the New Bonds, shall be substantially in the following form with such legends thereon and changes therein as may be deemed necessary or appropriate by the officer or officers executing the same, and the blanks therein to be properly filled:
(Form of Definitive Series 2014C Bond)

SOUTHERN CALIFORNIA EDISON COMPANY
First and Refunding Mortgage Bonds, Series 2014C, Due 2017

No. ____                                    $_____________

SOUTHERN CALIFORNIA EDISON COMPANY, a corporation organized and existing under and by virtue of the laws of the State of California (hereinafter called the “Company”), for value received, hereby promises to pay to _____________________, the registered owner hereof, the principal sum of $100,000,000 on November 1, 2017, and to pay interest on the unpaid principal amount hereof to the registered owner hereof from November 7, 2014, until said principal sum shall be paid, at the rate of 1.250% per annum, payable semiannually on May 1 and November 1 in each year, beginning May 1, 2015.  Such interest shall be paid to the person in whose name this Bond is registered at the close of business on (1) the business day immediately preceding the interest payment date if this Bond is in book-entry only form, or (2) the 15th calendar day before each interest payment date if this Bond is not in book-entry only form.

The principal of and interest on this Bond are payable at the offices of The Bank of New York Mellon Trust Company, N.A., as Trustee, in Chicago, Illinois, or at such other agency or agencies as may be designated by the Company, in such coin or currency of the United States of America as at the time of payment is legal tender for public and private debts.

3

This Bond is one of a series, designated as “Series 2014C, Due 2017,” of a duly authorized issue of bonds of the Company, known as its “First and Refunding Mortgage Bonds,” issued and to be issued in one or more series under and all equally and ratably secured by a Trust Indenture dated as of October 1, 1923, and indentures supplemental thereto, including the One Hundred Thirty-Third Supplemental Indenture, dated as of November 5, 2014, which have been duly executed, acknowledged and delivered by the Company to The Bank of New York Mellon Trust Company, N.A. and D. G. Donovan, or one of their predecessors, as Trustees, to which original indenture and indentures supplemental thereto (collectively, the “Trust Indenture”) reference is hereby made for a description of the property, rights and franchises thereby mortgaged and pledged, the nature and extent of the security thereby created, the rights of the holders of this Bond and of the Trustees in respect of such security, and the terms, restrictions and conditions upon which the bonds are issued and secured.

This Bond may be redeemed, in whole or in part, at the option of the Company, at any time prior to its maturity, after notice given in writing (including by facsimile transmission) to the registered owner hereof at the last address shown on the registry books of the Company, by the Company or The Bank of New York Mellon Trust Company, N.A., as Trustee, at least 30 days, but not more than 60 days, before the date fixed for redemption, at a redemption price equal to the greater of (1) the principal amount redeemed or (2) the sum of the present values of the remaining scheduled payments of principal and interest (excluding any interest accrued from the immediately preceding interest payment date to the date fixed for redemption) on this Bond being redeemed, discounted to the date fixed for redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Yield plus 7.5 basis points, plus accrued and unpaid interest to the date fixed for redemption.

“Treasury Yield” means, for any date fixed for redemption, (1) the yield for the maturity corresponding to the Comparable Treasury Issue (as defined below), under the heading that represents the average for the immediately preceding week, appearing in the most recently published statistical release designated “H.15(519)” or any successor publication that is published weekly by the Board of Governors of the Federal Reserve System and that establishes yields on actively traded United States Treasury securities adjusted to constant maturity under the caption “Treasury Constant Maturities,” provided, that if no maturity is within three months before or after the applicable stated maturity date for any of the bonds being redeemed the yields for the two published maturities most closely corresponding to the Comparable Treasury Issue will be determined and the Treasury Yield shall be interpolated or extrapolated from those yields on a straight line basis, rounding to the nearest month; or (2) if the release referred to in (1) (or any successor release) is not published during the week preceding the calculation date or does not contain the yields referred to above, the rate per year equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for the date fixed for redemption. The Treasury Yield will be calculated on the third business day preceding the redemption date. 
 

4

“Comparable Treasury Issue” means the United States Treasury security or securities selected by an Independent Investment Banker as having an actual or interpolated maturity comparable to the remaining term to stated maturity of the bonds to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the bonds to be redeemed. 
 
“Comparable Treasury Price” means, for any date fixed for redemption, the average Reference Treasury Dealer Quotations for the date fixed for redemption, after excluding the highest and lowest such Reference Treasury Dealer Quotations. 
 
“Independent Investment Banker” means either Citigroup Global Markets Inc. (“Citigroup”), SunTrust Robinson Humphrey, Inc. (“SunTrust”) or its successor, as applicable or, if such firm or its successor is unwilling or unable to select the Comparable Treasury Issue, one of the remaining Reference Treasury Dealers appointed by us. 
 
“Reference Treasury Dealer” means (1) Citigroup, SunTrust and any other primary U.S. Government securities dealer in the United States of America (a “Primary Treasury Dealer”) designated by, and not affiliated with, any of the foregoing or their successors; provided, however, that if any of the foregoing, or any of their designees, ceases to be a Primary Treasury Dealer, we will appoint another Primary Treasury Dealer as a substitute, and (2) any other Primary Treasury Dealer selected by us. 

“Reference Treasury Dealer Quotations” means, for each Reference Treasury Dealer and any date fixed for redemption, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by the Reference Treasury Dealer at 5:00 p.m. New York City time on the third business day preceding the date fixed for redemption.

If the Company elects to redeem fewer than all the Series 2014C Bonds, The Bank of New York Mellon Trust Company, N.A., as Trustee, will select the particular bonds to be redeemed on a pro rata basis, by lot or by such other method of random selection, if any, that The Bank of New York Mellon Trust Company, N.A., as Trustee, deems fair and appropriate; provided, however, that as long as this Bond is held with a depositary, any such selection shall be in accordance with such depositary’s applicable procedures.

Any notice of redemption, at the Company’s option, may state that the redemption will be conditional upon receipt by the paying agent, on or prior to the date fixed for the redemption, of money sufficient to pay the principal of and premium, if any, and interest, if any, on the Series 2014C Bonds to be redeemed and that if the money has not been so received, the notice will be of no force and effect and the Company will not be required to redeem this Bond.

The Trust Indenture makes provision for a Special Trust Fund and permits the use of moneys therein for the purpose, among others, of redeeming or purchasing this Bond.

5

If default shall be made in the payment of any installment of principal of or interest on this Bond or in the performance or observance of any of the covenants and agreements contained in the Trust Indenture, and such default shall continue as provided in the Trust Indenture, then the principal of this Bond may be declared and become due and payable as provided in the Trust Indenture.

This Bond is transferable only on the books of the Company at any of the places designated above for the payment of the principal of and premium, if any, or interest on this Bond, or at such other agency or agencies as may be designated by the Company, by the registered owner or by an attorney of such owner duly authorized in writing, on surrender hereof properly endorsed, and upon such surrender hereof, and the payment of charges, a new registered bond or bonds of this series, of an equal aggregate principal amount, will be issued to the transferee in lieu hereof, as provided in the Trust Indenture.

The terms of the Trust Indenture may be modified as set forth in the Trust Indenture; provided, however, that, among other things, (1) the obligation of the Company to pay the principal of and premium, if any, and interest on all bonds outstanding under the Trust Indenture, as at the time in effect, shall continue unimpaired, (2) no modification shall give any of said bonds any preference over any other of said bonds, and (3) no modification shall authorize the creation of any lien prior to the lien of the Trust Indenture on any of the trust property.

No recourse shall be had for the payment of the principal of and premium, if any, or interest on this Bond, or any part thereof, or for or on account of the consideration herefor, or for any claim based hereon, or otherwise in respect hereof, or of the Trust Indenture, against any past, present or future stockholder, officer or director of the Company or of any predecessor or successor company, whether for amounts unpaid on stock subscriptions, or by virtue of any statue or constitution, or by the enforcement of any assessment or penalty, or because of any representation or inference arising from the capitalization of the Company or of such predecessor or successor company, or otherwise; all such liability being, by the acceptance hereof and as a part of the consideration for the issue hereof, expressly released.

This Bond shall not be valid or obligatory for any purpose until it shall have been authenticated by the execution of the certificate of authentication hereon of The Bank of New York Mellon Trust Company, N.A., as Trustee, or its successor in trust.

IN WITNESS WHEREOF, Southern California Edison Company has caused this Bond to be executed in its name by its President or one of its Vice Presidents and its corporate seal to be hereto affixed and attested by its Secretary or one of its Assistant Secretaries, as of November __, 2014, such execution and attestation to be by manual or facsimile signatures.
	
			
	 
	 
	SOUTHERN CALIFORNIA EDISON COMPANY

	ATTEST: ______________________
	 
	By: ___________________________

	[Assistant] Secretary
	 
	[Vice] President

6

(Form of Certificate of Authentication for all Series 2014C Bonds)

Trustee’s Certificate

This is to certify that this Bond is one of the Bonds, of the series designated therein, described and referred to in the Trust Indenture within mentioned.

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., TRUSTEE

By _________________________________
[Authorized Agent]

(End of Form of Series 2014C Bond)
BE IT FURTHER RESOLVED, that New Bonds need not be issued at the same time and such series may be reopened at any time, without notice to, or the consent of, any then-existing holder or holders of any New Bonds, for issuances of additional New Bonds in an unlimited principal amount; and any such additional New Bonds will have the same interest rate, maturity and other terms as those initially issued, except for payment of interest accruing prior to the original issue date of such additional New Bonds and, if applicable, for the first interest payment date following such original issue date.
BE IT FURTHER RESOLVED, that pursuant to the Trust Indenture, as in effect following due execution and delivery of the Supplemental Indenture, the President or any Vice President and the Secretary or any Assistant Secretary of this corporation are authorized and directed, for and in the name and on behalf of this corporation and under its corporate seal (which seal may be either impressed, printed, lithographed or engraved thereon), to execute (which execution may be by a facsimile signature) and to deliver the New Bonds to The Bank of New York Mellon Trust Company, N.A., as Trustee, for authentication in temporary and/or definitive form, and in such aggregate principal amount up to $100,000,000 as the President or any Vice 

7

President and the Secretary or any Assistant Secretary of this corporation shall in their absolute discretion determine.
BE IT FURTHER RESOLVED, that the President or any Vice President and the Secretary or any Assistant Secretary of this corporation are authorized and directed for and in the name and on behalf of this corporation and under its corporate seal, to execute and to deliver to The Bank of New York Mellon Trust Company, N.A., as Trustee, the written order of this corporation for the authentication and delivery of the New Bonds pursuant to such sections of Article Two of the Trust Indenture as the officers acting may determine.
BE IT FURTHER RESOLVED, that the Secretary or any Assistant Secretary of this corporation is hereby authorized and directed to deliver to, and file with, The Bank of New York Mellon Trust Company, N.A., as Trustee, a copy of the this certificate of actions taken, certified by the Secretary or any Assistant Secretary of this corporation.
IN WITNESS WHEREOF, the undersigned has executed this certificate as of the date first written above.

/s/ George T. Tabata
__________________________________
George T. Tabata
Assistant Treasurer 
Southern California Edison Company

8GSK Collaboration and License Agreement

	
	
	CONFIDENTIAL
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

PLATFORM TECHNOLOGY TRANSFER, COLLABORATION AND LICENSE AGREEMENT
BY AND BETWEEN
CODEXIS, INC.
AND
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

EFFECTIVE AS OF

10 July 2014

TABLE OF CONTENTS

	
				
	 
	 
	Page

	1.
	DEFINITIONS
	1

	 
	1.1
	“Affiliate”
	1

	 
	1.2
	“Alliance Manager”
	2

	 
	1.3
	“Applicable Law”
	2

	 
	1.4
	“Arising Codexis Enzyme Technology”
	2

	 
	1.5
	“Arising Codexis Enzyme Technology IP”
	2

	 
	1.6
	“Arising Codexis Process Technology”
	2

	 
	1.7
	“Arising Codexis Process Technology IP”
	2

	 
	1.8
	“Arising GSK Enzyme Technology”
	2

	 
	1.9
	“Arising GSK Enzyme Technology IP”
	2

	 
	1.10
	“Arising GSK Process Technology”
	2

	 
	1.11
	“Arising GSK Process Technology IP”
	3

	 
	1.12
	“Background IP”
	3

	 
	1.13
	“Business Day”
	3

	 
	1.14
	“Calendar Quarter”
	3

	 
	1.15
	“Calendar Year”
	3

	 
	1.16
	“Change of Control”
	3

	 
	1.17
	“Clinical Proof of Concept”
	3

	 
	1.18
	“Codexis Core Patents”
	3

	 
	1.19
	“Codexis Core Technology”
	3

	 
	1.20
	“Codexis Core Technology Improvements”
	4

	 
	1.21
	“Codexis Core Technology Improvements IP”
	4

	 
	1.22
	“Codexis Documentation”
	4

	 
	1.23
	“Codexis Enzymes”
	4

	 
	1.24
	“Codexis Enzyme Patents”
	4

	 
	1.25
	“Codexis Exclusive Field”
	4

	 
	1.26
	“Codexis Initial Enzyme(s)”
	5

	 
	1.27
	“Codexis Initial Enzyme IP”
	5

	 
	1.28
	“Codexis Library”
	5

	 
	1.29
	“Codexis Materials”
	5

	 
	1.30
	“Codexis Mayflower Patents”
	5

	 
	1.31
	“Codexis Methods”
	5

	 
	1.32
	“Codexis Senior Management”
	5

	 
	1.33
	“Codexis Software”
	5

	 
	1.34
	“Codexis Team”
	5

	 
	1.35
	“Collaborative Project”
	5

	 
	1.36
	“Commercially Reasonable Efforts”
	6

	 
	1.37
	“Completion of Wave 1”
	6

	 
	1.38
	Completion of Wave 2”
	6

	 
	1.39
	Completion of Wave 3”
	6

	 
	1.40
	“Confidential Information”
	6

	 
	1.41
	“Controlled” or “Controls”
	6

	 
	1.42
	“Cover” or “Covers”
	6

	 
	1.43
	“Covered Enzyme”
	7

	 
	1.44
	“Dollar” or “$”
	7

- i -

TABLE OF CONTENTS

	
				
	 
	 
	Page

	 
	1.45
	“Embargo Period”
	7

	 
	1.46
	“Enzyme”
	7

	 
	1.47
	“Enzyme Product”
	7

	 
	1.48
	“FDA”
	7

	 
	1.49
	“Field”
	7

	 
	1.50
	“Final Round of Enzyme Evolution”
	7

	 
	1.51
	“First Commercial Sale”
	7

	 
	1.52
	“First Production Run”
	7

	 
	1.53
	“FTE”
	8

	 
	1.54
	“Fully Burdened Cost”
	8

	 
	1.55
	“Generic Version”
	8

	 
	1.56
	“Good Clinical Practices” or “GCP”
	8

	 
	1.57
	“Good Laboratory Practices” or “GLP”
	8

	 
	1.58
	“Good Manufacturing Practices” or “GMP”
	8

	 
	1.59
	“GSK Compound”
	9

	 
	1.60
	“GSK Exclusive Field”
	9

	 
	1.61
	“GSK Existing Pharmaceutical Product”
	9

	 
	1.62
	“GSK Initial Enzyme(s)”
	9

	 
	1.63
	“GSK Project Library”
	9

	 
	1.64
	“GSK Selected Enzyme”
	9

	 
	1.65
	“GSK Sole Project”
	9

	 
	1.66
	“GSK Team”
	9

	 
	1.67
	“IFRS”
	9

	 
	1.68
	“Improvements TT Term”
	9

	 
	1.69
	“Improvements TT Term Expiration Date”
	9

	 
	1.70
	“Initial Enzyme”
	9

	 
	1.71
	“Initial Enzyme Optimisation”
	10

	 
	1.72
	“Initial Technology Transfer Inventory”
	10

	 
	1.73
	“Initial Training”
	10

	 
	1.74
	“In-License Agreements”
	10

	 
	1.75
	“In-Licensed IP”
	10

	 
	1.76
	“In-Licensed Know-How”
	10

	 
	1.77
	“In-Licensed Patents”
	10

	 
	1.78
	“Intellectual Property”
	10

	 
	1.79
	“Invention”
	10

	 
	1.80
	“Invoice”
	10

	 
	1.81
	“Know-How”
	10

	 
	1.82
	“Licensed Additional Codexis IP”
	10

	 
	1.83
	“Licensed Accessory Product”
	11

	 
	1.84
	“Licensed Additional Codexis Know-How”
	11

	 
	1.85
	“Licensed Additional Codexis Patents”
	11

	 
	1.86
	“Licensed Collaborative Project GSK Selected Enzyme”
	11

	 
	1.87
	“Licensed Diagnostic Product”
	11

	 
	1.88
	“Licensed Enzyme Therapeutic Product”
	11

	 
	1.89
	“Licensed GSK Sole Project GSK Selected Enzyme”
	11

- ii -

TABLE OF CONTENTS

	
				
	 
	 
	Page

	 
	1.90
	“Licensed IP”
	11

	 
	1.91
	“Licensed Know-How”
	11

	 
	1.92
	“Licensed Other Therapeutic Product”
	11

	 
	1.93
	“Licensed Patents”
	11

	 
	1.94
	“Licensed Product”
	12

	 
	1.95
	“Licensed Prophylactic Product”
	12

	 
	1.96
	“Losses”
	12

	 
	1.97
	“Major Market Country”
	12

	 
	1.98
	“Net Sales”
	12

	 
	1.99
	“On-Site Training”
	12

	 
	1.100
	“Patent(s)”
	13

	 
	1.101
	“Person”
	13

	 
	1.102
	“Pharmaceutical Product”
	13

	 
	1.103
	“Phase 1b Clinical Trial”
	13

	 
	1.104
	“Phase 2a Clinical Trial”
	13

	 
	1.105
	“Platform Technology”
	13

	 
	1.106
	“Project”
	13

	 
	1.107
	“Project Enzyme”
	13

	 
	1.108
	“Prosecution”
	13

	 
	1.109
	“Regulatory Approval(s)”
	13

	 
	1.110
	“Regulatory Authority”
	14

	 
	1.111
	“Regulatory Filings”
	14

	 
	1.112
	“Restricted Enzyme”
	14

	 
	1.113
	“Round(s) of Enzyme Evolution”
	14

	 
	1.114
	“Royalty Term”
	14

	 
	1.115
	“Scientific Lead”
	14

	 
	1.116
	“Technology Transfer”
	14

	 
	1.117
	“Technology Transfer Plan”
	14

	 
	1.118
	“Territory”
	14

	 
	1.119
	“Third Party”
	15

	 
	1.120
	“TT Term”
	15

	 
	1.121
	“TT Term Expiration Date”
	15

	 
	1.122
	“Upfront Payment”
	15

	 
	1.123
	“United States” or “U.S.”
	15

	 
	1.124
	“Valid Claim”
	15

	 
	1.125
	“Wave”
	15

	 
	1.126
	Additional Definitions
	15

	2.
	TECHNOLOGY TRANSFER AND PROJECTS
	17

	 
	2.1
	Management of Technology Transfer; Projects; Alliance
	17

	 
	2.2
	Technology Transfer
	17

	 
	2.3
	Technology Transfer Projects
	20

	 
	2.4
	New Projects
	20

	 
	2.5
	Transfers of Materials
	21

	 
	2.6
	Project Reporting
	21

	 
	2.7
	Post- Project Enzyme Supply
	22

- iii -

TABLE OF CONTENTS

	
				
	 
	 
	Page

	 
	2.8
	Regulatory Responsibilities and Costs
	22

	 
	2.9
	Commercialization Responsibilities and Costs
	22

	 
	2.10
	Availability for Collaborative Projects; Additional Codexis Libraries
	22

	 
	2.11
	Party Employees
	23

	3.
	LICENSES
	23

	 
	3.1
	Licenses to Codexis
	23

	 
	3.2
	Licenses to GSK
	24

	 
	3.3
	Sublicensing
	25

	 
	3.4
	Limitations on Licenses
	26

	 
	3.5
	Codexis Core Technology Improvements Option
	30

	 
	3.6
	Third Party Licences
	31

	 
	3.7
	Restricted Enzymes
	31

	 
	3.8
	Responsibility for Freedom to Operate Analyses
	31

	 
	3.9
	Public Domain Information and Material
	32

	 
	3.10
	No Implied Licenses
	32

	4.
	PROJECTS
	32

	 
	4.1
	Collaborative Projects
	32

	 
	4.2
	Project Summaries
	32

	 
	4.3
	Project Activities
	33

	 
	4.4
	Subcontracting
	33

	 
	4.5
	Records
	33

	5.
	GOVERNANCE
	34

	 
	5.1
	Joint Steering Committee
	34

	 
	5.2
	Patent Committee
	36

	6.
	INTELLECTUAL PROPERTY
	37

	 
	6.1
	Background Rights
	37

	 
	6.2
	Ownership of Inventions
	37

	 
	6.3
	Further Assurances
	38

	 
	6.4
	Employees and Agents
	38

	 
	6.5
	Prosecution of Patents
	38

	 
	6.6
	Enforcement of Patents
	39

	 
	6.7
	Defense Against Claims of Infringement of Third Party Patents
	40

	7.
	FINANCIAL TERMS
	41

	 
	7.1
	Upfront Payment
	41

	 
	7.2
	Annual Option Fee
	41

	 
	7.3
	Technology Transfer Milestones
	41

	 
	7.4
	Collaborative Project Milestones
	41

	 
	7.5
	GSK Sole Project Milestones
	42

	 
	7.6
	GSK Existing Pharmaceutical Product Milestones
	43

	 
	7.7
	Enzyme Product Milestones
	44

	 
	7.8
	Manner of Milestone Payments and Other Payments
	46

	 
	7.9
	Royalties
	46

	 
	7.10
	Royalty Payment Reports
	46

	 
	7.11
	Applicability of Milestones and Royalties
	47

	 
	7.12
	Manner of Payment
	47

- iv -

TABLE OF CONTENTS

	
				
	 
	 
	Page

	 
	7.13
	Records Retention
	47

	 
	7.14
	Audit Rights
	47

	 
	7.15
	Taxes
	49

	 
	7.16
	Interest Due
	49

	8.
	REPRESENTATIONS, WARRANTIES, AND COVENANTS; DISCLAIMERS; LIMITATION OF LIABILITY
	50

	 
	8.1
	Mutual Representations and Warranties
	50

	 
	8.2
	Additional Representations and Warranties of Codexis
	50

	 
	8.3
	Mutual Covenants
	52

	 
	8.4
	Additional Covenants of GSK
	53

	 
	8.5
	Additional Covenant of Codexis
	53

	 
	8.6
	DISCLAIMERS
	54

	 
	8.7
	LIMITATION OF LIABILITY
	55

	9.
	CONFIDENTIALITY
	55

	 
	9.1
	Nondisclosure
	55

	 
	9.2
	Exceptions
	56

	 
	9.3
	Authorized Disclosure
	56

	 
	9.4
	Terms of this Agreement
	57

	 
	9.5
	Securities Filings
	57

	 
	9.6
	Publicity
	57

	10.
	INDEMNITY AND INSURANCE
	58

	 
	10.1
	GSK Indemnity
	58

	 
	10.2
	Codexis Indemnity
	59

	 
	10.3
	Indemnification Procedure
	59

	 
	10.4
	Insurance
	59

	11.
	TERM AND TERMINATION.
	60

	 
	11.1
	Term; Expiration
	60

	 
	11.2
	Termination for Material Breach
	60

	 
	11.3
	Insolvency or Bankruptcy
	60

	 
	11.4
	Termination for Challenge of any Codexis Patent
	61

	 
	11.5
	Consequences of Expiration or Termination
	61

	 
	11.6
	GSK Continuing Rights
	62

	 
	11.7
	GSK Termination at Will
	62

	 
	11.8
	Additional Consequence of Certain Terminations
	63

	 
	11.9
	Survival
	63

	12.
	DISPUTE RESOLUTION.
	63

	 
	12.1
	Resolution by Executive Officers
	63

	 
	12.2
	Mediation
	64

	 
	12.3
	Arbitration
	64

	 
	12.4
	Confidentiality and Patent Disputes
	66

	13.
	MISCELLANEOUS.
	66

	 
	13.1
	Non-Solicitation
	66

	 
	13.2
	Severability
	66

	 
	13.3
	Notices
	66

	 
	13.4
	Force Majeure
	67

- v -

TABLE OF CONTENTS

	
				
	 
	 
	Page

	 
	13.5
	Assignment
	67

	 
	13.6
	Change of Control of Codexis
	68

	 
	13.7
	GSK Divestments
	68

	 
	13.8
	Waivers and Modifications
	68

	 
	13.9
	Choice of Law
	68

	 
	13.10
	Relationship of the Parties
	68

	 
	13.11
	Entire Agreement
	69

	 
	13.12
	Counterparts
	69

	 
	13.13
	Interpretation
	69

	 
	13.14
	Anti-Bribery and Corruption
	70

	 
	13.15
	Ethical Standards and Human Rights
	70

	 
	13.16
	Good Data Management
	70

- vi -

Exhibits
Exhibit 1.18 – Codexis Core Patents
Exhibit 1.19 – Codexis Core Technology
Exhibit 1.24 – Codexis Enzyme Patents
Exhibit 1.30 – Codexis Mayflower Patents
Exhibit 1.74 – In-License Agreements
Exhibit 1.77 – In-Licensed Patents
Exhibit 1.80 – Invoice Requirements
Exhibit 1.112 – Restricted Enzyme
Exhibit 1.117 – Technology Transfer Plan
Exhibit 2.5 – Material Transfer Record Form
Exhibit 3.3.1 – Codexis Strain-Related Protocols
Exhibit 8.5.4 – Third Party In-License Agreements
Exhibit 9.6 – Press Release
Exhibit 13.14 – Prevention of Corruption – Third Party Guidelines

- i -

PLATFORM TECHNOLOGY TRANSFER, COLLABORATION AND LICENSE AGREEMENT
THIS PLATFORM TECHNOLOGY TRANSFER, COLLABORATION AND LICENSE AGREEMENT (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of 10 July 2014 (the “Effective Date”), by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063, United States of America, (“Codexis”) and GlaxoSmithKline Intellectual Property Development Limited, an English company headquartered at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”).  Codexis and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”   
RECITALS
WHEREAS, GSK possesses expertise in bioprocess development and scale up, including commercial scale manufacture, as well as certain expertise in biocatalyst development;
WHEREAS, Codexis possesses expertise in the engineering and optimization of biocatalysts for use in pharmaceutical compound synthesis and manufacture;
WHEREAS, GSK seeks to collaborate with Codexis on certain biocatalysis projects in order to develop biocatalytic approaches to synthesize compounds of interest to GSK and to practice the Platform Technology under the licenses granted by Codexis and in connection with a technology transfer from Codexis; and 
WHEREAS, Codexis desires to grant to GSK such license and perform such technology transfer, on the terms and conditions set forth herein.  
AGREEMENT
NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows:
1.    DEFINITIONS.The terms in this Agreement with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set forth below.
1.1    “Affiliate” means any Person that directly or indirectly is controlled by, controls or is under common control with a Party to this Agreement.  For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used with respect to a Person means (a) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast more than fifty percent (50%) of the votes in the election of directors, (b) in the case of a non-corporate entity, direct or indirect ownership of more than fifty percent (50%) of the equity interests with the power to direct the management and policies of such entity, or (c) any other arrangement 

- 1 -

whereby a Person controls or has the right to control the board of directors or equivalent governing body or management of a corporation or other entity; provided that, if local Applicable Law restricts foreign ownership, control shall be established by direct or indirect ownership of the maximum ownership percentage that may, under such local Applicable Law, be owned by foreign interests.
1.2    “Alliance Manager” has the meaning assigned to such term in Section 2.1.2.
1.3    “Applicable Law” means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, government or Regulatory Authority.
1.4    “Arising Codexis Enzyme Technology” means: (a) the amino acid sequence and structure of any Project Enzyme developed under a Project during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term) and (b) structure-activity data that describes the structure-activity relationship and other characteristics of any Project Enzyme(s) noted in (a), and in each of (a) and (b), which data and information are Controlled by Codexis during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term). 
1.5    “Arising Codexis Enzyme Technology IP” means Intellectual Property which has arisen directly from the Arising Codexis Enzyme Technology.
1.6    “Arising Codexis Process Technology” means methods of using Project Enzymes in compound synthesis, developed under a Project during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term) and which methods are Controlled by Codexis during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term); provided that Arising Codexis Process Technology shall exclude technology that is generally applicable to chemical process development and to the synthesis and scale up of small molecule compounds and that does not specifically require the use or performance of such Project Enzyme.  
1.7    “Arising Codexis Process Technology IP” means Intellectual Property which has arisen directly from the Arising Codexis Process Technology.
1.8    “Arising GSK Enzyme Technology” means: (a) the amino acid sequence and structure of any Project Enzyme researched under a Project during the TT Term and (b) structure-activity data that describes the structure-activity relationship and other characteristics of any Project Enzyme(s) noted in (a) and, in each of (a) and (b), which data and information are Controlled by GSK during the TT Term.  

- 2 -

1.9    “Arising GSK Enzyme Technology IP” means Intellectual Property which has arisen directly from the Arising GSK Enzyme Technology. 
1.10    “Arising GSK Process Technology” means methods of using Project Enzymes developed under a Project during the TT Term; provided that Arising GSK Process Technology shall exclude technology that is generally applicable to chemical process development and to the synthesis and scale up of small molecule compounds and that does not specifically require the use or performance of such Project Enzyme, which methods are Controlled by GSK during the TT Term. 
1.11    “Arising GSK Process Technology IP” means Intellectual Property which has arisen directly from the Arising GSK Process Technology. 
1.12    “Background IP” means any and all Intellectual Property which is Controlled by a Party and  (a) exists as of the Effective Date and/or (b) arises independently of the other Party during the Term.
1.13    “Business Day” means a day other than Saturday, Sunday or any day on which commercial banks located in New York, New York are authorized or obligated by Applicable Law to close.
1.14    “Calendar Quarter” means the period beginning on the Effective Date and ending on the last day of the calendar quarter in which the Effective Date falls and, thereafter, each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30 or December 31.  
1.15    “Calendar Year” means the period beginning on the Effective Date and ending on December 31st of the calendar year in which the Effective Date falls, and thereafter, each successive period of twelve (12) consecutive calendar months commencing on January 1 and ending on December 31. 
1.16    “Change of Control” means, with respect to a Party, any one of the following events: (a) any entity or two or more entities acting in concert shall have acquired beneficial ownership, directly or indirectly, of more than fifty percent (50%) of the total voting power of the stock then outstanding of the Party normally entitled to vote in elections of directors; (b) the Party consolidates with or merges into another entity, or any entity consolidates with or merges into the Party, in either event pursuant to a transaction in which more than fifty percent (50%) of the total voting power of the stock outstanding of the surviving entity normally entitled to vote in elections of directors is not held by the parties holding at least fifty percent (50%) of such total voting power of the Party preceding such consolidation or merger; or (c) the Party conveys, transfers or leases all or substantially all of its assets to a another entity that is not an Affiliate of the Party (such entity or entities in each of (a), (b) and (c), the “Acquiring Entity”).

- 3 -

1.17    “Clinical Proof of Concept” means the initial demonstration of clinical efficacy of an Enzyme Product in a patient population demonstrated through the conduct of a Phase 1b Clinical Trial or a Phase 2a Clinical Trial. 
1.18    “Codexis Core Patents” means the Patents set forth on Exhibit 1.18.
1.19    “Codexis Core Technology” means those (i) tools, processes and methods Controlled by Codexis; and (ii) generally applicable tools, processes and methods which Codexis has the ability to transfer to or license to GSK, in each of (i) and (ii) above: (a) used to identify, select, optimise, isolate, modify, engineer, research, develop, make, have made and/or import enzymes, Covered Enzymes and Enzymes, through the recombination and/or rearrangement and/or mutation of genetic material for the creation of genetic diversity, using any methods, including but not limited to Codexis Software, in silico, in vitro, and/or in vivo technologies, (b) screening techniques, methodologies and/or processes of using the resulting genes and/or proteins to identify and assess their potential utility, (c) gene expression methods applicable in high throughput screening, (d) techniques for cultivation of microorganisms, (e) techniques for producing, harvesting, and/or purifying proteins, and (f) Codexis Software, in each of (a) – (f) above, as described in Exhibit 1.19. 
1.20    “Codexis Core Technology Improvements” means any improvement or advance to the Codexis Core Technology practiced by Codexis or any Affiliate of Codexis which are licensed to GSK under Section 3.2, that is generated by either Party, or both Parties, or on behalf of either Party or both Parties, or by Codexis with a Third Party, during the TT Term and is Controlled by Codexis, excluding any improvement or advance to the Codexis Core Technology which arises from GSK’s Background IP. 
1.21    “Codexis Core Technology Improvements IP” means any and all Intellectual Property which is generated by or on behalf of either Party or any Affiliate of the Parties or jointly between the Parties or any Affiliate of the Parties which Covers the Codexis Core Technology Improvements. 
1.22    “Codexis Documentation” means any documentation disclosed by Codexis to GSK pursuant to Article 2 (including with respect to Codexis Core Technology Improvements or the Platform Technology), including all Codexis Methods, the Technology Transfer Plan, and documentation related to the Codexis Software and the documentation described in the Technology Transfer Plan and any and all copies thereof, in whole or in part.   
1.23    “Codexis Enzymes” means any Covered Enzyme which is Controlled by Codexis and transferred to GSK pursuant to the Technology Transfer Plan.  For clarity, Codexis Enzymes does not include GSK Initial Enzymes and GSK Selected Enzymes.
1.24    “Codexis Enzyme Patents” means the Patents set forth on Exhibit 1.24.

- 4 -

1.25    “Codexis Exclusive Field” means, the use, research or development (whether in vitro or in vivo), or commercialization of any Enzyme or Enzyme fusion protein (except where the use of any Enzyme or Enzyme fusion protein which is used by GSK solely: (i) as a research reagent or a research tool, or (ii) to synthesize any GSK Compound), that: (a) effects a chemical transformation in humans, (b) facilitates, assists or enables the action, dispersion, absorption or bioavailability of a molecule, biologic agent, drug product, therapeutic agent, or other compound (other than such Enzyme or Enzyme fusion protein) in humans, or (c) transports a molecule, biologic agent, drug product, therapeutic agent, or any other compound (other than such Enzyme or Enzyme fusion protein) in humans, in each of cases (a) through (c) for any purpose, including without limitation the use of Enzymes for medicinal or therapeutic purposes, such as the treatment of lysosomal storage diseases, removal of toxic metabolites and by-products resulting from defects in metabolism, metabolite depletion therapy (e.g., for the treatment of cancer), permeabilization of tissue for improved uptake of a molecule, biologic agent, drug product, therapeutic agent, or any other compound into cells (e.g., hyaluronidase type application, [***], etc.), as well as combinations of the above; provided that the Codexis Exclusive Field [***].
1.26    “Codexis Initial Enzyme(s)” means any Codexis Enzyme or any Enzyme derived from a Codexis Enzyme or a Codexis Library which is designated as an Initial Enzyme pursuant to a Project.
1.27    “Codexis Initial Enzyme IP” means any and all Intellectual Property which Codexis Controls during the Term and which Covers any Codexis Initial Enzymes. 
1.28    “Codexis Library” means any collection, set or sub-set of expression vectors containing genes Controlled by Codexis that encode for Covered Enzymes, Enzymes or enzymes, transferred to GSK under the Technology Transfer Plan, for the propagation of additional enzyme stock. 
1.29    “Codexis Materials” means those materials disclosed or transferred to GSK by Codexis for the practice of the Platform Technology, including (a) the Codexis Libraries and Codexis Enzymes, and (b) the Codexis Core Technology Improvements to which GSK is entitled pursuant to Section 2.2.9.
1.30    “Codexis Mayflower Patents” means the Patents set forth on Exhibit 1.30.
1.31    “Codexis Methods” means (a) as of the Effective Date, the methods and protocols listed in Appendix IV of the Technology Transfer Plan, and (b) after the Effective Date, the methods and protocols disclosed by Codexis and drafted by Codexis, documenting all 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 5 -

material methods relating to the Codexis Core Technology in sufficient detail to enable a scientist with reasonable skills and experience in the field of protein engineering or protein biochemistry to practice the Platform Technology.  The Codexis Methods shall include the most current and complete procedures used by Codexis as of the date on which they are disclosed to GSK with respect to the procedures described therein. 
1.32    “Codexis Senior Management” means, as of the Effective Date, [***]. 
1.33    “Codexis Software” means [***], and all other software disclosed under the Technology Transfer Plan, as amended from time to time, together with all software Controlled by Codexis and disclosed by Codexis under this Agreement, including all versions and improvements practiced by Codexis during the TT Term.  
1.34    “Codexis Team” has the meaning assigned to it in Section 2.2.5(b).
1.35    “Collaborative Project” means any collaborative enzyme evolution project in the GSK Exclusive Field agreed by the JSC as such prior to the commencement of such collaborative enzyme evolution project, using the Platform Technology where both Codexis and GSK perform the research plan to identify a GSK Selected Enzyme.  
1.36    “Commercially Reasonable Efforts” means, with respect to a Party’s obligations under this Agreement, efforts consistent with the efforts and resources normally used by a similarly situated pharmaceutical, biotechnology or technology company in the exercise of its reasonable business discretion relating to the development or commercialization of a product with similar product characteristics that is of similar market potential at a similar stage of development or commercialization, taking into account issues of efficacy, safety, patent and regulatory exclusivity, product profile, anticipated or approved labeling, present and future market potential, competitive market conditions, the proprietary position of the compound or product, the regulatory structure involved, and other technical, legal, scientific, medical or commercial factors, and the profitability of the product, including in light of pricing and reimbursement issues.
1.37    “Completion of Wave 1” means achievement of all the “Wave 1 Milestone Success Criteria” as defined under the Technology Transfer Plan. 
1.38    Completion of Wave 2” means achievement of all the “Wave 2 Milestone Success Criteria” as defined under the Technology Transfer Plan. 
1.39    Completion of Wave 3” means achievement of all the “Wave 3 Milestone Success Criteria” as defined under the Technology Transfer Plan. 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 6 -

1.40    “Confidential Information” means all trade secrets, processes, formulae, Know-How, improvements, inventions, chemical or biological materials, chemical structures, techniques, marketing plans, strategies, customer lists, suppliers, or other information that has been created, discovered, or developed by a Party, or has otherwise become known to a Party, or to which rights have been assigned or licensed to a Party, as well as any other information and materials that are deemed confidential or proprietary to or by a Party (including all information and materials of a Party’s customers and any other Third Party and their consultants), in each case that are disclosed by such Party to the other Party, regardless of whether any of the foregoing are marked “confidential” or “proprietary” or communicated to the other Party by the disclosing Party in oral, written, graphic or electronic form.  
1.41    “Controlled” or “Controls” means, when used in reference to an item or to Intellectual Property rights, the legal authority or right of a Party (or any of its Affiliates) (whether by ownership, assignment or by license, other than pursuant to this Agreement) to grant the right to use such item or a license or sublicense of such Intellectual Property rights to the other Party, or to otherwise disclose proprietary or trade secret information to such other Party, without violating any Applicable Law, breaching the terms of any agreement with any Third Party, or misappropriating the proprietary or trade secret information or other Know-How of a Third Party. 
1.42    “Cover” or “Covers” means a particular item or method claimed in any Intellectual Property that, but for a license under or ownership right in such Intellectual Property, the use, making, having made, offering for sale, sale, importation, or other exploitation of such item would infringe or misappropriate such Intellectual Property (assuming, in the case of pending Patent applications, that such pending Patent applications were issued Patents). 
1.43    “Covered Enzyme” means any immature or mature peptide or protein, including derivatives, with enzymatic or biocatalytic activity Covered by the Licensed IP pursuant to this Agreement.
1.44    “Dollar” or “$” means the lawful currency of the United States.
1.45    “Embargo Period” means the period beginning on the Effective Date and continuing until and ending on the five (5) year anniversary of the Effective Date.
1.46    “Enzyme” means any immature or mature peptide or protein, including derivatives, with enzymatic or biocatalytic activity derived from the use of the Platform Technology pursuant to this Agreement.   
1.47    “Enzyme Product” means any of: (a) Licensed Enzyme Therapeutic Product, (b) Licensed Diagnostic Product, (c) Licensed Accessory Product, (d) Licensed Prophylactic Product, or (e) Licensed Other Therapeutic Product.

- 7 -

1.48    “FDA” means the U.S. Food and Drug Administration, or any successor agency thereto.
1.49    “Field” means (a) the manufacture and commercialization of compounds, molecules and products (including, but not limited to, Licensed Products) for the treatment of any human disease or medically treatable human condition; (b) the prophylaxis, diagnosis, or treatment of any human disease or medically treatable human condition; and (c) the research and development of compounds, molecules and products (including, but not limited to, Licensed Products) for the treatment of any human disease or medically treatable human condition.  
1.50    “Final Round of Enzyme Evolution” means that final one (1) Round of Enzyme Evolution in the series of successive Rounds of Enzyme Evolution in which the GSK Selected Enzyme was identified.
1.51    “First Commercial Sale” means the first sale of a Licensed Product in a given country or other regulatory jurisdiction in the Territory by or on behalf of GSK, its Affiliates or sublicensees to a Third Party, after receipt of Regulatory Approval (including pricing approval, to the extent required for sale of Licensed Products in a given country or regulatory jurisdiction, and the completion of any necessary labeling negotiations that may be required after Regulatory Approval and such pricing approval) for Licensed Products in such country or regulatory jurisdiction.  First Commercial Sale shall specifically exclude sales or transfers for clinical study purposes or compassionate use, named-patient, indigent patient or similar uses, if such uses do not result in monetary compensation to GSK above the cost of goods.  
1.52    “First Production Run” means the use of a Licensed Collaborative Project GSK Selected Enzyme or a Licensed GSK Sole Project GSK Selected Enzyme in the synthesis of a GSK Compound (a) for use in clinical trials or (b) for commercial sales. 
1.53    “FTE” means the equivalent of the work performed after the Effective Date of one (1) Codexis scientist or one (1) GSK scientist, full time for one (1) year.  In no event will one (1) person count for more than one (1) FTE in any Calendar Year.
1.54    “Fully Burdened Cost” means [***].  For the avoidance of doubt, the calculation of “Fully Burdened Cost” shall exclude for all purposes the cost of any and all materials supplied by GSK.  [***]. 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 8 -

1.55    “Generic Version” means, with respect to a Pharmaceutical Product, a product meeting all of the following criteria: (a) such product contains the same active pharmaceutical ingredient(s) in the same dosage form and the same formulation as is contained in such Pharmaceutical Product, and (b) such product is A/B Rated with respect to such Pharmaceutical Product.  For the purposes of this definition, “A/B Rated” means, inside the United States, “therapeutically equivalent” as evaluated by the FDA, applying the definition of “therapeutically equivalent” set forth in the preface to the then-current edition of the FDA publication “Approved Drug Products With Therapeutic Equivalence Evaluations” and, outside the United States, such equivalent determination by the applicable Regulatory Authorities as is necessary to permit pharmacists or other individuals authorized to dispense pharmaceuticals under Applicable Law to substitute one product for another product in the absence of specific instruction from a physician or other authorized prescriber under Applicable Law.  
1.56    “Good Clinical Practices” or “GCP” means the then-current international ethical and scientific quality standards for designing, conducting, recording and reporting trials that involve the participation of human subjects.  In the United States, GCP shall be based on Good Clinical Practices established through FDA guidance (including ICH E6) and, outside the United States, GCP shall be based on ICH E6.  
1.57    “Good Laboratory Practices” or “GLP” means the then-current Good Laboratory Practice (or similar standards) for the performance of laboratory activities for pharmaceutical products as are required by applicable Regulatory Authorities or Applicable Law.  In the United States, Good Laboratory Practices are established through FDA regulations (including 21 C.F.R. Part 58), FDA guidance, FDA current review and inspection standards and current industry standards. 
1.58    “Good Manufacturing Practices” or “GMP” means the then-current Good Manufacturing Practices for the manufacture of products as are required by applicable Regulatory Authorities or Applicable Law.  In the United States, GMP shall be as defined under the rules and regulations of the FDA, as the same may be amended from time to time.
1.59    “GSK Compound” means any compound which is Controlled by GSK or its Affiliates [***], in any form including, but not limited to the final active pharmaceutical ingredient (i.e., an API) form (but excluding, for clarity, any Enzyme). 
1.60    “GSK Exclusive Field” means the development and/or use of any Enzyme for the synthesis of any GSK Compound, within the Field.   
1.61    “GSK Existing Pharmaceutical Product” means any GSK product containing a GSK Compound which has obtained Regulatory Approval and where the first such GSK product sold in a Major Market Country did not include the use of a GSK Selected Enzyme within the route of synthesis of the GSK Compound included within the product.

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 9 -

1.62    “GSK Initial Enzyme(s)” means any enzyme (which for clarity is not an “Enzyme”) that is provided by GSK and which is designated as an Initial Enzyme pursuant to a Project excluding, for clarity, Enzymes derived from a Codexis Enzyme or a Codexis Library.
1.63    “GSK Project Library” means any collection, set or sub-set of Enzymes and/or expression vectors containing genes that encode for Enzymes derived from a Project.
1.64    “GSK Selected Enzyme” means an Enzyme derived from an Initial Enzyme and has been selected by GSK from a Project for use pursuant to this Agreement to synthesize any GSK Compound.  
1.65    “GSK Sole Project” means any Enzyme evolution project that was initiated using a GSK Initial Enzyme or a Codexis Initial Enzyme, conducted in the GSK Exclusive Field by GSK or any Affiliate of GSK, whether or not in collaboration with any Third Party permitted under this Agreement, using the Platform Technology which may involve limited Codexis’ participation (which, for clarity, would not constitute such level of participation that the JSC would otherwise deem such participation as constituting a Collaborative Project). 
1.66    “GSK Team” shall have the meaning assigned to it in Section 2.2.5(a).  
1.67    “IFRS” means the International Financial Reporting Standards.
1.68    “Improvements TT Term” means the period beginning on the expiration of the TT Term and continuing until and ending on the earlier of (a) the Improvements TT Term Expiration Date, (b) the date on which GSK fails to timely pay an Annual Option Fee in accordance with Section 7.2 or (c) the early termination of this Agreement by Codexis in accordance with Sections 11.2 or 11.4.
1.69    “Improvements TT Term Expiration Date” means, if GSK exercises the Option under Section 3.5.2 and timely pays the First Annual Option Fee and each Annual Option Fee set forth in Section 7.2, the three (3) year anniversary of the TT Term Expiration Date or a later date if the Improvements TT Term is extended in accordance with Section 3.5.4. 
1.70    “Initial Enzyme” means any GSK Initial Enzyme or Codexis Initial Enzyme contributed to a Project which is selected to undergo Initial Enzyme Optimisation.
1.71    “Initial Enzyme Optimisation” means the process of optimising Initial Enzymes for desired characteristics directly using the Platform Technology in any Project.
1.72    “Initial Technology Transfer Inventory” means all of the items set out in Appendix I of the Technology Transfer Plan.
1.73    “Initial Training” has the meaning assigned to such term in Section 2.2.6.   

- 10 -

1.74    “In-License Agreements” means the agreements set forth in Exhibit 1.74 in the versions sent by Codexis to GSK in an e-mail(s) dated July 7, 2014. 
1.75    “In-Licensed IP” means the In-Licensed Patents and any In-Licensed Know-How.
1.76    “In-Licensed Know-How” means all Know-How of Third Parties Controlled by Codexis as of the Effective Date and licensed to Codexis pursuant to the In-License Agreements, in each case that Covers the Codexis Documentation, the Codexis Materials, the Codexis Software or the practice of the Platform Technology.
1.77    “In-Licensed Patents” means all Patents of Third Parties Controlled by Codexis as of the Effective Date and licensed or sub-licensed to Codexis pursuant to the In-License Agreements, in each case, that Cover the Codexis Documentation, the Codexis Materials, the Codexis Software or the practice of the Platform Technology, set forth on Exhibit 1.77.  
1.78    “Intellectual Property” means Patents, Know-How, copyrights and software, including all applications for registration for the foregoing and all other similar proprietary rights as may exist anywhere in the world. 
1.79    “Invention” means any discovery, invention, contribution, method, finding, or improvement, whether or not patentable, and all related Know-How.
1.80    “Invoice” means any invoice submitted to GSK by Codexis under this Agreement, produced in accordance with GSK’s processing requirements, as set forth in Exhibit 1.80. 
1.81    “Know-How” means non-public materials and technical information, including techniques, methods, processes, technology, recipes, designs, equipment configurations and uses, biological samples, compounds and cell lines, and biological, chemical, pharmacological, toxicological, clinical, assay and related trade secrets, and manufacturing data, preclinical and clinical data, the specifications of ingredients, the manufacturing processes, formulation, specifications, sourcing information, quality control and testing procedures, and related know-how and trade secrets.  
1.82    “Licensed Additional Codexis IP” means Licensed Additional Codexis Know-How and Licensed Additional Codexis Patents.
1.83    “Licensed Accessory Product” means [***]. 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 11 -

1.84    “Licensed Additional Codexis Know-How” means any and all Know-How which (a) Codexis or any Codexis Affiliate comes to Control during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term) and (b) which Covers (i) the Platform Technology, (ii) Arising Codexis Enzyme Technology, (iii) Arising Codexis Process Technology, (iv) any Codexis Core Technology Improvements, (v) the Codexis Documentation and (vi) Codexis Materials.
1.85    “Licensed Additional Codexis Patents” means any and all Patents which (a) Codexis or any Affiliate comes to Control during the TT Term (and, if GSK exercises the Option, during the Improvements TT Term) and (b) which Covers (i) the Platform Technology, (ii) Arising Codexis Enzyme Technology, (iii) Arising Codexis Process Technology, or (iv) any Codexis Core Technology Improvements.
1.86    “Licensed Collaborative Project GSK Selected Enzyme” means any GSK Selected Enzyme arising from a Collaborative Project. 
1.87    “Licensed Diagnostic Product” means [***].
1.88    “Licensed Enzyme Therapeutic Product” means [***].
1.89    “Licensed GSK Sole Project GSK Selected Enzyme” means any GSK Selected Enzyme arising from a GSK Sole Project. 
1.90    “Licensed IP” means (a) the Licensed Patents, (b) the In-Licensed Patents, (c) the Licensed Know-How, (d) the In-Licensed Know-How, (e) the Licensed Additional Codexis Know-How, and (f) the Licensed Additional Codexis Patents. 
1.91    “Licensed Know-How” means any Know-How Controlled by Codexis as of the Effective Date which is disclosed or provided to GSK hereunder in accordance with Section 2.2.3, including the Codexis Documentation, Codexis Materials and Codexis Software but only to the extent existing as of the Effective Date. 
1.92    “Licensed Other Therapeutic Product” means [***].
1.93    “Licensed Patents” means (a) the Codexis Core Patents and (b) the Codexis Enzyme Patents.  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 12 -

1.94    “Licensed Product” means an Enzyme Product and/or a Pharmaceutical Product.
1.95    “Licensed Prophylactic Product” means [***].
1.96    “Losses” means any claim, threatened claim, suit, proceeding, liability, loss, damage, expense (including reasonable legal expenses, costs of litigation, and attorneys’ fees) or judgment, whether for money or equitable relief, of any kind. 
1.97    “Major Market Country” means [***]. 
1.98    “Net Sales” means gross invoiced sales of the Licensed Product to Third Parties, in each quarter less the following deductions from such gross amounts which are actually incurred, allowed, paid, accrued or specifically allocated to the extent that such amounts are deducted from gross invoiced sales amounts as reported in financial statements in accordance with the International Financial Reporting Standards (“IFRS”), applied on a consistent basis:  
1.98.1    credits or allowances actually granted for damaged Licensed Product, returns or rejections of Licensed Product, price adjustments, and billing errors;
1.98.2    governmental and other rebates (or equivalents thereof) to national, state/provincial, local and other governments, their agencies and purchasers, and reimbursers, or to trade customers;
1.98.3    normal and customary trade, cash and quantity discounts, allowances, and credits actually allowed or paid; 
1.98.4    commissions allowed or paid to Third Party distributors, brokers or agents other than sales personnel, sales representatives and sales agents; 
1.98.5    transportation costs, including insurance, for outbound freight related to delivery of Licensed Product to the extent included in the gross amount invoiced; 
1.98.6    sales taxes, value added taxes, and other taxes directly linked to the sales of Licensed Product to the extent included in the gross amount invoiced; and 
1.98.7    any other items actually deducted from gross invoiced sales amounts as reported in financial statements in accordance with the IFRS, applied on a consistent basis.  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 13 -

For purposes of this definition, the Licensed Product shall be considered “sold” and “deductions” allowed when recorded as invoiced in financial statements prepared in accordance with IFRS.
1.99    “On-Site Training” has the meaning assigned to such term in Section 2.2.7. 
1.100    “Patent(s)” means (a) patents and patent applications anywhere in the world, (b) all divisionals, continuations, continuations in-part thereof or any other patent application claiming priority, or entitled to claim priority, directly or indirectly to (i) any such patents or patent applications, or (ii) any patent or patent application from which such patents or patent applications claim, or is entitled to claim, direct or indirect priority, and (c) all patents issuing on any of the foregoing anywhere in the world, together with all registrations, reissues, re-examinations, patents of addition, renewals, substitutions, validations, and re-validations, supplemental protection certificates or extensions of any of the foregoing anywhere in the world, and (d) all provisional and any other priority patent applications filed worldwide.
1.101    “Person” means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture, governmental authority, association or other entity.  
1.102    “Pharmaceutical Product” means any product containing a GSK Compound that includes a GSK Selected Enzyme within its route of synthesis, and which has been formulated into such product.
1.103    “Phase 1b Clinical Trial” means a pilot human clinical trial usually conducted in patients diagnosed with the disease, or condition for which the study drug is intended, who demonstrate some biomarker, surrogate, or possible clinical outcome.
1.104    “Phase 2a Clinical Trial” means a human clinical trial, the principal purpose of which is a determination of efficacy and safety, in the target population, at the intended clinical dose or doses, to confirm the optimal manner of use.
1.105    “Platform Technology” means (a) the Codexis Core Technology, (b) the Codexis Enzymes and (c) the Codexis Libraries which are provided to GSK by Codexis under this Agreement in such a state and condition and in the detail which are necessary to enable a scientist with reasonable skills and experience in the field of protein engineering or protein biochemistry to use, identify, select, optimise, isolate, modify, engineer, research, develop, make, have made and/or import any Enzyme, in each of (a), (b) and (c), that (i) is described in, and embodies the subject matter of, the Codexis Documentation, and (ii) uses the Codexis Materials and the Codexis Software.
1.106    “Project” means any GSK Sole Project or Collaborative Project.

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 14 -

1.107    “Project Enzyme” means any Enzyme derived from an Initial Enzyme arising from a Round of Enzyme Evolution.
1.108    “Prosecution” means the preparation, drafting, filing, prosecution (including any interferences, reissue proceedings, reexaminations, inter partes reviews, post-grant reviews, oppositions and Patent office appeals) and maintenance of Patents in the Territory.  When used as a verb, “Prosecute” means to engage in Prosecution.
1.109    “Regulatory Approval(s)” means, with respect to any Licensed Product in any jurisdiction, all approvals from any Regulatory Authority necessary for the commercial manufacture, marketing and sale of any product containing such Licensed Product in such jurisdiction in accordance with Applicable Law, including without limitation, receipt of pricing and reimbursement approvals, where required. 
1.110    “Regulatory Authority” means any national or supranational governmental authority, including without limitation the FDA, that has responsibility in countries in the Territory over the development and/or commercialization of any Licensed Product, as applicable.  
1.111    “Regulatory Filings” means any and all regulatory applications, filings, approvals and associated correspondence required to develop any Licensed Product in each country or jurisdiction in the Territory.
1.112    “Restricted Enzyme” means any immature or mature peptide or protein with enzymatic or biocatalytic activity, or any vector that encodes for any such peptide or protein, listed in Exhibit 1.112, which list as of the Effective Date will be provided in accordance with Section 3.7.1.  During the Term, Exhibit 1.112 may be revised in accordance with Section 3.7.1.  
1.113    “Round(s) of Enzyme Evolution” means round of Initial Enzyme Optimisation conducted during a Project resulting in Project Enzymes comprising a GSK Project Library. 
1.114    “Royalty Term” means, on a country-by-country and Enzyme Product-by-Enzyme Product basis, the period commencing as of the date of First Commercial Sale of such Enzyme Product in such country and ending upon [***]: (a) [***] years after the date of First Commercial Sale of such Enzyme Product in such country, and (b) the date of expiration of the last to expire Valid Claim of the last to expire Patent that claims the composition of matter or method of use of the Enzyme Product that would be infringed by the manufacture, use or sale of such Enzyme Product in such country, but for the licenses granted to GSK under this Agreement.  
1.115    “Scientific Lead” shall have the meaning assigned to it in Section 2.1.1.

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 15 -

1.116    “Technology Transfer” means (a) the transfer of the Codexis Documentation, Codexis Software and Codexis Materials and (b) the training with respect to the Platform Technology, in each case to be conducted in accordance with the Technology Transfer Plan and Article 2.  
1.117    “Technology Transfer Plan” means that plan for the Technology Transfer as mutually agreed between the Parties and set forth in Exhibit 1.117 as of the Effective Date and as may be amended by the Parties during the TT Term in accordance with Section 2.2.4, itemising each Party’s responsibilities and obligations, the activities to be performed by each Party, and a timeline for performance of such activities, in connection with the Technology Transfer from Codexis to GSK to fully implement the Platform Technology within GSK.  
1.118    “Territory” means worldwide. 
1.119    “Third Party” means any Person other than GSK and Affiliates of GSK, and Codexis and Affiliates of Codexis.
1.120    “TT Term” means the period beginning on the Effective Date and ending on the earlier of (a) the date on which Codexis receives notification from GSK, in accordance with Section 7.3, of Completion of Wave 3, (b) the third (3rd) anniversary of the Effective Date, or (c) the date GSK initiates the first GSK Sole Project that is not a Technology Transfer Project and for which GSK will provide prompt notification to Codexis of such initiation date.
1.121    “TT Term Expiration Date” means the earlier of (a) the date on which Codexis receives notification from GSK, in accordance with Section 7.3, of Completion of Wave 3, (b) the third (3rd) anniversary of the Effective Date, or (c) the date GSK initiates the first GSK Sole Project that is not a Technology Transfer Project and for which GSK will provide prompt notification to Codexis of such initiation date.   
1.122    “Upfront Payment” shall have the meaning assigned to it in Section 7.1.
1.123    “United States” or “U.S.” means the United States of America and all its territories and possessions.
1.124    “Valid Claim” means either (a) a claim of an issued and unexpired Patent which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal and that is not admitted to be invalid or unenforceable through reissue, disclaimer or otherwise (i.e., only to the extent the subject matter is disclaimed or is sought to be deleted or amended through reissue), or (b) a claim of a pending Patent application that has not been abandoned, finally rejected or expired without the possibility of appeal or refiling. 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 16 -

1.125    “Wave” means each phase of the Technology Transfer noted as Wave 1, Wave 2 and Wave 3 of the Technology Transfer Plan in force as of the Effective Date, and from time-to-time during the TT Term. 
1.126    Additional Definitions.  Each of the following terms has the meaning set forth in the corresponding section of this Agreement indicated below:
	
		
	Definition:
	Section:

	AAA
	12.3

	A/B Rated
	1.55

	Acquiring Entity
	1.16

	Agreement
	Preamble

	Annual Option Fee
	7.2

	Bankruptcy Code
	11.3

	Breaching Party
	11.2

	Challenging Party
	11.4

	Codexis
	Preamble

	Codexis Indemnitees
	10.1

	Codexis Patents
	6.5.2

	Covered Patent Claim
	3.1.3

	Cure Period
	11.2

	Disclosing Party
	9.1

	Dispute
	12.1

	Effective Date
	Preamble

	Exclusive Option
	3.5.1

	First Annual Option Fee
	7.2

	Force Majeure
	13.4

	GSK
	Preamble

	GSK Indemnitees
	10.2

	GSK Patents
	6.5.3

	Indemnification Claim
	10.3

	Indemnitee
	10.3

	Indemnitor
	10.3

	Infringement Action
	6.6.1

	Joint Steering Committee or JSC
	5.1.1

	Lactosan
	3.4.6

	Material
	2.5

	Material Transfer Record Form
	2.5

	Non-Breaching Party
	11.2

	Non-Exclusive Option
	3.5.1

	Non-Solicitation Period
	13.1

	Option
	3.5.1

- 17 -

	
		
	Definition:
	Section:

	Option Period
	3.5.2

	Parties
	Preamble

	Party
	Preamble

	Patent Challenge
	11.4

	Patent Claim
	3.1.3

	Patent Committee
	5.2.1

	Patent Committee Embargo License Period
	3.1.4(a)

	Potentially Restricted Enzyme
	3.7.1

	Project Team
	5.1.3

	Receiving Party
	9.1

	Royalties
	7.9

	Technology Transfer
	1.116

	Technology Transfer Project
	2.3

	Technology Transfer Project Activities
	2.3

	Technology Transfer Project Plan
	2.3

	Term
	11.1

	Termination Audit Right
	11.5.3

	Terminated Country
	11.5.2

	Transferor
	2.5

	Transferee
	2.5

2.    TECHNOLOGY TRANSFER AND PROJECTS
2.1    Management of Technology Transfer; Projects; Alliance.
2.1.1    Scientific Lead.  Each Party shall designate in writing within fifteen (15) days after the Effective Date, a “Scientific Lead” with all necessary scientific skill and expertise to fulfil such role in accordance with this Article 2, to be the primary contact for such Party responsible for managing day-to-day communications between the Parties with respect to the technical aspects of the Technology Transfer and other scientific and technical activities set forth in this Agreement, including responsibility for scheduling teleconferences and coordinating meetings and technical support as required hereunder.  Each Party may respectively appoint a substitute Scientific Lead to represent it under this Section 2.1.1.  
2.1.2    Alliance Manager.  Each Party shall designate in writing within fifteen (15) days after the Effective Date, an “Alliance Manager” with all necessary business skill and expertise as necessary to be the primary contact for such Party as regards all business development and/or contract-related communications between the Parties for all matters in connection with this Agreement, outside of the purview of the technical matters for which the Scientific Leads are responsible.  The Alliance Managers shall be responsible for initially 

- 18 -

addressing any finance, legal and business issues that may arise.  Each Party may respectively appoint a substitute Alliance Manager to represent it under this Section 2.1.2.
2.1.3    Limitations.  The Scientific Leads and the Alliance Managers shall not have the authority to amend, modify or waive compliance with this Agreement, through meeting minutes, e-mails or otherwise.
2.2    Technology Transfer.
2.2.1    Codexis Methods.  Except for the protocols listed under the heading “Protocols to be Generated in the Context of Training during Technology Transfer” in Appendix IV of the Technology Transfer Plan, Codexis shall provide the Codexis Methods within thirty (30) days after the Effective Date. 
2.2.2    Codexis Technology Transfer.  Codexis shall transfer to GSK the Initial Technology Transfer Inventory and: (a) the Codexis Materials, (b) the Codexis Documentation, and (c) the Codexis Software, each in accordance with the Technology Transfer Plan.  The Parties shall perform the Technology Transfer during the TT Term pursuant to the timelines under the Technology Transfer Plan.  
2.2.3    Technology Transfer Plan.  Upon the Effective Date the Parties shall commence the Technology Transfer in sequential order of Waves as described in, and in accordance with, the Technology Transfer Plan.  Each Party shall perform the activities assigned to such Party under the Technology Transfer Plan at the sites identified in Section 2.2.6 and 2.2.7 and shall perform all such activities in compliance with Applicable Law.  Notwithstanding anything to the contrary, subject to any updates to the Technology Transfer Plan pursuant to Section 2.2.4, Codexis shall not be obligated to transfer to GSK any information and/or materials not described in the Technology Transfer Plan.
2.2.4    Updates to Technology Transfer Plan.  In the event that errors and/or omissions in the Technology Transfer Plan are discovered by GSK and/or Codexis during the TT Term and the Parties mutually agree to update the Technology Transfer Plan pursuant to any reasonable scientific rationale agreed between the Parties to enable GSK to practice the Platform Technology, the Parties shall then update the Technology Transfer Plan accordingly. 
2.2.5    Technology Transfer Teams.  In order to effect Section 2.2:
(a)    GSK shall identify a Technology Transfer team of personnel and in such numbers as it may so determine (the “GSK Team”) to participate in each Wave of the Technology Transfer.  GSK shall change any member(s) of the GSK Team in its sole discretion at any time.  The GSK Team shall have all reasonable skills and experience in the field of protein engineering to perform the Technology Transfer.

- 19 -

(b)    Codexis shall identify a Technology Transfer team to lead the GSK Team in each Wave of the Technology Transfer, including the Initial Training and the On-Site Training [***] (the “Codexis Team”) as detailed in the Technical Transfer Plan.  Codexis, in its sole discretion, may change any member(s) of the Codexis Team at any time.  Each member of the Codexis Team shall have all necessary scientific experience and expertise to perform the Technology Transfer. 
2.2.6    Initial Training at Codexis’ Facility.  After the Effective Date, the GSK Team will participate in Wave 2 of Technology Transfer at Codexis’ facility in Redwood City, California, which training shall be completed as outlined in the Technology Transfer Plan (the “Initial Training”).  GSK shall bear its own costs and expenses of participating in such Initial Training.
2.2.7    On-Site Training at GSK’s Upper Merion West Campus Facility.  On an agreed-upon date, promptly following Completion of Wave 1 the Codexis Team and the GSK Team will participate in Wave 2 Technology Transfer activities at a GSK facility in Upper Merion West Campus facility (or any other GSK facility nominated by GSK in the greater Philadelphia region). Codexis shall bear its own costs and expenses of providing such training (the “On-Site Training”).  The On-Site Training shall be conducted by the Codexis Team in accordance with the Technology Transfer Plan.  The On-Site Training shall include training on all items identified in the Technology Transfer Plan as required at the On-Site Training.
2.2.8    Acceptance by GSK of the Initial Technology Transfer Inventory; Completion of Technology Transfer.  The Initial Technology Transfer Inventory to be transferred in accordance with the Technology Transfer Plan shall be deemed to have been accepted by GSK [***] (the “Initial Technology Transfer Inventory Acceptance Criteria”).  In the event that any item in the Initial Technology Transfer Inventory fails to meet the Initial Technology Transfer Inventory Acceptance Criteria, GSK shall notify Codexis in writing [***].  In the event that any item of the Initial Technology Transfer Inventory fails to meet the Initial Technology Transfer Inventory Acceptance Criteria and GSK so notifies Codexis of such, Codexis shall promptly provide replacements for any item of the Initial Technology Transfer Inventory which shall meet the Initial Technology Transfer Inventory Acceptance Criteria.  The Technology Transfer will have been completed when each item of the Initial Technology Transfer Inventory and each step in the Technology Transfer Plan has been successfully completed[***].  
2.2.9    Codexis Core Technology Improvements, Arising Codexis Enzyme Technology and Arising Codexis Process Technology During the TT Term.

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 20 -

(a)    Initial Disclosure.  Within [***] days after the end of the Calendar Quarters ending June 30 and December 31:
(i)    during the TT Term and, if GSK exercises the Option, during the Improvements TT Term, Codexis’ Alliance Manager shall disclose to GSK’s Alliance Manager [***] Codexis Core Technology Improvements by or on behalf of Codexis, or any Affiliate of Codexis and [***] corresponding Licensed Additional Codexis IP during the applicable half year period, if any; and
(ii)    during the TT Term, Codexis’ Alliance Manager shall disclose to GSK’s Alliance Manager [***] Arising Codexis Enzyme Technology and/or Arising Codexis Process Technology by or on behalf of Codexis, or any Affiliate of Codexis and [***] corresponding Licensed Additional Codexis IP during the applicable half year period, if any.  
(b)    Subsequent Disclosure.  If the GSK Alliance Manager requests further information regarding Codexis Core Technology Improvements, Arising Codexis Enzyme Technology and/or Arising Codexis Process Technology by or on behalf of Codexis, or any Affiliate of Codexis, and [***] corresponding Licensed Additional IP during the TT Term and, if GSK exercises the Option, during the Improvements TT Term, and corresponding Licensed Additional Codexis IP disclosed to GSK in accordance with Section 2.2.9(a), GSK shall, within [***] days after receipt of the initial disclosure of Codexis Core Technology Improvements by Codexis pursuant to Section 2.2.9(a) request the disclosure of such further information Controlled by Codexis, and with respect to Section 2.2.9(a), in sufficient detail as reasonably necessary for GSK to make a decision as to whether to exercise its rights pursuant to Section 3.5.2 to obtain a license to such Codexis Core Technology Improvements and corresponding Licensed Additional Codexis IP. All information, documents and other materials disclosed by Codexis to GSK pursuant to this Section 2.2.9 shall constitute the Confidential Information of Codexis.
(c)    Disclosure of Codexis Core Technology Improvements During the TT Term and, if GSK exercises the Option, during the Improvements TT Term.  During the TT Term and, if GSK exercises the Option, during the Improvements TT Term, GSK shall have [***] days after the disclosure of such further information relating to the Codexis Core Technology Improvements and corresponding Licensed Additional Codexis IP pursuant to Section 2.2.9(b) to request in writing that Codexis disclose such Codexis Core Technology Improvement(s) and [***] corresponding Licensed Additional Codexis IP to GSK.  If GSK makes such request during such period, Codexis shall disclose such Codexis Core Technology and Licensed Additional Codexis IP to GSK as promptly as possible, and in any event no later than within [***] days and such Codexis Core Technology and Licensed Additional Codexis IP shall be deemed licensed to GSK under Section 3.2.1.  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 21 -

(d)    Role of Scientific Lead.  For one (1) Calendar Year following the end of the TT Term, and during the Improvements TT Term, if GSK exercises the Option, Codexis shall make its Scientific Lead reasonably available to provide telephonic or web-based advisory technical support and assistance to GSK in GSK’s practice of the Platform Technology pursuant to the licenses granted pursuant to Section 3.5.3.  
2.2.10    Arising GSK Enzyme Technology and Arising GSK Process Technology During the TT Term.
(a)    Initial Disclosure.  Within [***] days after the end of the Calendar Quarters ending June 30 and December 31, during the TT Term, GSK shall disclose to Codexis’ Alliance Manager [***] Arising GSK Enzyme Technology and Arising GSK Process Technology, if any.  
(b)    Subsequent Disclosure.  If the Codexis Alliance Manager requests further information regarding Arising GSK Enzyme Technology and/or Arising GSK Process Technology, Codexis shall, within [***] days after receipt of the initial disclosure of such Arising GSK Enzyme Technology and/or such Arising GSK Process Technology by GSK pursuant to Section 2.2.10(a) request the disclosure of such further information Controlled by GSK.
2.3    Technology Transfer Projects.  During the TT Term, the Parties shall conduct at least four (4) Projects as set forth in the Technology Transfer Plan (each, a “Technology Transfer Project”) pursuant to the terms of written project plans (each, a “Technology Transfer Project Plan”) agreed upon and approved by the JSC at appropriate times during the TT Term in light of the schedule set forth in the Technology Transfer Plan.  The Parties acknowledge and agree that Technology Transfer Projects [***] (as described in the Technology Transfer Plan) shall be [***], and Technology Transfer Projects [***] (as described in the Technology Transfer Plan) shall be [***]. Subject to Article 7, each Party shall be solely responsible for all costs and expenses arising from activities performed by such Party pursuant to the Technology Transfer Project Plans (“Technology Transfer Project Activities”).  Each such Technology Transfer Project shall be deemed completed upon satisfaction of the criteria for such project as set forth in the Technology Transfer Plan.   
2.4    New Projects.  Upon reasonable request by GSK during the TT Term, the JSC shall meet to discuss in good faith one or more additional Collaborative Projects to be conducted by the Parties under this Agreement.  If the JSC agrees that any such Collaborative Project shall be performed by the Parties, the Parties shall prepare in good faith a written research plan for such Collaborative Project and submit such written research plan to the JSC for approval.  If the JSC approves such Collaborative Project, the written research plan will automatically be made a part of this Agreement. 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 22 -

2.5    Transfers of Materials.  In the event that the Parties mutually agree that a transfer of any biopharmaceutical, biological, chemical or other material (“Material(s)”) from GSK or Codexis (the “Transferor”) to Codexis or GSK (as applicable) (the “Transferee”)  is necessary or desirable to facilitate the Parties’ collaborative activities pursuant to this Agreement, except where Codexis Materials are transferred by Codexis to GSK pursuant to the Technology Transfer Plan (which in all cases shall be itemised and recorded in writing, such written records to be sent to GSK for confirmation of receipt of all such items), the Parties shall document such transfer using the material transfer record form set out in Exhibit 2.5 (the “Material Transfer Record Form”) and the Transferor shall effect such transfer in accordance with the following provisions: 
2.5.1    the Transferor shall complete and submit to the Transferee for counter-signature, the Material Transfer Record Form prior to the transfer of the Material.
2.5.2    both Parties warrant that they have the full right and authority to transfer the Materials to the Transferee for use within the contemplated research program.
2.5.3    the Material and related information provided by Transferor will remain the property of Transferor or remain under the control of Transferor and will be kept securely by Transferee and will not be provided by Transferee, without the prior written consent of Transferor, to any Third Party.
2.5.4    the Transferee shall only use the Material for the purpose of the performing the applicable work as laid out under any applicable Project or in connection with the Platform Technology, in each case in accordance with Applicable Law.
2.5.5    the Transferee acknowledges that the Material is experimental in nature and provided “AS IS.” 
2.5.6    the Transferee shall use the Material at its own risk and in accordance with Applicable Law and any safety instructions provided by the Transferor. 
2.5.7    all right title and interest in Materials transferred in accordance with this Section 2.5 shall remain vested in the Transferor and the Transferee shall gain no right, title or interest of any sort, other than as may be granted to the Transferee pursuant to the rights and licenses in this Agreement, in such Material.  
2.6    Project Reporting.  At each JSC meeting or as otherwise agreed between the Parties (but in no event less than once per Calendar Quarter), each Party will provide the JSC with presentations regarding the Technology Transfer Project Activities performed by it, including a summary of results relating to each Technology Transfer Project. 

- 23 -

2.7    Post- Project Enzyme Supply.   
2.7.1    Request, Audit and Supply Terms.  Subject to the limitations in Section 2.7.2, GSK, during the Term, may request that Codexis supply to GSK any Enzyme for use in any Project.  Prior to obtaining supply of any Enzyme from Codexis, GSK shall have the right to perform a quality and technical audit of Codexis’ manufacturing facility to determine such facility’s suitability for manufacture of the Enzyme and compliance with Applicable Law, including without limitation, whether such facility (a) holds necessary permits and licenses; and (b) maintains such Good Laboratory Practices and/or Good Manufacturing Practices, in each case as may be applicable to the Enzyme to be obtained from Codexis.  If GSK elects to proceed with obtaining supply from Codexis after satisfactory completion of the audit, the Parties shall negotiate in good faith to agree to mutually acceptable commercial supply and quality terms, defining the roles and responsibilities related to Codexis’ manufacture and delivery of the Enzyme to GSK.  [***]. 
2.7.2    Limitations.  GSK may only request the use of [***], and Codexis will have no obligation under Section 2.7.1 to supply Enzyme to GSK [***].
2.8    Regulatory Responsibilities and Costs. As between the Parties, GSK shall prepare, file, maintain and own all Regulatory Filings and related submissions with respect to all Licensed Products and shall bear the cost of such preparation, filing, maintenance and ownership.  GSK shall be responsible for all safety reporting obligations globally with respect to all Licensed Products and shall maintain the global safety database for all Licensed Products.  GSK shall be solely responsible for communicating with the FDA and/or any other Regulatory Authority in any country or jurisdiction regarding all Licensed Products.
2.9    Commercialization Responsibilities and Costs.  GSK shall be solely responsible for all commercialization activities relating to Licensed Products, at GSK’s sole cost and expense, and shall have sole decision-making authority with respect to the foregoing.  GSK shall conduct all commercialization activities under this Agreement in compliance with all Applicable Law.  For clarity, nothing in this Agreement shall require GSK to develop or commercialize any minimum number of Licensed Products or limit the number of Licensed Products that GSK may develop or commercialize. 
2.10    Availability for Collaborative Projects; Additional Codexis Libraries.  During the TT Term, [***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 24 -

[***]; provided that the JSC agrees that the performance of such Project Activities by such members of the Codexis Team will not impact negatively the Technology Transfer or any Technology Transfer Project.  
2.11    Party Employees.  Notwithstanding anything to the contrary under this Agreement, under no circumstance would any employee, contractor, contingent worker or consultant of a Party be considered an employee, contractor, contingent worker or consultant of the other Party.  The Party who sends any employee, contractor, contingent worker or consultant to work at the other Party’s premises shall assume all liability for such employees, contractors, contingent workers or consultants working at the other Party’s premises and shall procure  that its employees, contractors, contingent workers or consultants comply with all security, health and safety and other policies applicable to occupiers of the hosting Party’s premises.
3.    LICENSES
3.1    Licenses to Codexis.
3.1.1    GSK Background IP License.  Subject to the terms and conditions of this Agreement, GSK hereby grants to Codexis a worldwide, non-exclusive, non-transferable (except as provided in Section 13.5), fully paid-up, royalty-free right and license, with the right to grant sublicenses solely to Affiliates, under GSK’s Background IP in the GSK Exclusive Field solely as necessary for Codexis to perform its obligations during the Technology Transfer and under each Project as set forth in the written research plan applicable to such Project.  
3.1.2    Arising GSK Enzyme Technology IP and Arising GSK Process Technology IP.  Subject to the terms and conditions of this Agreement, GSK hereby grants to Codexis a worldwide, non-exclusive, non-transferable (except as provided in Section 13.5), fully paid-up, royalty-free right and license, with the right to grant sublicenses through multiple tiers, under the Arising GSK Enzyme Technology IP and the Arising GSK Process Technology IP (in each case, if any) for any use outside of the GSK Exclusive Field; provided that the foregoing license [***] which shall include any GSK Selected Enzyme.  
3.1.3    Embargo License.  If it is determined pursuant to Section 3.1.4(a) that GSK, during the Embargo Period, used Platform Technology in any way with respect to any Enzyme or Enzyme fusion protein within the Codexis Exclusive Field that is claimed in any Patent (whether or not filed during the Embargo Period) that is Controlled by GSK, licensed to GSK by a Third Party or licensed by GSK to a Third Party  and that such Patent claims the composition, manufacture or use of any product or product candidate in the Codexis Exclusive Field that is Controlled by Codexis or, if applicable, an exclusive licensee or 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 25 -

assignee of Codexis with respect to such product or product candidate ( “Patent Claim”), then GSK hereby grants to Codexis or, if applicable, each such exclusive licensee or assignee a worldwide, non-exclusive, non-transferable (except as provided in Section 13.5, fully paid-up, royalty-free right and license, with the right to grant sublicenses only to Affiliates, and collaborators, partners, suppliers or vendors, under each Patent Controlled by GSK that includes a Patent Claim, to develop, make, use, sell, offer for sale, market, import and export such product or product candidate in the Codexis Exclusive Field.
3.1.4    Patent Claims.
(a)    The determination of the existence of a Patent Claim, as described in Section 3.1.3, shall be made by the Patent Committee pursuant to Section 5.2.1, provided, however, that if the Patent Committee is unable to resolve such matter within thirty (30) days (the “Patent Committee Embargo License Period”), then notwithstanding Section 5.2.3 and Article 12, the determination will be made pursuant to Section 3.1.4(b).
(b)    Independent Patent Counsel.  If the Patent Committee cannot make a determination under Section 3.1.4(b), the determination of the existence of a Patent Claim, notwithstanding Article 12, will be made by independent patent counsel in accordance with the following procedure: 
(i)    Selection of Independent Patent Counsel.  The Parties’ representatives on the Patent Committee, within fifteen (15) days after the end of the Patent Committee Embargo License Period, shall mutually agree on, and the Patent Committee shall select, one person to serve as an independent patent counsel.
(ii)    Process.  The Parties may submit evidence and written arguments as deemed necessary by the independent patent counsel; provided, however, that any evidence and arguments shall be submitted within fifteen (15) days or any longer period of time mutually agreed between the Parties after the selection of the independent patent counsel. 
(iii)    Costs and Expenses.  Each Party will share equally the cost and expenses of the independent patent counsel selected in 3.1.4(b)(i).  Each Party shall bear its own costs and expenses and attorneys’ fees in connection with any such determination; provided, however, that the prevailing Party in any such determination shall be entitled to recover from the other Party the reasonable attorneys’ fees, costs and expenses incurred by such prevailing Party in connection with such determination.
(iv)    Binding Decision.  The decision of the independent patent counsel shall be the sole, exclusive and binding decision regarding the determination of the existence of a Patent Claim.  The independent patent counsel shall prepare and deliver to the Parties a written, reasoned opinion conferring its decision.

- 26 -

(c)    After the grant of a second license under Section 3.1.3, GSK will be deemed in material breach of this Agreement, and Codexis shall have a right to terminate this Agreement pursuant to Section 11.2, such termination to be effective immediately upon notice to GSK, notwithstanding the sixty (60) day cure period set forth in such Section 11.2. 
3.2    Licenses to GSK.  
3.2.1    Platform Technology Licenses.  Subject to the terms and conditions of this Agreement (including the restrictions under Section 3.4), Codexis hereby on behalf of itself and its Affiliates, grants to GSK, during the Term, a nontransferable (except as provided in Section 13.5), right and license, with the right to grant sublicenses to Affiliates and Third Parties, in accordance with, and to the extent permitted under, Section 3.3, under the Licensed IP in the Territory, with respect to enzymes, including any enzyme owned or otherwise controlled by GSK under this Agreement or otherwise, to use the Platform Technology (or any aspect of the Platform Technology), which right and license shall be:
(a)    exclusive in the GSK Exclusive Field; and
(b)    non-exclusive otherwise in the Field; 
in each of Sections 3.2.1(a) and 3.2.1(b), solely to research, develop, use, optimize, modify, isolate, engineer, identify, select, make, have made, import and/or export Enzymes, other than any Restricted Enzyme.  
3.2.2    Manufacturing Licenses.  Subject to the terms and conditions of this Agreement (including the restrictions under Section 3.4), Codexis hereby on behalf of itself and its Affiliates grants to GSK, during the Term, a non-transferable (except as provided in Section 13.5) right and license, with the right to grant sublicenses solely to Affiliates, contract manufacturing organizations (CMOs),  contract research organizations (CROs), or other contract service organizations in accordance with and to the extent permitted under Section 3.3 under the Licensed IP in the Territory, solely to make or have made, for the purpose of sale or to have sold:
(a)    Pharmaceutical Products, which shall be exclusive in the GSK Exclusive Field and otherwise non-exclusive in the Field; and
(b)    Enzyme Products, which shall be a non-exclusive license in the Field.  
3.2.3    Loss of Pharmaceutical Product Exclusivity.  The exclusive licenses granted by Codexis to GSK in the GSK Exclusive Field pursuant to Sections 3.2.1, 3.2.2 and 3.5.3 shall become non-exclusive, on a Pharmaceutical Product-by-Pharmaceutical 

- 27 -

Product and country-by-country basis, on the first date that both a first and a second Generic Version of such Pharmaceutical Product is commercially available in such country. 
3.3    Sublicensing.  To the extent that either Party is permitted to grant sublicenses under the licenses granted to it under this Agreement, either Party shall have the right to grant such sublicenses through multiple tiers of sublicensees; provided that:
3.3.1    no sublicense may be granted to any Third Party under Section 3.2.1 [***].  For clarity, nothing in this Section 3.3 shall permit the grant by GSK of any sublicense to any Codexis Enzyme or any Codexis Core Technology (except the specific Codexis Methods listed on Exhibit 3.3.1); 
3.3.2    in relation to the rights under Section 3.3.1, any sublicense agreement between GSK and a Third Party sublicensee relating to the performance of GSK’s obligations or exercise of GSK’s rights under this Agreement shall include material transfer terms, and non-use and non-disclosure confidentiality terms, that are no less stringent than terms consistent with GSK’s ordinary practice involving GSK proprietary materials and information of a similar nature;
3.3.3    any such sublicense is consistent with and subject to the terms of this Agreement and shall terminate automatically upon termination of the corresponding license hereunder; 
3.3.4    each Party, within thirty (30) days after the effective date of any sublicense, shall provide written notice to the other Party of the grant, the date, and the identity of the Third Party of any sublicense to a Third Party; 
3.3.5    each Party shall not be relieved of its obligations pursuant to this Agreement as a result of such sublicense; and
3.3.6    any sublicense granted by GSK shall (a) prohibit the sublicensee from using the Platform Technology for any purpose other than as specified in Section 3.2.1 and Section 3.2.2 and (b) require the sublicensee to destroy all Platform Technology, and all Confidential Information of Codexis, in possession of such sublicensee after completion of the sublicensee’s obligations under such sublicense. 
3.4    Limitations on Licenses.
3.4.1    In-Licensed Patents.  With respect to any aspect of the In-Licensed Patents for which Codexis has less than fully exclusive, worldwide rights (e.g., co-exclusive, non-exclusive, limited territorial or otherwise restricted rights), the licenses provided 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 28 -

in Sections 3.2.1, 3.2.2 and 3.5.3 shall be limited to the scope of those rights that Codexis Controls.
3.4.2    Codexis Mayflower Patents.  Notwithstanding anything set forth in this Article 3, GSK shall have no right under the Codexis Mayflower Patents with respect to:
(a)    the making, having made, using and selling of reagents, instruments and services for the diagnostics and research supply markets, only as follows: (a) clinical and diagnostic tests, including those conducted to identify genetic disease predisposition, genetic or other disease conditions, and infectious or pathogenic agents, as well as those conducted for other medical, agricultural or veterinary purposes; (b) tests for analytical/bioanalytical purposes, including those conducted for biomedical, chemical, or medical research or treatment purposes, for environmental purposes, and for forensic purposes, including paternity, maternity or identity tests; and (c) sequencing and sequence analysis of nucleic acids or other biological polymers for any purposes; but excluding (i) the use of a reagent, other than a nucleic acid array, that specifically binds to selected cells, organs or tissue, and that is sold for medical use in procedures to image selected cells, organs or tissue, which procedure is carried out inside the body of an animal or human, and that requires FDA approval, and (ii) the sale of products and performance of services requiring a license under the In-Licensed Patents, to identify compounds that bind to receptors for use as pharmaceuticals;
(b)    any (i) amino acid (including any natural, synthetic, modified or other amino acid analogue) chain that is a human or humanized protein, or any variant, homology, derivative, mutant or fragment thereof, and (ii) any molecule described in subsection (i) that is conjugated or otherwise coupled to any other molecule, in each of cases (i) and (ii) expressly including (iii)(A) any amino acid (including any natural, synthetic, modified or other amino acid analogue) chain that is a cytotoxic T lymphocyte associated antigen 4 or any variant, homolog, derivative, mutant or fragment thereof, and (B) any molecule described in subsection (iii)(A) that is conjugated or otherwise coupled to any other molecule, and (iv)(A) any amino acid (including any natural, synthetic, modified or other amino acid analogue) chain that is a human or animal protein or any variant, homolog, derivative, mutant or fragment of the foregoing, and (B) any molecule described in subsection (iv)(A) that is conjugated or otherwise coupled to any other molecule, and any pharmaceutical products that contain any of the foregoing as an ingredient; 
(c)    any formulation containing one or more antigens (or a nucleic acid sequence encoding an Antigen) in the form of (a) an infectious agent (e.g., bacteria, viruses, parasite, protozoa) whether live, attenuated or dead, (b) protein(s), (c) nucleic acid(s), (d) cells, spores and vectors (i.e., viruses or virus-like particles, liposomes, beads or other substrates for Antigen presentation), (e) fragments of any of the foregoing, or (f) a combination of any of the preceding, which formulation is administered or is intended to be administered to induce an Antigen-Specific Response in the human or animal recipient to at least one such 

- 29 -

antigen for the prevention of the onset of, or treatment of, a disease state, symptom or condition in humans or animals caused by an infectious agent; where “Antigen” means a molecule (e.g., protein, nucleic acid, polypeptide, peptide, carbohydrate, glycoprotein, glycolipid or any combination of the foregoing) that is produced naturally by, or is derived in whole or in part from, an infectious agent (e.g., bacteria, viruses, parasite, protozoa) that produces an Antigen-Specific Response to such molecule in a human or animal recipient (but excluding any molecule that is derived from, in whole or in part, any human gene or protein); and “Antigen-Specific Response” means an immune state resulting from the modulation of activity (i.e., an increase, decrease or qualitatively different activity) or one or more lymphoid cells (e.g., B cells, NK cells, T cells or professional antigen-presenting cells, such as monocytes, macrophages, Langerhans cells, dendritic cells) following the administration of a stimulus, where such immune state is induced in a human or animal recipient to an Antigen that is specifically directed to the subject Antigen; 
(d)    the development, production and/or sale of any and all polypeptides more than twelve (12) amino acids in length, and the development of organisms and vectors (including without limitation plant vectors and plant hosts) for the expression of such polypeptides, in the areas of (a) processes for textile or garment production, (b) processes for the production of leather, (c) cleaning processes or cleaning products, (d) starch processing, (e) food production processes, (f) animal feed processing, (g) personal care processes, excluding pharmaceutical products and oral, topical and intravaginal medications, (g) the processing of wood, paper, pulp and derived lignin and cellulose, (i) oil drilling, (j) dyestuffs and dyeing processes, (k) electronics industry waste water treatment, (l) detoxification of pesticides, chemical weapons and biological weapons, (m) utilization of industrial waste or co-products to generate energy, compost or industrial raw materials including fermentable substrates for e.g. citric acid production from agricultural waste, (n) polymer production, modification or processing of polymers (tetramers of higher) from monomers (including polymers made by addition of dimers or trimers for reactions proceeding to completion in the same reactor), and the enzymatic modification of chemically synthesized polymers, (o) waste water treatment, sewage sludge treatment or cleanup of contaminated soil, (p) synthesis of fuels including bio-diesel and hydrogen, and (q) bioremediation of water, soil and municipal waste, including without limitation biological waste, sewage and sludge (including without limitation biological waste treatment and cleaning of sewer and drain pipes). 
(e)    any and all human or humanized granulocyte-colony stimulating factor (G-CSF) protein, or any and all variants, derivatives, mutants or fragments thereof, and any and all pharmaceutical products that contain any of the foregoing.
3.4.3    Government Rights.  GSK acknowledges that certain of the inventions claimed in the Codexis Core Technology and/or the Codexis Enzymes and the Intellectual Property rights therein have been made with funds provided by the U.S. government, and that with respect thereto the U.S. government retains a non-exclusive license as set forth in 35 U.S.C. § 202.  In addition, GSK acknowledges that this Agreement is subject 

- 30 -

to all of the terms and conditions of 35 U.S.C. § 200 et seq., which sets forth additional obligations with regard to inventions made with U.S. government funds and products based thereon, including a preference for manufacture in the U.S. pursuant to 35 U.S.C. § 204.
3.4.4    Prohibited GSK Activities.  During the Embargo Period, GSK shall not, and shall cause its Affiliates and permitted sublicensees not to, alone or with a Third Party, on behalf of GSK, its Affiliates or any Third Party, conduct any activities (including, without limitation, any research, drug discovery, development or commercialization activities) in the Codexis Exclusive Field using any Platform Technology; provided that the foregoing restriction shall not apply to the use by GSK of any Platform Technology in connection with the use of an Enzyme or Enzyme fusion protein that is contained within a Licensed Accessory Product in combination with a GSK Compound; and it shall not constitute a breach of this Section 3.4 if GSK generates and/or uses Enzymes solely as research reagents or research tools within the Field.  
3.4.5    No Use for Third Parties.  GSK shall not use, and shall cause its Affiliates and permitted sublicensees not to use, the Platform Technology to engineer, synthesize, manufacture or otherwise develop or produce any Enzymes, molecules, biologic agents, drug products, therapeutic agents or any other compounds for or on behalf of any Third Party and to that Third Party’s order or direction.  [***].  If GSK or any Affiliate exclusively licenses, assigns, divests or otherwise transfers to a Third Party all of GSK’s or such Affiliate’s rights relating specifically to a GSK Compound(s) and/or a Licensed Product(s), and GSK or such Affiliate, at the time of such transfer, uses an Enzyme developed using the Platform Technology to manufacture such GSK Compound(s) and/or a Licensed Product(s), then (A) GSK or its Affiliates may synthesize, manufacture and supply such Enzyme (and no other Enzyme) for and to such Third Party solely to manufacture such GSK Compound(s) and/or a Licensed Product(s), and (B) GSK may grant to such Third Party a limited sublicense under the Platform Technology solely to the extent necessary for such Third Party to make and use such Enzyme (and no other Enzyme) solely in connection with the development, making, use, sale, offer for sale, import and export of such GSK Compound(s) and/or a Licensed Product(s) and products incorporating such GSK Compound(s) and/or a Licensed Product(s), but not to make or use such Enzyme (and no other Enzyme) in connection with any other compounds or products.  Notwithstanding anything to the contrary herein, GSK shall remain responsible for any payments due to Codexis under Article 7 on account of such Enzyme or such GSK Compounds and/or Licensed Products.  For clarity, no payments, other than payments due under Article 7, shall be due to Codexis. 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 31 -

3.4.6    Enzyme Supplier.  [***] would supply to GSK or its Affiliates any Enzymes developed using rights licensed by Codexis to GSK under the terms of this Agreement, [***]. 
3.4.7    Certain Kits and Panels.  In the event that GSK or an Affiliate of GSK desires to have a kit or panel containing any Codexis Materials developed for use by GSK or an Affiliate of GSK which was transferred to GSK pursuant to the Technology Transfer, and such kit or panel is not otherwise available, either through development by GSK or an Affiliate of GSK or commercially through Codexis or a Third Party, GSK, subject to the conditions set forth in Section 3.3, [***] request that Codexis develop such kit or panel, [***] exclusively for use by GSK and Affiliates of GSK.  Codexis shall have no obligation to develop such GSK requested kit or panel but, if Codexis agrees to develop such a kit or panel, [***] subject to other reasonable terms and conditions agreed upon by the Parties for such work by Codexis.  [***]. 
3.5    Codexis Core Technology Improvements Option.
3.5.1    Option Grant.  Subject to the terms and conditions of this Agreement, Codexis hereby grants to GSK an option, exercisable at GSK’s sole discretion in accordance with Section 3.5.2, to acquire the rights described in Section 3.5.3, which option shall be exclusive as to the GSK Exclusive Field (the “Exclusive Option”) and non-exclusive otherwise in the Field (the “Non-Exclusive Option”, together with the Exclusive Option, the “Option”).  
3.5.2    Option Exercise.  At any time during the period beginning on the earlier of the second (2nd) anniversary of the Effective Date and the TT Term Expiration Date, and ending on the date that is three (3) months after the TT Term Expiration Date (an 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 32 -

“Option Period”), GSK may exercise the Option by (a) providing written notice thereof to Codexis and (b) paying the First Annual Option Fee.  If GSK does not exercise the Option prior to the expiration of the Option Period, the Option shall automatically expire and be of no further force or effect. 
3.5.3    Grant of Rights.  Subject to the terms and conditions of this Agreement, effective upon GSK’s exercise of the Option in accordance with Section 3.5.2, Codexis hereby on behalf of itself and its Affiliates grants to GSK a worldwide, non-transferrable (except as permitted under Section 13.5), non-sublicensable (except in accordance with Section 3.2.1 and Section 3.2.2) license, which license shall be exclusive in the GSK Exclusive Field and non-exclusive otherwise in the Field, under all of Codexis’ rights to Codexis Core Technology Improvements practiced by Codexis during the Improvements TT Term.  Codexis shall provide any technology transfer or scientific or technical resources reasonably requested by GSK, and reasonably necessary for GSK, to practice such Codexis Core Technology Improvements, at GSK’s reasonable expense.  During the Improvements TT Term, Codexis’ Alliance Manager will periodically disclose to GSK’s Alliance Manager information regarding new, updated or improved Enzyme kits or panels (as defined in this Section 3.5.3 below) [***].  For purposes of this Section 3.5.3, the term “new, updated or improved Enzyme kits or panels” means a collection of multiple, genetically-diverse Enzymes, Controlled by Codexis, that are first made commercially available to the general public by Codexis through Codexis’ catalog or website.  All information, documents and other materials provided by Codexis to GSK pursuant to this Section 3.5.3 shall constitute Confidential Information of Codexis. 
3.5.4    Extension of the Improvements TT Term.  Upon mutual written agreement of the Parties, and payment by GSK to Codexis of an amount to be mutually agreed in good faith by the Parties, within the sixty (60) day period prior to the then-current Improvements TT Term Expiration Date, the Improvements TT Term Expiration Date may be extended by one (1) year.  The Parties may extend the Improvements TT Term Expiration Date any number of times in accordance with this Section 3.5.4.  
3.6    Third Party Licences.  [***].  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 33 -

3.7    Restricted Enzymes.  
3.7.1    During the Term, in its ordinary course of business, Codexis will conduct research and development activities for Third Parties under the Licensed IP using the Platform Technology and, in connection with such research and development activities, will generate Potentially Restricted Enzymes that, in certain cases, on a Potentially Restricted Enzyme-by- Potentially Restricted Enzyme basis,(a) will be owned by such Third Parties or exclusively licensed by Codexis to such Third Parties and (b) will not be Controlled by Codexis.  For purposes of this Section 3.7.1, the term “Potentially Restricted Enzyme” means any peptide or protein, including derivatives, with enzymatic or biocatalytic activity, or any vector that encodes for any such peptide or protein, derived from the use of the Platform Technology by Codexis after the Effective Date that, in either case, may not be Controlled by Codexis.  In the event that any Potentially Restricted Enzyme generated by Codexis is owned by a Third Party or exclusively licensed by Codexis to a Third Party, Codexis, subject to confidentiality obligations owed by Codexis to such Third Party, will inform the Patent Committee of such Potentially Restricted Enzyme at its next regularly scheduled meeting and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzyme.  The Patent Committee will review information provided by Codexis with respect to any such Potentially Restricted Enzyme and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzymes and, in accordance with Section 5.2.3, determine whether the list of Restricted Enzymes set forth on Exhibit 1.112 shall be revised to include such Potentially Restricted Enzyme and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzyme.  Codexis will provide GSK with the initial list of Restricted Enzymes on Exhibit 1.112 within [***] days after the Effective Date.
3.7.2    In the event that GSK wishes to exercise its rights under Section 3.2 to any Restricted Enzyme for any specific field(s) and/or use(s), it shall notify Codexis in writing of such request.  Codexis shall then have [***] days in which to confirm to GSK in writing whether Codexis Controls such Restricted Enzyme for such specific field(s) and/or use(s) requested by GSK.  In the event that Codexis does Control such Restricted Enzyme for such specific field(s) and/or use(s) then effective upon the date of such written confirmation from Codexis, such Restricted Enzyme shall be an Enzyme for such specific field(s) or use(s) for the purpose of Section 3.2. 
3.8    Responsibility for Freedom to Operate Analyses.  GSK acknowledges and agrees that it is within GSK’s discretion to conduct freedom to operate analyses with respect to the use of any enzyme, other than a Codexis Enzyme, to generate an Enzyme and, in addition, any Enzyme generated in accordance with the terms of the license granted by Codexis to GSK and, whether or not GSK elects to conduct a freedom to operate analysis, GSK will be solely responsible for any such enzyme (other than a Codexis Enzyme) and any such Enzyme. 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 34 -

3.9    Public Domain Information and Material.  Codexis acknowledges and agrees that GSK shall be free to utilize, without restriction, any information or material that is (a) within the Platform Technology and (b) wholly within the public domain.  
3.10    No Implied Licenses.  No license or other right is or shall be created or granted hereunder by implication, estoppel or otherwise.  All licenses and rights are or shall be granted only as expressly provided in this Agreement.  All rights not expressly granted by a Party under this Agreement are reserved by such Party and may be used by such Party for any purpose.  For clarity, there shall be no implied license or implied other right in favor of Codexis to any Enzyme, and there shall be no implied license or implied other right in favor of GSK to any Patent(s) of Codexis or any Know-How of Codexis.  
4.    PROJECTS
4.1    Collaborative Projects.  Beginning on the Effective Date and continuing during the TT Term and if mutually agreed for such period following the TT Term, GSK and Codexis (or Affiliates of GSK and Codexis) shall work on Collaborative Projects pursuant to the terms of written project plans to be mutually agreed by the Parties.  Upon mutual agreement by the Parties, or agreement of the JSC as applicable, if the JSC is then in existence, upon agreement by the Parties of the written research plan for any Collaborative Project, such research plan shall be attached to and made part of this Agreement.  Each such written research plan shall describe each Party’s responsibilities and obligations, and the activities to be performed by each Party, in connection with the applicable Collaborative Project and the frequency and content of any reports to be provided by one Party to the other Party.  Any amendment to a written research plan in respect of a Collaborative Project must be in writing and signed by both GSK and Codexis or approved by the JSC if the JSC is then in existence.  In the event that GSK subsequently decide to resume a terminated Collaborative Project, whether resumed and progressed independently or in further collaboration with Codexis, such project shall continue to be deemed a Collaborative Project for the purposes of Codexis’ eligibility to earn such associated milestone payments in Section 7.4.
4.2    Project Summaries.  During the Term, within thirty (30) days after the end of the Calendar Year ending December 31 or such other date within such Calendar Year as mutually agreed between the Parties, GSK shall disclose to Codexis a summary of [***].  Such summary shall be provided to Codexis in sufficient detail to provide to Codexis reasonable information into GSK activities with respect to GSK’s use of the Platform Technology for the purpose of enabling Codexis to anticipate GSK’s progression toward achievement of milestone events as set forth in Article 7 and to monitor GSK’s compliance with this Agreement.  Each such summary shall include [***] 

- 35 -

[***]; provided that, in the event [***], the information provided by GSK in any such summary report from such time onwards [***].  
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.
4.3    Project Activities.  Each Party shall perform the research activities assigned to such Party under each written research plan in respect of a Collaborative Project and shall perform all such research activities in compliance with all Applicable Law.  Subject to Article 7, each Party shall be solely responsible for all costs and expenses of research activities performed by such Party, unless otherwise specified in the applicable written research plan; provided that, if the Parties agree to perform a Collaborative Project after the expiration of the TT Term, the Parties shall negotiate in good faith and mutually agree upon reasonable compensation from GSK to Codexis for the research activities performed by Codexis in connection with such Collaborative Project. 
4.4    Subcontracting.  
4.4.1    Generally.  Subject to the limitations set forth in Section 4.4.2, GSK may perform any of its obligations or exercise any of its rights under this Agreement through one or more Third Party contractors, contract manufacturing organizations (CMOs), contract research organizations (CROs) or other contract service organizations [***].  Codexis may perform any of its obligations under [***] (as described in the Technology Transfer Plan) and [***] (as described in the Technology Transfer Plan) through one or more Third Party contractors, contract service organizations and academic or government collaborators; provided that the activities corresponding to such obligations were performed through subcontractors in the ordinary course of Codexis’ business as of the Effective Date including, for illustrative purposes, protein analysis, gene and oligonucleotide synthesis and analysis, polynucleotide and polypeptide sequencing, microbiological testing, protein immobilization, and crystallization.  
4.4.2    Limitations.
(a)    GSK may not subcontract any activities to a Third Party that would permit such a Third Party to receive and/or use the Platform Technology;
(b)    Any agreement between GSK and a Third Party contractor relating to the performance of GSK’s obligations or exercise of GSK’s rights under this Agreement shall include material transfer terms, and non-use and non-disclosure confidentiality 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 36 -

terms, that are no less stringent than terms consistent with GSK’s ordinary practice involving GSK proprietary materials and information of a similar nature; and 
(c)    GSK may not subcontract activities to any contract service organization unless Codexis consents to the choice of the contract service organization, such consent not to be unreasonably withheld, conditioned, or delayed. 
4.5    Records.  Each Party shall, and shall require its Affiliates and subcontractors to, maintain complete and accurate records of all research activities under a Project conducted pursuant to a written research plan and Technology Transfer Project Activities and all results, information and data generated in performing such research activities and Technology Transfer Project Activities.  Such records shall be complete and accurate and shall fully and properly reflect all work done and results achieved in sufficient detail and in a manner appropriate for accounting, Patent and regulatory purposes.  
5.    GOVERNANCE
5.1    Joint Steering Committee.
5.1.1    Establishment.  Within thirty (30) days after the Effective Date, the Parties shall establish a joint steering committee (the “Joint Steering Committee” or “JSC”) to have overall responsibility for managing and directing the Projects and to oversee and make certain decisions regarding the Projects, as set forth in this Section 5.1.  The JSC shall also provide a forum for sharing advice, progress and results relating to the activities conducted by the Parties under the Projects and shall attempt to facilitate the resolution of any disputes between the Parties, as described in Section 5.1.4.  At each meeting of the JSC, each Party shall brief the JSC regarding the content, execution and results achieved by such Party under each Project, as described in Section 2.6.  Each Party, through its representatives on the JSC, shall be permitted to provide advice and commentary with respect to the Projects.  The JSC shall have the following specific responsibilities:
(a)    oversee, review and provide advice regarding the overall progress of the Projects;
(b)    coordinate by way of each Party’s Scientific Leads, the research activities under a written research plan relating to a Project agreed by the Parties and coordinate sharing of results and data arising therefrom;
(c)    appoint and oversee subcommittees as it deems appropriate for carrying out activities under this Agreement, including for oversight of any specific aspects of any Projects or other matters;
(d)    review each written research plan and, if appropriate, propose modifications thereto to the Parties; 

- 37 -

(e)    review the Technology Transfer Plan and, if appropriate, propose modifications thereto to the Parties; 
(f)    perform any other activities or functions as the Parties may mutually agree in writing; and
(g)    determine the initiation and termination of Collaborative Projects. 
5.1.2    Membership; Meetings.  The JSC shall be composed of two (2) employees from each of GSK and Codexis and shall meet, in person, by teleconference, or by video-teleconference, at least one (1) time per Calendar Quarter, or more or less often as the Parties shall determine; provided that nothing under this Agreement shall prevent the Parties from meeting in person, by teleconference, or by video-teleconference more frequently as may be mutually agreed by the JSC representatives, in connection with the Technology Transfer. In-person meetings shall alternate between Codexis and GSK locations within the United States whenever possible unless otherwise agreed by the Parties.  The first such meeting shall be within forty-five (45) days after the Effective Date.  Any member of the JSC may designate a substitute, who shall be an employee of the applicable Party, to attend with prior written notice to the other Party.  Ad hoc guests who are subject to written confidentiality obligations at least as stringent as the provisions in Article 9 may be invited to JSC meetings.  Each Party may replace its JSC members with other of its employees, at any time, upon written notice to the other Party.
5.1.3    Project Teams.  The JSC may establish one (1) or more sub-committees (each, a “Project Team”) that includes each Party’s Scientific Leads.  Such Project Team shall have day-to-day oversight of individual Collaborative Projects and/or the Technology Transfer, shall provide primary scientific and technical expertise with respect to such activities and shall regularly and proactively provide updates to the JSC and escalate issues for discussion and resolution, as appropriate.  Any dispute of technical feasibility of any Project that cannot be resolved through good faith negotiation between the members of such Project Team shall be referred for resolution to the JSC.  
5.1.4    Decision-Making; Limitations on JSC.  Except as provided under Section 5.1.6, decisions of the JSC shall be made by consensus, including issues concerning technical feasibility and the deployment of Codexis resources, with each Party having collectively one (1) vote in all decisions.  The JSC shall have only such powers as are specifically delegated to it in this Agreement, and such powers shall be subject to the terms and conditions set forth herein.  Without limiting the generality of the foregoing, the JSC shall have no power to amend this Agreement or the Technology Transfer Plan.  The Parties shall be alternately responsible for preparing and circulating minutes, for approval by the non-preparing Party, within fourteen (14) days after each meeting including but not limited to a list of topics of discussion at the meeting and a list of any actions, decisions or determinations approved and a list of any issues and actions to be resolved.  If the JSC is unable to reach a consensus decision 

- 38 -

on a matter that is within its decision-making authority within thirty (30) days after it has met and attempted to reach such decision, then either Party may refer such matter for resolution by the executive officers designated by the Parties for attempted resolution pursuant to Section 12.1.  In the event that the executive officers are unable to resolve such matter within the time period specified in Section 12.1, then in the case of any decision relating to the conduct of a Collaborative Project, such Collaborative Project shall immediately terminate.  Any matter not expressly provided for hereunder and any matter relating to any GSK Background IP, GSK Compound, Licensed Product, Platform Technology, Licensed IP, or Codexis Background IP shall remain outside of the scope of the JSC.  
5.1.5    Duration of JSC.  The JSC shall be automatically disbanded upon the expiration of the TT Term or the earlier expiration or termination of this Agreement; provided that the Parties may, by mutual written agreement, extend the term of the JSC for additional one (1) year periods after the expiration of the TT Term, with a separate mutual written agreement required for each such one (1) year extension.
5.1.6    Matters Reserved for GSK.  Notwithstanding anything contained in this Section 5.1, GSK shall determine in its sole discretion, decisions in connection with the following matters:
(a)    Collaborative Project selection and termination;
(b)    GSK Sole Projects;
(c)    Selection and use of any GSK Selected Enzyme; and
(d)    [***].
5.2    Patent Committee.  
5.2.1    Establishment.  Within sixty (60) days after the Effective Date, the Parties shall establish a Patent committee (the “Patent Committee”) to discuss, oversee and coordinate the Prosecution (or abandonment) of Patents, enforcement of Patents, and defense against claims of infringement of Third Party patents relating to Intellectual Property licensed under Article 3, Sections 2.2.9 and 2.2.10, including for example Codexis Core Technology Improvements IP, Arising Codexis Enzyme Technology IP, Arising Codexis Process Technology IP, Arising GSK Enzyme Technology IP and Arising GSK Process Technology IP, and any related Intellectual Property matters regarding any Inventions made during the Term, including for example, the Licensed Additional Codexis IP; and to provide recommendations to the Parties regarding the Prosecution of such Patents and related Intellectual Property matters. Within thirty (30) days after the end of each half year, each Party shall provide the Patent Committee with a report listing all Patents relating to such Parties’ utilization of the Platform Technology filed by that Party during that half year. 
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 39 -

5.2.2    Membership; Meetings.  The Patent Committee shall be composed of one (1) employee from each of GSK and Codexis knowledgeable in U.S. patent law and the technology areas that are the subject of this Agreement. The Patent Committee shall meet, in person, by teleconference, or by video-teleconference, at least one (1) time per Calendar Quarter, or more or less often as the Parties shall determine.  In-person meetings shall alternate between Codexis and GSK locations within the United States whenever possible unless otherwise agreed by the Parties.  The first such meeting shall be within ninety (90) days after the Effective Date.  Any member of the Patent Committee may designate a substitute, who shall be an employee of the applicable Party, to attend with prior written notice to the other Party.  Ad hoc guests who are subject to written confidentiality obligations at least as stringent as the provisions in Article 9 may be invited to Patent Committee meetings.  Each Party may replace its Patent Committee members with other of its employees with the qualifications set forth in this Section 5.2.2, at any time, upon written notice to the other Party.  
5.2.3    Decision-Making; Limitations on Patent Committee.  Decisions of the Patent Committee shall be made by consensus, with each Party having collectively one (1) vote in all decisions.  The Patent Committee shall have only such powers as are specifically delegated to it in this Agreement, and such powers shall be subject to the terms and conditions set forth herein.  Without limiting the generality of the foregoing, the Patent Committee shall have no power to amend this Agreement, the Technology Transfer Plan or any written research plan.  If the Patent Committee is unable to reach a consensus decision on a matter that is within its decision-making authority within thirty (30) days after it has met and attempted to reach such decision, then either Party may refer such matter for resolution by the executive officers designated by the Parties for attempted resolution pursuant to Section 12.1.  In the event that the executive officers of each Party are unable to resolve such matter within the time period specified in Section 12.1, then Codexis shall have final decision-making authority with respect to any dispute relating specifically to Restricted Enzymes and Codexis Patents and GSK shall have final decision-making authority with respect to any dispute relating specifically to GSK Patents.  The Patent Committee shall provide status updates to the JSC once per Calendar Quarter as long as the JSC is in existence and, thereafter, to the Parties. 
5.2.4    Duration of Patent Committee.  The Patent Committee shall endure beyond the expiration of the TT Term and shall automatically renew on a year-to-year basis.  Notwithstanding the aforementioned, the Patent Committee may be disbanded at any time upon mutual written agreement of the Parties.  
6.    INTELLECTUAL PROPERTY
6.1    Background Rights.  Each Party shall retain all right, title and interest to its Background IP, and, except as expressly set forth in this Agreement, no right or license to such Patents, Know-How and other Intellectual Property rights is granted by either Party to the other Party.  

- 40 -

6.2    Ownership of Inventions.  
6.2.1    Generally.  Inventorship of Inventions shall be determined by application of U.S. patent laws.  Subject to Sections 6.2.2, 6.2.3 and 6.2.4, all patentable Inventions invented solely by or on behalf of either Party or jointly by or on behalf of both Parties under this Agreement, including without limitation in the performance of any responsibilities under a written research plan relating to a Project, and all Intellectual Property rights therein, shall be owned in accordance with inventorship.  
6.2.2    Codexis Core Technology Improvements IP.  Codexis shall own any and all Codexis Core Technology Improvements and Codexis Core Technology Improvements IP arising during the TT Term and, if GSK exercises the Option, during the Improvements TT Term.  GSK hereby assigns to Codexis all of GSK’s right, title and interest in and to the Codexis Core Technology Improvements IP.
6.2.3    Arising Enzyme Technology IP.  GSK shall own any and all Arising GSK Enzyme Technology, Arising GSK Enzyme Technology IP, Arising Codexis Enzyme Technology and Arising Codexis Enzyme Technology IP arising during the TT Term and, if GSK exercises the Option, during the Improvements TT Term.  Codexis hereby assigns to GSK all of Codexis’ right, title and interest in and to the Arising Codexis Enzyme Technology Improvements IP. 
6.2.4    Arising Process Technology IP.  GSK shall own any and all Arising GSK Process Technology, Arising GSK Process Technology IP, Arising Codexis Process Technology and Arising Codexis Process Technology IP arising during the TT Term and, if GSK exercises the Option, during the Improvements TT Term.  Codexis hereby assigns to GSK all of Codexis’ right, title and interest in and to the Arising Codexis Process Technology IP.
6.2.5    Ownership of Enzymes.  GSK shall exclusively own all Enzymes derived from GSK’s use of the Platform Technology pursuant to this Agreement.
6.3    Further Assurances.  Each Party and its Affiliates shall sign and deliver to the other Party all writings and do all such things as may be necessary or appropriate to vest in such other Party all right, title and interest in and to all Codexis Core Technology Improvements IP, Arising Enzyme Technology IP and Arising Process Technology IP in accordance with Section 6.2.  
6.4    Employees and Agents.  Each Party shall ensure that all employees, agents, consultants, contractors and subcontractors (as permitted under Section 4.4) performing activities under or contemplated by this Agreement, have assigned or are obligated to assign their interest in any Invention invented in the course of such activities to the Party for which such employee, agent, consultant, contractor or subcontractor is providing its services.  
6.5    Prosecution of Patents.  

- 41 -

6.5.1    In General.  The Patent Committee shall have oversight regarding the Prosecution of Patents disclosing and/or claiming Inventions directly related to Codexis Core Technology Improvements, Arising GSK Enzyme Technology, Arising GSK Process Technology, Arising Codexis Enzyme Technology and Arising Codexis Process Technology and shall provide recommendations to the Parties to maximize the value of such Patents.  To the extent necessary, the Parties agree to cooperate in good faith to coordinate the Prosecution of such Patents, including submissions of Patent applications worldwide (e.g., to coordinate the filing of Patent applications to ensure that the Parties file related applications on the same day).  The Parties shall agree in good faith on a strategy with respect to Prosecution of any Patents disclosing and/or claiming any jointly-owned Inventions.
6.5.2    Codexis Prosecution.  As between the Parties, Codexis shall have the sole right, but not the obligation, to Prosecute all Patents disclosing and/or claiming all Codexis Core Technology, Codexis Core Technology Improvements, Codexis Enzymes and Codexis Libraries (the “Codexis Patents”), in Codexis’ sole discretion and at Codexis’ sole cost and expense. 
6.5.3    GSK Prosecution.  As between the Parties, GSK shall have the sole right, but not the obligation, to Prosecute all Patents disclosing and/or claiming all Arising GSK Enzyme Technology, Arising GSK Process Technology, Arising Codexis Enzyme Technology, and Arising Codexis Process Technology (collectively, the “GSK Patents”), in GSK’s sole discretion and at GSK’s sole cost and expense. 
6.5.4    Back-Up Rights.  If GSK decides not to Prosecute, or not to continue Prosecuting, any GSK Patent, GSK shall provide Codexis with written notice of such decision at least forty-five (45) days prior to the date upon which the subject matter of such GSK Patent shall lapse or become abandoned.  The basis for such decision shall be discussed by the Patent Committee pursuant to Section 5.2 and Codexis shall thereupon have the right (but not the obligation) to assume responsibility for Prosecution of such GSK Patent at Codexis’ expense, and with counsel of Codexis’ choosing, except (a) any GSK Patent covering any Licensed Product; and (b) any GSK Patent relating to any GSK Compound, any GSK Existing Pharmaceutical Product, any GSK Initial Enzyme, and/or any GSK Selected Enzyme.  Effective upon the date Codexis assumes responsibility for Prosecution of such GSK Patent, and the costs and expenses relating thereto, GSK hereby assigns any and all interest held by GSK in, to and under such GSK Patent to Codexis.  
6.5.5    CREATE Act.  Each Party acknowledges and agrees that this Agreement is a “joint research agreement” as contemplated by 35 U.S.C. § 102(c), and that all inventions arising under any Collaborative Projects hereunder are intended to have the benefit of the rights and protections conferred by the Cooperative Research and Enhancement Act of 2004 (CREATE Act). Each Party agrees to disclose the names of both Parties in each Patent application for all inventions arising under all Collaborative Projects in accordance with the requirements of 35 U.S.C. § 102(c)(3).

- 42 -

6.6    Enforcement of Patents.  
6.6.1    Notice.  If either Party becomes aware of any suspected infringement of any GSK Patent or Codexis Patent, or any GSK Patent or Codexis Patent is challenged in any action or proceeding (any of the foregoing, an “Infringement Action”), such Party shall notify the other Party’s representative on the Patent Committee, and following such notification, the Parties shall confer.  
6.6.2    Enforcement.  As between the Parties, GSK will have the first right, but not the obligation, to bring any Infringement Action with respect to any GSK Patent at its sole cost and expense, and Codexis shall have the sole right, but not the obligation, to bring any Infringement Action with respect to any Codexis Patent at its sole cost and expense.  
6.6.3    Procedure for Enforcement.
(a)    The non-enforcing Party pursuant to Section 6.6.2 shall reasonably assist the enforcing Party (at the enforcing Party’s expense) in any Infringement Action if so requested, such assistance to be coordinated through the Parties' Patent Committee members, and the non-enforcing Party shall lend its name and be joined as a party plaintiff to such action if reasonably requested by such enforcing Party or required by Applicable Law.  The non-enforcing Party shall have the right to participate and be represented in any such action by its own counsel at its own expense.  The non-enforcing Party shall cooperate, at the enforcing Party’s cost and expense, with the enforcing Party in investigating or terminating any suspected infringement, whether through legal action, negotiation or otherwise, including by producing all reasonably pertinent records, papers, information, samples, specimens and similar items, and directing its employees to testify and grant interviews, upon the request of the enforcing Party.  The enforcing Party will keep the non-enforcing Party reasonably informed of the status of the action through the enforcing Party’s Patent Committee members.  
(b)    A settlement, consent judgment or other voluntary final disposition of a suit under this Section 6.6.3 may be entered into by the enforcing Party without the consent of the non-enforcing Party; provided that any such settlement, consent judgment or other disposition of any action or proceeding by an enforcing Party under this Article 6 shall not, without the consent of the non-enforcing Party (not to be unreasonably withheld), (a) impose any liability or obligation on the non-enforcing Party, (b) include the grant of any license, covenant or other rights to any Third Party that would conflict with or reduce the scope of the subject matter included under the licenses granted to the non-enforcing Party under this Agreement, (c) conflict with or reduce the scope of the subject matter claimed in any Patent owned by the non-enforcing Party, or (d) adversely affect the interest of the non-enforcing Party in any material respect.  
6.6.4    Damages.  In the event that a Party exercises the rights conferred in this Section 6.6, and such Party recovers any damages or other sums in such action or in 

- 43 -

settlement thereof, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by the Parties in connection therewith, including attorneys’ fees.  If such recovery is insufficient to cover all such costs and expenses of both Parties, it shall be shared in proportion to the total of such costs and expenses incurred by each Party.  If, after such reimbursement of the Parties’ cost and expenses, any funds shall remain from such damages or other sums recovered, such remaining funds shall be retained by the prosecuting Party. 
6.7    Defense Against Claims of Infringement of Third Party Patents.
6.7.1    Claims of Infringement Relating to Enzyme Products.  If a Third Party asserts, or either Party becomes aware of a Third Party’s intention to assert, that a Patent owned or otherwise controlled by the Third Party is infringed by the manufacture, use, sale, offer for sale, import or export of an Enzyme Product in the Territory, the Party first obtaining knowledge of such a claim shall immediately provide the other Party written notice of such claim along with the related facts in reasonable detail.  In such event, unless the Parties otherwise agree, as between the Parties GSK shall have the first right, but not the obligation, at its expense, to control the defense of such claim with respect to such Enzyme Product.  Each Party shall cooperate with the defending Party, at the defending Party’s reasonable request and expense, such cooperation to be coordinated through the Parties' Patent Committee members, and the defending Party shall have the right to be represented separately by counsel of its own choice, but at its own expense.  The defending Party shall also control settlement of such claim; provided, however, that no settlement shall be entered into without the prior consent of the other Party if such settlement would adversely affect the rights and benefits of, or impose or adversely affect any obligations on, the other Party, such consent not to be unreasonably withheld.
6.7.2    Claims of Infringement Relating to Licensed Rights.  If a Third Party asserts, or either Party becomes aware of a Third Party’s intention to assert, that a Patent owned or otherwise controlled by the Third Party is infringed by the exercise by GSK or its Affiliates of any rights licensed to GSK hereunder (other than by the manufacture, use, sale, offer for sale, import or export of an Enzyme Product in the Territory), the Party first obtaining knowledge of such a claim shall immediately provide the other Party notice of such claim along with the related facts in reasonable detail.  In such event, as between the Parties Codexis shall have the sole right, but not the obligation, at its expense, to control the defense of such claim.  GSK shall cooperate with Codexis, at Codexis’ reasonable request and expense, such cooperation to be coordinated through GSK’s Patent Committee members, and GSK shall have the right to be represented separately by counsel of its own choice, but at its own expense.  Codexis shall also control settlement of such claim; provided, however, that no settlement shall be entered into without the prior consent of GSK if such settlement would adversely affect the rights and benefits of, or impose or adversely affect any obligations on, GSK, such consent not to be unreasonably withheld. 
7.    FINANCIAL TERMS

- 44 -

7.1    Upfront Payment.  In consideration, along with Section 7.3, of the Technology Transfer under this Agreement within [***] Business Days after receiving an Invoice from Codexis, after the Effective Date, GSK shall pay to Codexis a non-creditable, non-refundable upfront payment of six million Dollars ($6,000,000) (the “Upfront Payment”).
7.2    Annual Option Fee.  In consideration of the licenses granted by Codexis to GSK under Section 3.5.3, upon GSK’s exercise of the Option, as set forth in Section 3.5.2, GSK shall pay, after GSK receipt of an Invoice from Codexis, to Codexis a non-creditable, non-refundable payment of one million Dollars ($1,000,000) (the “First Annual Option Fee”).  On each of the first (1st) and second (2nd) anniversaries of the TT Term Expiration Date, GSK shall pay to Codexis,  after GSK receipt of an Invoice from Codexis, an additional non-creditable, non-refundable payment of one million Dollars ($1,000,000) (each such payment and the First Annual Option Fee, an “Annual Option Fee”); provided that GSK’s failure to timely pay any Annual Option Fee during the Improvements TT Term shall not constitute a breach of this Agreement, but instead shall cause the Improvements TT Term to immediately terminate without opportunity to cure. 
7.3    Technology Transfer Milestones.  In consideration for the Technology Transfer, GSK shall pay to Codexis, after GSK receipt of an Invoice from Codexis, each of the milestone payments set forth in this Section 7.3 upon achievement of the applicable milestone event.  Such milestone payments shall be non-creditable and non-refundable. 
	
		
	Technology Transfer Milestone Event
	Milestone Payment

	Completion of Wave 1 including delivery of all deliverables therefor specified in the Technology Transfer Plan.
	$5,000,000

	Completion of Wave 2, including delivery of all deliverables therefor specified in the Technology Transfer Plan.
	$6,500,000

	The earlier to occur of the event described in (a) Section 1.120(a) or (b) Section 1.120(c).
	$7,500,000

7.4    Collaborative Project Milestones.  GSK shall pay to Codexis, after GSK receipt of an Invoice from Codexis,  each of the milestone payments set forth in this Section 7.4 upon achievement of the applicable milestone event with respect to a Licensed Collaborative Project GSK Selected Enzyme (or the associated Pharmaceutical Product, as applicable).  Each milestone achieved with respect to an associated Pharmaceutical Product shall be paid on a Pharmaceutical Product-by-Pharmaceutical Product basis. Each milestone payment will be made for each Licensed Collaborative Project GSK Selected Enzyme (or the associated Pharmaceutical 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 45 -

Product as applicable) that achieves the applicable milestone event, regardless of the number of Collaborative Projects that achieve each such milestone event. For clarity, each milestone payment will be made only once with respect to each Licensed Collaborative Project GSK Selected Enzyme (or the associated Pharmaceutical Product, as applicable).  Such milestone payments shall be non-creditable and non-refundable.  Notwithstanding the foregoing, no milestone payments shall be owed by GSK to Codexis under this Section 7.4 with respect to any GSK Sole Project or any Enzyme Product.
	
		
	Collaborative Project Milestone Event
	Milestone Payment

	Initiation of [***] of the Licensed Collaborative Project GSK Selected Enzyme used in the synthesis of a GSK Compound for [***].
	$[***]

	Initiation of [***] of the Licensed Collaborative Project GSK Selected Enzyme used in the synthesis of a GSK Compound for [***] of a Pharmaceutical Product.
	$[***]

	[***] of a Pharmaceutical Product in [***].
	$[***]

	First time annual Net Sales of a Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])
	$[***]

	First time annual Net Sales of a Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])
	$[***]

	First time annual Net Sales of a Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])
	$[***]

7.5    GSK Sole Project Milestones.  GSK shall pay to Codexis after GSK receipt of an Invoice from Codexis, each of the milestone payments set forth in this Section 7.5 upon achievement of the applicable milestone event with respect to a Licensed GSK Sole Project GSK Selected Enzyme (or the associated Pharmaceutical Product, as applicable).  Each milestone achieved with respect to an associated Pharmaceutical Product shall be paid on a Pharmaceutical Product-by-Pharmaceutical Product basis. Each milestone payment will be made for each GSK Sole Project GSK Selected Enzyme (or the associated Pharmaceutical Product, as 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 46 -

applicable), that achieves the applicable milestone event; provided that each milestone payment shall be made no more than two (2) times, on the first two (2) achievements of the applicable milestone event, regardless of the number of GSK Sole Projects that achieve such milestone event.  For clarity, each milestone payment will be made only once with respect to each GSK Sole Project GSK Selected Enzyme (or the associated Pharmaceutical Product, as applicable).  Such milestone payments shall be non-creditable and non-refundable.  Notwithstanding anything to the contrary, no milestone payments shall be owed by GSK to Codexis under this Section 7.5 with respect to any GSK Collaborative Project or Enzyme Product.
	
		
	GSK Sole Project Milestone Event
	Milestone Payment

	Initiation of [***] of the Licensed GSK Sole Project GSK Selected Enzyme for use in synthesis of a GSK Compound for [***] of a Pharmaceutical Product.
	$[***]

	[***] of a Pharmaceutical Product in [***].
	$[***]

	First time annual Net Sales of Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])
	$[***]

	First time annual Net Sales of Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])
	$[***]

	First time annual Net Sales of Pharmaceutical Product in the Territory achieve [***] Dollars ($[***])
	$[***]

7.6    GSK Existing Pharmaceutical Product Milestones.  GSK shall pay to Codexis after GSK receipt of an Invoice from Codexis, each of the milestone payments set forth in this Section 7.6 upon achievement of the applicable milestone event with respect to a GSK Existing Pharmaceutical Product (or the Licensed (GSK Sole or Collaborative, as the case may be) Project GSK Selected Enzyme used in the synthesis of such GSK Existing Pharmaceutical Product, as applicable). Each milestone achieved with respect to an associated Pharmaceutical Product shall be paid on a Pharmaceutical Product-by-Pharmaceutical Product basis. For a GSK Existing Pharmaceutical Product that is the subject of a GSK Sole Project, each milestone payment will be made for each GSK Existing Pharmaceutical Product (or Licensed GSK Sole Project GSK Selected Enzyme used in the synthesis of such GSK Existing Pharmaceutical 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 47 -

Product, as applicable) that achieves the applicable milestone event; provided that with respect to all GSK Sole Projects described in BOTH Sections 7.5 and 7.6, each milestone payment shall be made no more than three (3) times, on the first three (3) achievements of the applicable milestone event, regardless of the number of GSK Sole Projects. By way of example, if milestones were paid twice for any milestone event per Section 7.5, there would remain one additional opportunity for the equivalent milestone event to be earned by Codexis in Section 7.6. For a GSK Existing Pharmaceutical Product that is the subject of a Collaborative Project, each milestone payment will be made for each GSK Existing Pharmaceutical Product (or Licensed Collaborative Project GSK Selected Enzyme used in the synthesis of such GSK Existing Pharmaceutical Product, as applicable) with respect to Collaborative Projects that achieves the applicable milestone event, regardless of the number of GSK Existing Pharmaceutical Products (or Licensed GSK Collaborative Project GSK Selected Enzyme used in the synthesis of such GSK Existing Pharmaceutical Product, as applicable) with respect to Collaborative Projects that achieve each such milestone event.  For clarity, each milestone payment will be made only once with respect to each GSK Existing Pharmaceutical Product (or Licensed Collaborative Project GSK Selected Enzyme used in the synthesis of such GSK Existing Pharmaceutical Product, as applicable). Such milestone payments shall be non-creditable and non-refundable.  
	
			
	GSK Existing Pharmaceutical Product Milestone Event
	Milestone Payment for Collaborative Project
	Milestone Payment for GSK Sole Project

	Initiation of a Project following selection of an Initial Enzyme for Initial Enzyme Optimization.
	$[***]
	$[***]

	Initiation of [***] of the GSK Selected Enzyme used in the synthesis of a GSK Existing Pharmaceutical Product for [***] of a Pharmaceutical Product.
	$[***]
	$[***]

	[***] of a GSK Existing Pharmaceutical Product synthesized using a GSK Selected Enzyme in [***].
	$[***]
	$[***]

	First time annual Net Sales of a GSK Existing Pharmaceutical Product synthesized using a GSK Selected Enzyme in the Territory achieve [***] Dollars ($[***])
	$[***]
	$[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 48 -

7.7    Enzyme Product Milestones. GSK shall pay to Codexis, after GSK receipt of an Invoice from Codexis, each of the milestone payments set forth in this Section 7.7 upon achievement of the applicable milestone event with respect to an Enzyme Product.  Each milestone payment will be made on an Enzyme Product-by-Enzyme Product basis; provided that with respect to each of Enzyme Products listed in Column 2 and Column 3s, each milestone payment shall be made no more than two (2) times with respect Enzyme Products listed in Column 2 and no more than two (2) times with respect to Enzyme Products listed in Column 3, on the first two (2) achievements of the applicable milestone event with respect to Enzyme Products listed in Column 2 and the first two (2) achievements of the applicable milestone event with respect to Enzyme Products listed in Column 3, regardless of the number of Enzyme Products listed in Column 2 and Column 3 that achieve such milestone event.  Each milestone payment will be made for each Licensed Enzyme Therapeutic Product listed in Column 1 that achieves the applicable milestone event, regardless of the number of Licensed Enzyme Therapeutic Products that achieve each such milestone event.  For clarity, each milestone payment will be made only once with respect to each Enzyme Product.  Such milestone payments shall be non-creditable and non-refundable.  
	
				
	Enzyme Product Milestone Event
	Column 1
Milestone Payment for Licensed Enzyme Therapeutic Products
	Column 2
Milestone Payment for Licensed Prophylactic Products, Licensed Other Therapeutic Products and Licensed Accessory Products
	Column 3
Milestone Payment for Licensed Diagnostic Products

	Demonstration of [***] for an Enzyme Product.
	$[***]
	$[***]
	$[***]

	[***] of an Enzyme Product in [***].
	$[***]
	$[***]
	$[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 49 -

	
				
	First time annual Net Sales of an Enzyme Product in the Territory achieve [***] Dollars ($[***])
	$[***]
	$[***]
	$[***]

	First time annual Net Sales of an Enzyme Product in the Territory achieve [***] Dollars ($[***])
	$[***]
	$[***]
	$[***]

	First time annual Net Sales of an Enzyme Product in the Territory achieve [***] Dollars ($[***])
	$[***]
	$[***]
	$[***]

	First time annual Net Sales of an Enzyme Product in the Territory achieve [***] Dollars ($[***])
	$[***]
	$[***]
	$[***]

7.8    Manner of Milestone Payments and Other Payments.  GSK shall notify Codexis in writing of the achievement of any milestone event under Sections 7.3 - 7.7  as applicable, within [***] days after its achievement.  Each such milestone event together with the First Annual Option Fee and any Annual Option Fee and all other payments agreed under this Agreement shall be made within [***] days after receipt of an Invoice from Codexis. 
7.9    Royalties. GSK, on an Enzyme Product-by-Enzyme Product and country-by-country basis, shall pay to Codexis royalties based upon the total quarterly Net Sales in the Territory, during a Calendar Quarter in which such Enzyme Product is sold, during the Royalty Term, at a rate equal to [***] percent ([***]%) of Net Sales of Licensed Enzyme Therapeutic Products in Column 1, [***] percent ([***]%) of Net Sales of Enzyme Products listed in Column 2 of the table in Section 7.7  and [***] percent ([***]%) of Net Sales of Enzyme Products listed in Column 3 (collectively, “Royalties”).  With respect to Enzyme Products listed in Column 2 and Column 3 of the table in Section 7.7, Royalties will be due only with respect to the first two (2) Enzyme Products listed in Column 2 and the first two (2) Enzyme Products listed in Column 3 of the table in Section 7.7 to achieve First Commercial Sale, regardless of the number of Enzyme Products listed in Column 2 and Column 3 of the table in Section 7.7 that are commercialized by or on behalf of GSK.  Royalties will be due with respect to all Licensed Enzyme Therapeutic Products in Column 1 of the table in Section 7.7 that achieve First Commercial Sale, regardless 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 50 -

of the number of Licensed Enzyme Therapeutic Products that are commercialized by or on behalf of GSK. 
7.10    Royalty Payment Reports.  After the First Commercial Sale of an Enzyme Product that is subject to the payment of Royalties in accordance with Section 7.9, and for the Royalty Term for such Product, GSK shall furnish to Codexis a written report, within [***] days after the end of each Calendar Quarter (or portion thereof if this Agreement terminates during a Calendar Quarter), showing the amount of Royalties due for such Calendar Quarter (or portion thereof) pursuant to Section 7.9.  Royalty payments for each Calendar Quarter shall be due at the same time as such written report for the Calendar Quarter.  With each quarterly payment, GSK shall deliver to Codexis a full and accurate accounting to include at least the following information:  
(a)    the Net Sales on an Enzyme Product-by-Enzyme Product and country-by-country basis in the reporting currency in which sales were made and in Dollars after the application of the exchange rate during the reporting period as reported in Section 7.10(c);
(b)    the Royalties payable in Dollars which shall have accrued hereunder in respect of such Net Sales and the basis for calculating such Royalties;
(c)    the exchange rates used in converting into Dollars, from the currencies in which sales were made; 
(d)    dispositions of Enzyme Products other than pursuant to sale for cash for which a royalty is due; and 
(e)    withholding taxes, if any, required by Applicable Law to be deducted in respect of such Royalties. 
7.11    Applicability of Milestones and Royalties.  All milestone payments and Royalties set forth in Sections 7.3 through 7.9, inclusive, shall be made during the Term and, after expiration or termination of this Agreement, with respect to all applicable Pharmaceutical Products or Enzyme Products, regardless of whether the applicable Project was initiated during or after the TT Term, or before or after the effective date of expiration or termination of this Agreement; provided that the applicable Project is initiated or, in the case of an Enzyme Product, any Enzyme is generated using the Platform Technology, in either case, prior to the [***] of (a) the date of expiration of the last-to-expire Patent within the Codexis Core Technology licensed to GSK under this Agreement and (b) the date that is [***] years after the Effective Date.
7.12    Manner of Payment.  All payments to be made by GSK to Codexis hereunder shall be made in Dollars by wire transfer of immediately available funds to such U.S. bank account as shall be designated by Codexis; provided, however, that any notice by Codexis 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 51 -

of a change in such account shall not be effective until [***] days after receipt thereof by GSK.  Late payments shall bear interest at the rate provided in Section 7.16.
7.13    Records Retention.  Commencing with the First Commercial Sale of a Product, GSK shall keep, and shall cause each of its Affiliates and permitted sublicensees to keep, full and accurate books of accounting in accordance with IFRS, containing all particulars that may be necessary for the purpose of calculating all Royalties payable to Codexis under this Article 7, for a period of [***] years after the Calendar Year in which such sales occurred, in sufficient detail to permit Codexis to confirm the accuracy of Royalties paid hereunder.  Such books of accounting, including those of GSK’s Affiliates and Sublicensees, shall be kept at the GSK site where such records are stored in the normal course of GSK’s business.
7.14    Audit Rights.
7.14.1    Technical Audit Right.  If Codexis has a reasonable basis for believing that a product sold by or on behalf of GSK for which GSK has not paid any milestone payments or Royalties under Sections 7.4 through 7.9, inclusive, constitutes a Licensed Product for which such milestone payments and/or Royalties may be payable, Codexis may notify GSK of its belief in writing.  GSK shall allow a designee chosen by Codexis and reasonably acceptable to GSK to review such reasonable documentation and other reasonable materials of GSK as is necessary for such designee to determine whether such product constitutes a Licensed Product.  Results of such investigation shall be made available to both GSK and Codexis; provided that such designee shall disclose to Codexis only its determination of whether the product constitutes a Licensed Product and shall disclose no other information revealed in such investigation to Codexis.  Any materials examined by such designee shall be deemed GSK’s Confidential Information, which may not be disclosed by such designee to any Third Party.  GSK may require such designee to enter into an appropriate written agreement obligating it to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations set forth in Article 9.  If, as a result of any such investigation, such designee determines that such product constitutes a Licensed Product, then GSK shall (a) make all payments required to be made to Codexis under Sections 7.4 through 7.9, inclusive, with respect to such Licensed Product for achievement of milestones and/or Net Sales that occurred prior to the date the Parties receive such results, within [***] days after such date, and shall be responsible for any such payments with respect to such Licensed Product thereafter, (b) pay interest on all late payments in accordance with Section 7.16 and (c) pay Codexis’ reasonable out-of-pocket costs of the investigation.  
7.14.2    Financial Audit Right.  During the Term and for a period of [***] years thereafter, GSK shall permit an independent, certified public accountant appointed by Codexis, and reasonably acceptable to GSK, during normal business hours and upon [***] days prior written notice, but in no case more than [***] per Calendar Year, to examine (but not copy) such records as may be necessary for the sole purpose of verifying the calculation and reporting of Net Sales and milestone payments and the correctness of any 
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 52 -

payment made under this Agreement for any period within the preceding [***] years.  The report of the independent public accountant shall be shared with GSK prior to distribution to Codexis such that GSK can provide the independent, certified public accountant with justifying remarks for inclusion in the report prior to sharing the conclusions of such report with Codexis.  Results of any such examination shall be made available to both GSK and Codexis.  The independent, certified public accountant shall disclose to Codexis only the amounts that the independent auditor believes to be due and payable hereunder to Codexis and details concerning any discrepancy from the amount paid and the amount due, and shall disclose no other information revealed in such audit.  Any and all records examined by such independent accountant shall be deemed GSK’s Confidential Information, which may not be disclosed by said independent, certified public accountant to any Third Party.  GSK may require such independent accountant to enter into an appropriate written agreement obligating it to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations set forth in Article 9.  If, as a result of any inspection of the books and records of GSK, it is shown that payments under this Agreement were less than the amount that should have been paid, then GSK shall make all payments required to be made to Codexis to eliminate any discrepancy revealed by such inspection within [***] days.  Codexis shall pay for such audits, except that in the event that the audited amounts were underpaid by GSK by more than [***] of the undisputed amounts that should have been paid during the period in question as per the audit, GSK shall pay Codexis’ out-of-pocket costs of the audit and pay interest on all late payments in accordance with Section 7.16.  In the event that the audited amounts were overpaid by GSK, GSK shall withhold such overpayment from future Royalties or milestone payments.
7.14.3    In the event that GSK is determined, as a consequence of an audit conducted by Codexis pursuant to either Section 7.14.1 or Section 7.14.2, as applicable, to have:
(a)    not paid to Codexis any milestone payments or Royalties with respect to a Licensed Product for which milestone payments and/or Royalties are payable; or
(b)    underpaid any amounts by more than [***] of the undisputed amounts that should have been paid to Codexis; and
(c)    whether in the case of (a) or (b), for each occurrence after the first occurrence that GSK is determined, as a consequence of a separate, independent audit conducted by Codexis pursuant to either Section 7.14.1 or Section 7.14.2, as applicable, to have:
(i)    not paid any milestone payments or Royalties with respect to a Licensed Product for which milestone payments and/or Royalties are payable; or 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 53 -

(ii)    underpaid any amounts by more than [***] of the undisputed amounts that should have been paid to Codexis;
GSK shall pay to Codexis, in accordance with Section 7.8: (A) the outstanding amount due to Codexis as determined under this Section 7.14.3; (B) the amount calculated to be [***] percent ([***]%) of the amount noted in (A) above; and (C) the interest of due in respect of the amount noted in (A) above pursuant to Section 7.16.
7.15    Taxes.
7.15.1    No Deductions or Withholding.  GSK will make all payments to Codexis under this Agreement without deduction or withholding for taxes, except to the extent that any such deduction or withholding is required by Applicable Law in effect at the time of payment.
7.15.2    Withholding Required by Applicable Law.  Any tax required to be withheld on amounts payable under this Agreement shall be paid promptly by GSK on behalf of Codexis to the appropriate governmental authority, and GSK will furnish Codexis with proof of payment of such tax.  Any such tax required to be withheld will be borne by Codexis. 
7.15.3    Cooperation.  GSK and Codexis will cooperate with respect to all documentation required by any taxing authority or reasonably requested by GSK to secure a reduction in the rate of applicable withholding taxes.  Within thirty (30) days after the execution of this Agreement, Codexis will deliver to GSK an accurate and complete Internal Revenue Service Form W-9. 
7.15.4    Reimbursement.  If GSK had a duty to withhold taxes in connection with any payment it made to Codexis under this Agreement but GSK failed to withhold, and such taxes were assessed against and paid by GSK, then Codexis will reimburse GSK for such taxes actually paid by GSK.  If GSK makes a claim under this Section 7.15.4, it will comply with the obligations imposed by Section 7.15.2 as if GSK had withheld taxes from a payment to Codexis.  
7.16    Interest Due.  Without limiting any other rights or remedies available to either Party, GSK shall pay to Codexis interest on any payments that are not paid on or before the date such payments are due under this Agreement at a rate equal to the lesser of (a) [***] as reported by Citibank, New York, New York, on the date such payment was due to be paid or (b) the maximum applicable legal rate on such date, in either (a) or (b), calculated on the total number of days payment was delinquent. 
8.    REPRESENTATIONS, WARRANTIES, AND COVENANTS; DISCLAIMERS; LIMITATION OF LIABILITY

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 54 -

8.1    Mutual Representations and Warranties.  Each Party represents and warrants to the other Party as of the Effective Date, that:
8.1.1    such Party is duly organized, validly existing, and in good standing under the Applicable Law of the jurisdiction of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;
8.1.2    execution of this Agreement and the performance by such Party of its obligations hereunder have been duly authorized;
8.1.3    this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation of such Party, enforceable against it in accordance with the terms hereof;
8.1.4    the performance of this Agreement by such Party does not create a breach or default under any other agreement to which it is a party, which breach or default would adversely affect the other Party;
8.1.5    the execution, delivery, and performance of this Agreement by such Party does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Law of any court, governmental body or administrative or other agency having jurisdiction over such Party;
8.1.6    no government authorization, consent, approval, license, exemption, filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Applicable Law currently in effect, is or will be necessary for, or in connection with, the transaction contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by such Party of its obligations under this Agreement and such other agreements, except as may be required to obtain applicable Regulatory Approvals or Regulatory Filings related to the development of any Licensed Product; and
8.1.7    such Party has not employed and, to its knowledge, has not used a contractor or consultant that has employed, any individual or entity (a) debarred by the FDA (or subject to a similar sanction of any other applicable Regulatory Authority), (b) who is the subject of an FDA debarment investigation or proceeding (or similar proceeding of any other applicable Regulatory Authority), or (c) has been charged with or convicted under Applicable Law of the United States for conduct relating to the development or approval, or otherwise relating to the regulation of any product under the Generic Drug Enforcement Act of 1992, in each case, in the conduct of its activities prior to the Effective Date.
8.2    Additional Representations and Warranties of Codexis.  Codexis, on behalf of itself and its Affiliates, hereby represents and warrants to GSK that, except as 

- 55 -

otherwise disclosed in writing by Codexis to GSK and accepted in writing by GSK, as of the Effective Date:  
8.2.1    [***];
8.2.2    Codexis is the sole and exclusive owner of the Licensed Patents (other than In-Licensed Patents) and the Licensed Know-How (other than In-Licensed Know-How) and has the full authority to grant the full and unencumbered scope of rights and licenses (other than as set forth in Section 3.4.2) granted to GSK under this Agreement; 
8.2.3    to the knowledge of the Codexis Senior Management, no licenses under any Third Party Intellectual Property rights are necessary for Codexis to grant to GSK the licenses hereunder (other than licenses to commercially available software such as, by way of example only, [***] or [***]); 
8.2.4    the Licensed Patents are all of the Patents Controlled by Codexis that are (i) necessary to practice the Platform Technology; and (ii) which Cover the practice of the Platform Technology;  
8.2.5    the Licensed Know-How accounts for all of the Codexis Know-How that is (i) necessary to practice the Platform Technology; and (ii) which Cover the practice of the Platform Technology;  
8.2.6    neither Codexis nor any of its Affiliates has granted any right, license or interest to any Third Party relating to or under the Licensed IP or to the Platform Technology that would conflict or would otherwise be inconsistent with any of the rights, licenses or interests granted to GSK under this Agreement; 
8.2.7    the Licensed Know-How (other than In-Licensed Know How) were generated either by employees or contractors of Codexis, and in each case the terms of employment or engagement of such employees or contractors vested in Codexis all right, title and interest in and to any Know-How generated by them or has obtained or has the legal right to obtain assignments of all such Licensed Know-How; 
8.2.8    to the knowledge of Codexis Senior Management, no Third Party has rights in the Licensed Patents, the Licensed Know-How or the Platform Technology that would adversely affect GSK’s rights under this Agreement;  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 56 -

8.2.9    [***]; 
8.2.10    [***]; 
8.2.11    [***]; 
8.2.12    to the knowledge of Codexis Senior Management, neither Codexis nor any of its Affiliates:
(a)    is a party to any legal action relating to the Licensed IP; and
(b)    [***];  
8.2.13    in respect of each of the In-License Agreements, to the knowledge of Codexis Senior Management: 
(a)    each of the In-License Agreements is in full force and effect and neither Codexis nor its Affiliates have materially breached or received any written or oral notice of any breach or any written or oral notice of the intent to terminate under any of the In-License Agreements; 
(b)    each sublicense granted to GSK has been granted to GSK pursuant to the terms of each respective In-License Agreement; and
(c)    each of the In-License Agreements disclosed to GSK is true, accurate and not misleading as to the terms thereof that have not been redacted; 
8.2.14    the license limitations in Section 3.4.2 with respect to the Codexis Mayflower Patents are exhaustive, complete, accurate and not misleading; and 
8.2.15    [***].  
8.3    Mutual Covenants.  Each Party hereby covenants to the other Party that:

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 57 -

8.3.1    all employees of such Party or its Affiliates, and all agents, consultants, contractors and subcontractors (as provided in Section 4.4) of such Party or its Affiliates performing any research activities under a research plan under a Project shall be under the obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, if any, to such Party as the sole owner thereof;  
8.3.2    such Party shall perform its obligations and activities in compliance with Applicable Law and industry standards, including, without limitation, GLP, GCP and GMP, in each case as applicable under Applicable Law of the country and the state and local government wherein such activities are conducted, and with respect to the care, handling and use in research and development activities hereunder of any non-human animals by or on behalf of such Party, shall at all times comply (and shall ensure compliance by any of its subcontractors) with Applicable Law, and also with the standards in the pharmaceutical industry for the development and manufacture of pharmaceutical products, and (b) with individuals who are appropriately trained and qualified; 
8.3.3    neither Party shall employ (or, to its knowledge, use any contractor or consultant that employs) any individual or entity (a) debarred by the FDA (or subject to a similar sanction of any other applicable Regulatory Authority), (b) who is the subject of an FDA debarment investigation or proceeding (or similar proceeding of any other applicable Regulatory Authority), or (c) has been charged with or convicted under any Applicable Law of the United States for conduct relating to the development, approval or otherwise relating to the regulation of any product under the Generic Drug Enforcement Act of 1992, in each case, in the conduct of its activities under this Agreement; and
8.3.4    neither Party shall, during the Term, grant any right or license to any Third Party relating to any of the Intellectual Property rights it Controls that would conflict or interfere with any of the rights or licenses granted to the other Party hereunder.
8.4    Additional Covenants of GSK.  GSK hereby covenants to Codexis that:
8.4.1    GSK acknowledges and agrees that the use of any enzyme, other than a Codexis Enzyme, to generate an Enzyme and, in addition, any Enzyme generated in accordance with the terms of the license granted by Codexis to GSK may be Covered by a Patent(s) owned or otherwise controlled by a Third Party;  
8.4.2    all GSK employees and contractors that will have access to Codexis Confidential Information and/or Platform Technology shall be subject to a confidentiality obligations with GSK subjecting the employee or contractor to GSK’s maintenance, non-disclosure, and non-use obligations under Article 9; 
8.4.3    the financial information contained in any GSK report delivered pursuant to Article 7 will be generated using the same financial reporting system, using the same 

- 58 -

data, and in the same manner that GSK uses to generate financial information for GSK’s public reporting obligations; and
8.4.4    GSK shall pay Codexis’ costs relating to the prosecution of the [***] Patents in accordance with Section 7.8 up to a maximum amount of [***] dollars ($[***]) per Calendar Year. 
8.5    Additional Covenant of Codexis.  Codexis hereby covenants to GSK that:  
8.5.1    with respect to each In-License Agreement, Codexis shall maintain and keep such In-License Agreement in full force and effect under each In-License Agreement’s respective terms for the term of the In-Licensed IP licensed pursuant to such In-License Agreement; 
8.5.2    Codexis shall not amend any such In-License Agreement in a manner that adversely affects GSK’s rights under Section 3.2 and/or imposes any additional obligations upon GSK not disclosed to GSK under the In-License Agreements; and 
8.5.3    except in respect of Section 8.4.4, Codexis, pursuant to the terms of the In-License Agreements, shall be responsible for any and all annual maintenance fees due to all Third Party licensors during the Term required to maintain each In-License Agreement; provided, however, that (i) GSK shall be responsible for any and all milestones and royalties due to such Third Party licensors during the Term as a consequence of GSK’s activities under the terms of this Agreement and (ii) nothing contained herein shall require Codexis to be responsible for Losses arising from the breach of such In-License Agreements by GSK as a sublicensee.  
8.5.4    In the event of the termination of any of the In-License Agreements set forth on Exhibit 8.5.4, Codexis shall, at GSK’s sole discretion, either: 
(a)    [***]; or 
(b)    [***].  
Notwithstanding anything to the contrary, Codexis shall have no obligation under this Section 8.5.4 in the event of (i) expiration of any of the In-License Agreements set forth on Exhibit 8.5.4 in accordance with the terms of such In-License Agreement or (ii) a decision by the relevant 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 59 -

Third Party licensor to abandon the Patents licensed under any of the In-License Agreements set forth on Exhibit 8.5.4 and dedicate the subject matter of such abandoned Patents to the public domain.  
8.6    DISCLAIMERS.
8.6.1    CODEXIS DISCLAIMER.  EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 8.1 THROUGH 8.5, CODEXIS MAKES NO REPRESENTATIONS, WARRANTIES OR COVENANTS OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY CODEXIS CONFIDENTIAL INFORMATION, CODEXIS PATENTS, CODEXIS CORE TECHNOLOGY, CODEXIS CORE TECHNOLOGY IMPROVEMENTS, ARISING CODEXIS ENZYME TECHNOLOGY OR ARISING CODEXIS PROCESS TECHNOLOGY OR ANY LICENSE GRANTED BY CODEXIS HEREUNDER, OR WITH RESPECT TO THE PRODUCTS.  EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 8.1 THROUGH 8.5, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE CODEXIS PATENTS ARE VALID OR ENFORCEABLE OR THAT USE OF THE CODEXIS PATENTS, CODEXIS CORE TECHNOLOGY, CODEXIS CORE TECHNOLOGY IMPROVEMENTS, ARISING CODEXIS ENZYME TECHNOLOGY AND ARISING CODEXIS PROCESS TECHNOLOGY CONTEMPLATED HEREUNDER [***].
8.6.2    GSK DISCLAIMER.  EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 8.1 AND 8.4, GSK MAKES NO REPRESENTATIONS, WARRANTIES OR COVENANTS OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY GSK CONFIDENTIAL INFORMATION OR ANY LICENSE GRANTED BY GSK HEREUNDER.  EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 8.1 AND 8.5, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE GSK BACKGROUND IP, ARISING GSK ENZYME TECHNOLOGY OR ARISING GSK PROCESS TECHNOLOGY ARE VALID OR ENFORCEABLE OR THAT THE USE OF THE GSK BACKGROUND IP, ARISING GSK ENZYME TECHNOLOGY OR ARISING GSK PROCESS TECHNOLOGY CONTEMPLATED HEREUNDER [***].
8.7    LIMITATION OF LIABILITY.  EXCEPT FOR A BREACH OF [***], OR CLAIMS OF A THIRD PARTY THAT ARE SUBJECT TO 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 60 -

INDEMNIFICATION UNDER ARTICLE 10, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY INCIDENTAL, INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION, LOST PROFITS, LOSS OF USE, DAMAGE TO GOODWILL OR LOSS OF BUSINESS.
9.    CONFIDENTIALITY
9.1    Nondisclosure.  Each Party agrees that, during the Term and for a period of ten (10) years thereafter, a Party (the “Receiving Party”) receiving Confidential Information from the other Party (the “Disclosing Party”) (or that has received any such Confidential Information from the other Party prior to the Effective Date) shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than reasonable efforts, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted pursuant to Section 9.3, and (c) not use such Confidential Information for any purpose, except as permitted by this Agreement (it being understood that this clause (c) shall not create or imply any rights or licenses not expressly granted under this Agreement).  
9.2    Exceptions.  The obligations in Section 9.1 shall not apply with respect to any portion of the Confidential Information received from the Disclosing Party that the Receiving Party can show by competent written proof:
9.2.1    was publicly disclosed by the Disclosing Party, either before or after disclosure to the Receiving Party hereunder; 
9.2.2    was known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party, as evidenced by contemporaneous written records; 
9.2.3    was subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; 
9.2.4    was published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is disclosed to the Receiving Party; or 
9.2.5    was developed independently by or for the Receiving Party or its Affiliates, as evidenced by written records, without reference to or reliance upon the Disclosing Party’s Confidential Information.  

- 61 -

9.3    Authorized Disclosure.  The Receiving Party may disclose Confidential Information belonging to the Disclosing Party, and Confidential Information deemed to belong to both Parties under the terms of this Agreement, to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances:
9.3.1    Prosecuting Patents;
9.3.2    Regulatory Filings;
9.3.3    Prosecuting or defending litigation, including responding to a subpoena in a Third Party litigation;
9.3.4    subject to Section 9.5, complying with Applicable Law (including the rules and regulations of the Securities and Exchange Commission or any national securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; and
9.3.5    disclosure, solely on a “need to know basis,” to Affiliates, potential and future collaborators (including sublicensees), potential or actual acquirers, merger partners, or assignees permitted under Section 13.5, potential or actual research and development collaborators, permitted subcontractors, investment bankers, investors, lenders or other potential financial partners, and their and each of the Parties’ respective directors, employees, consultants, contractors and agents, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use no less restrictive than the obligations set forth in this Article 9; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Section 9.3.5 to treat such Confidential Information as required under this Article 9.
If and whenever any Confidential Information is disclosed in accordance with this Section 9.3, such disclosure shall not cause any such information to cease to be Confidential Information, except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement).  Where reasonably possible and subject to Section 9.5 and other than pursuant to Section 9.3.5, the Receiving Party shall notify the Disclosing Party of the Receiving Party’s intent to make such disclosure pursuant to this Section 9.3 sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information, and the Receiving Party will provide reasonable assistance to the Disclosing Party with respect thereto; provided that, in any event, the Receiving Party will use reasonable measures to ensure confidential treatment of such information.
9.4    Terms of this Agreement.  The Parties acknowledge that this Agreement and all of the respective terms of this Agreement shall be treated as Confidential Information of both Parties. 

- 62 -

9.5    Securities Filings.  In the event either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document which describes or refers to the terms and conditions of this Agreement under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other securities Applicable Law, the Party shall notify the other Party of such intention and shall provide such other Party with a copy of relevant portions of the proposed filing prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto relating to the terms and conditions of this Agreement, and shall use reasonable efforts to obtain confidential treatment of the terms and conditions of this Agreement that such other Party reasonably requests be kept confidential, and shall only disclose Confidential Information that it is advised by counsel is legally required to be disclosed.  No such notice shall be required under this Section 9.5 if the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by the either Party hereunder or otherwise approved by the other Party.
9.6    Publicity.  
9.6.1    Upon execution of this Agreement, Codexis shall issue the press release mutually agreed upon by the Parties and set forth in Exhibit 9.6.  [***].  Notwithstanding the foregoing, any disclosure that is required by Applicable Law (including the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended), or the rules of a securities exchange or the Securities and Exchange Commission or the securities regulations of any state or other jurisdiction, may be made by Codexis or GSK; provided that any such required disclosure will not contain any Confidential Information of, respectively, GSK or Codexis and, if disclosure of such information is required by Applicable Law or such rules or regulations, the Parties will comply with Sections 9.3.4 and 9.5, as applicable, and will use reasonable efforts to minimize such disclosure and obtain confidential treatment for any such information that is disclosed to a governmental agency.  Notwithstanding the foregoing, Codexis may publicly disclose any information that has previously been disclosed in accordance with this Section 9.6 without any requirement to receive GSK’s approval thereof or to provide GSK with an opportunity to review such disclosure.
9.6.2    Codexis agrees to provide to GSK a copy of any public announcement regarding this Agreement or the subject matter thereof within a reasonable period of time under the circumstances prior to its scheduled release, which period of time shall not be less than fifteen (15) Business Days where practicable, for GSK’s review.  Except as otherwise required by Applicable Law, Codexis shall remove any Confidential Information of GSK that GSK deems to be inappropriate for disclosure.  Codexis agrees not to use the name or trademark 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 63 -

of GSK, its Affiliates, or its employees, without the prior written consent of GSK, except that Codexis may disclose that GSK is a licensee of Codexis hereunder. 
9.6.3    GSK may make public announcements and publications regarding any Pharmaceutical Product in its sole discretion, and such announcement or publication shall not be subject to this Section 9.6.  In addition, GSK may publish scientific papers and make scientific presentations; provided, however, that such publications and presentations do not include the Confidential Information of Codexis. 
10.    INDEMNITY AND INSURANCE
10.1    GSK Indemnity. GSK shall indemnify, defend, and hold harmless Codexis and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns, and representatives (the “Codexis Indemnitees”), from and against any and all Losses from Third Party claims to the extent arising out of or relating to, directly or indirectly:  (a) the negligence, recklessness or wrongful intentional acts or omissions of GSK, its Affiliates, and sublicensees and its or their respective directors, officers, employees and agents, in connection with GSK’s performance of its obligations or exercise of its rights under this Agreement, including without limitation under any Project; (b) any breach by GSK of any representation, warranty or covenant set forth in this Agreement; (c) research, development, synthesis, transfer, handling, storage, sale, use, optimization, modification, isolation, engineering, identification, selection, making, having made, importation, exportation or other disposition of any Licensed Product by or on behalf of GSK or any of its Affiliates, sublicensees, agents and contractors (other than Codexis) , including for each of clauses (a), (b), and (c) above, claims and threatened claims based on (i) product liability, bodily injury, risk of bodily injury, death or property damage or (ii) the failure to comply with Applicable Law; except (A) in any such case for Losses from Third Party claims to the extent reasonably attributable to any Codexis Indemnitee having committed an act or acts of negligence, recklessness or willful misconduct, (B) any breach by Codexis of any representation, warranty or covenant; or (C) for which Codexis is required to indemnify GSK pursuant to Section 10.2. 
10.2    Codexis Indemnity. Codexis shall indemnify, defend and hold harmless GSK and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns, and representatives (the “GSK Indemnitees”), from and against any and all Losses from Third Party claims, to the extent arising out of or relating to, directly or indirectly: (a) the negligence, recklessness or wrongful intentional acts or omissions of Codexis, its Affiliates, and sublicensees (excluding GSK) and its or their respective directors, officers, employees and agents, in connection with Codexis’ performance of its obligations or exercise of its rights under this Agreement, including without limitation under any Project; and (b) any breach by Codexis of any representation, warranty or covenant set forth in this Agreement; including for each of clauses (a) and (b), claims and threatened claims based on (i) product liability, bodily injury, risk of bodily injury, death or property damage or (ii) the 

- 64 -

failure to comply with Applicable Law; except (A) in any such case for Losses from Third Party claims to the extent reasonably attributable to any GSK Indemnitee having committed an act or acts of negligence, recklessness or willful misconduct, (B) any breach by GSK of any representation, warranty or covenant; or (C) for which GSK is required to indemnify Codexis pursuant to Section 10.1.  
10.3    Indemnification Procedure.  A claim to which indemnification applies under Section 10.1 or Section 10.2 shall be referred to herein as an “Indemnification Claim.”  If any Person or Persons (collectively, the “Indemnitee”) intends to claim indemnification under this Article 10, the Indemnitee shall notify the other Party (the “Indemnitor”) in writing promptly upon becoming aware of any claim that may be an Indemnification Claim (it being understood and agreed, however, that the failure by an Indemnitee to give such notice shall not relieve the Indemnitor of its indemnification obligation under this Agreement, except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice).  The Indemnitor shall have the right to assume and control the defense of the Indemnification Claim at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential conflicting interests between such Indemnitee and the Indemnitor; provided that the Indemnitor shall not be obligated to pay the fees of more than one counsel retained by all Indemnitees.  If the Indemnitor does not assume the defense of the Indemnification Claim as described in this Section 10.3 above, the Indemnitee may defend the Indemnification Claim, but shall have no obligation to do so.  The Indemnitee shall not settle or compromise the Indemnification Claim without the prior written consent of the Indemnitor, and the Indemnitor shall not settle or compromise the Indemnification Claim in any manner which would have an adverse effect on the Indemnitee’s interests (including any rights under this Agreement, or the scope or enforceability of any Patent within the Codexis Patent Rights or of the Codexis Know-How), without the prior written consent of the Indemnitee, which consent, in each case, shall not be unreasonably withheld or delayed.  The Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor’s reasonable expense and shall make available to the Indemnitor all pertinent information under the control of the Indemnitee, which information shall be subject to Article 9. 
10.4    Insurance.  Each Party shall maintain at all times during the Term commercial general liability insurance and product liability insurance in respect of any Third Party claim, the subject of Section 10.1 and Section 10.2, from a recognized, creditworthy insurance company, with coverage limits of at least [***] Dollars ($[***]) per Third Party claim.  With respect to GSK, such product liability insurance shall include coverage for any Third Party claim subject to Section 10.1 in respect of any Licensed Product undergoing clinical trials.  The minimum level of insurance set forth herein shall not be construed to create a limit on either Party’s liability hereunder.  Within ten (10) days following reasonable written request from either Party, the other Party shall furnish to such Party a certificate of insurance 
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 65 -

evidencing such coverage.  In the case of a material modification or cancellation of such coverage, the covered Party shall notify the other Party as soon as reasonably practicable and provide such other Party with a new certificate of insurance evidencing that the covered Party’s coverage meets the requirements of this Section 10.4.  Notwithstanding the aforementioned, each Party may elect to self-insure or re-insure all or parts of the limits described above and, in such event, this Section 10.4 shall apply to such self-insurance or re-insurance arrangements mutatis mutandis. 
11.    TERM AND TERMINATION.
11.1    Term; Expiration.  This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article 11, or by mutual agreement of the Parties, shall remain in effect until the expiration on a country-by-country basis of all payment obligations under this Agreement.  The period from the Effective Date until the date of expiration of this Agreement, or termination of this Agreement pursuant to this Article 11, shall be the “Term”.
11.2    Termination for Material Breach.  Either Party (the “Non-Breaching Party”) may, without prejudice to any other remedies available to it at law or in equity, terminate this Agreement, in its entirety, in the Non-Breaching Party’s sole discretion in the event the other Party (the “Breaching Party”) has materially breached this Agreement, and such material breach has continued for sixty (60) days (the “Cure Period”) after written notice thereof is provided to the Breaching Party by the Non-Breaching Party, such notice describing the alleged material breach in sufficient detail to put the Breaching Party on notice.  If at the end of the Cure Period, the Breaching Party can demonstrate that it is actively seeking to remedy such material breach, then at the Breaching Party’s request and with the consent of the Non-Breaching Party (not to be unreasonably withheld), the Non-Breaching Party shall grant an additional forty-five (45) days for the Breaching Party to remedy such breach.
11.3    Insolvency or Bankruptcy.  To the extent permitted under Applicable Law, either Party may terminate this Agreement, (a) if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of the Party or of substantially all of its assets, or (b) if the other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within ninety (90) days after the filing thereof, or (c) if the other Party shall propose or be a party to any dissolution or liquidation, or (d) if the other Party shall make an assignment of substantially all of its assets for the benefit of creditors.  Each Party agrees to give the other Party prompt notice of the foregoing events giving rise to termination under this Section 11.3.  All rights and licenses granted under or pursuant to any section of this Agreement are and shall otherwise be deemed to be for purposes of Section 365(n) of Title 11, United States Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code.  The Parties shall retain and may fully 

- 66 -

exercise all of their respective rights and elections under the Bankruptcy Code.  All materials required to be delivered by the non-bankrupt Party under this Agreement (including all manufacturing information) shall be considered to be “embodiments” of such intellectual property for purposes of Section 365(n) of the Bankruptcy Code.  Upon the bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a complete duplicate of, or complete access to, any intellectual property licensed to the non-bankrupt Party, and such, if not already in its possession, shall be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement.  All written agreements entered into in connection with the Parties’ performance under this Agreement from time to time shall be considered agreements “supplementary” to this Agreement for purposes of Section 365(n) of the Bankruptcy Code.
11.4    Termination for Challenge of any Codexis Patent.  If GSK or any of its Affiliates (the “Challenging Party”) challenges the validity, scope or enforceability of or otherwise opposes any Codexis Patent in any country (each, a “Patent Challenge”), Codexis has the right to give notice to the Challenging Party that this Agreement will terminate in its entirety forty-five (45) days after such notice, and, unless the Challenging Party withdraws or causes to be withdrawn such Patent Challenge within such forty-five (45) day period, this Agreement will so terminate.  
11.5    Consequences of Expiration or Termination.  
11.5.1    In General.  Expiration or termination of this Agreement for any reason shall not (a) release either Party from any obligation that has accrued prior to the effective date of such expiration or termination; (b) preclude either Party from claiming any other damages, compensation, or relief that it may be entitled to upon such expiration or termination; or (c) terminate any right to obtain performance of any obligation provided for in this Agreement that shall survive expiration or termination.  Upon any expiration or termination of this Agreement, each Party shall return to the other Party and cease using all Confidential Information of such other Party; provided that the legal department of each Party may retain one (1) copy of such Confidential Information.  Upon expiration (but not earlier termination) of this Agreement, the licenses granted to GSK pursuant to Sections 3.5.2 (if GSK exercised the Option) and 3.2.2 shall become perpetual and non-exclusive in the Field; provided that GSK shall remain responsible for any payments due to Codexis after the effective date of such expiration in accordance with Section 7.11. In the event of termination of this Agreement in accordance with this Article 11, [***] GSK shall have no rights to practice the Platform Technology.
11.5.2    Partial Termination of Licenses.  All licenses granted to GSK under this Agreement shall terminate on a country-by-country basis to the extent that they relate to a country in the Territory that GSK has selected for termination in accordance with Section 11.7.  Upon termination of this Agreement by GSK with respect to a country in the Territory (a 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 67 -

“Terminated Country”), Codexis’ rights and GSK’s obligations under Section 11.5.3 shall apply as to the Terminated Country.  In addition, the certification signed by [***], or a successor, provided to Codexis pursuant to Section 11.5.3 shall certify that all use of Platform Technology by GSK, its Affiliates or sublicensees, either alone or with a Third party, in the Terminated Country(ies) has ceased as of the date of such certification.  For the avoidance of doubt, partial termination of this Agreement with respect to any Terminated Country(ies) does not relieve GSK of obligations under Article 7 that arise from GSK’s exercise of rights or obligations under this Agreement within such Terminated Country(ies) existing as of the effective date of such partial termination.  For clarity, in the event that GSK, on a country-by-country basis, terminates this Agreement with respect to all countries in the Territory, this Agreement will be deemed to be terminated in its entirety.  
11.5.3    Codexis Audit Right on GSK Breach or Termination. In the event of termination of this Agreement by Codexis as a result of GSK’s material breach under Section 11.2, or by GSK pursuant to Section 11.7, GSK shall provide to Codexis, within ninety (90) days after the effective date of such termination, a certification signed by [***] certifying that all Codexis proprietary materials, information, and technology in custody or control of GSK or sublicensee of GSK has been destroyed.  In addition, Codexis shall have a right to conduct an audit to determine that all Codexis materials, information, and/or technology have been destroyed and that such destruction is complete (the “Termination Audit Right”).  Under the Termination Audit Right, GSK shall allow a designee chosen by Codexis and reasonably acceptable to GSK to review documentation, materials, and facilities of GSK as reasonably necessary for such designee to determine whether all Codexis materials, information, and/or technology has been destroyed.  Results of such investigation shall be made available to both GSK and Codexis; provided that such designee shall disclose to Codexis only its determination of whether all Codexis materials, information, and/or technology has been destroyed.  GSK may require such designee to enter into an appropriate written agreement obligating it to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are comparable to the obligations set forth in Article 9.  The Termination Audit Right shall continue until the earlier of (a) ten (10) years after the effective date of termination of this Agreement by Codexis as a result of GSK’s material breach under Section 11.2, or by GSK pursuant to Section 11.7 or (b) until a designee determines, pursuant to the Codexis’ exercise of the Termination Audit Right, that all Codexis materials, information, and/or technology has been destroyed.  All reasonable expenses arising from the first audit shall be at Codexis’ expense, and all subsequent audits, if any, shall be at GSK’s expense.
11.6    GSK Continuing Rights.  Upon termination of this Agreement by GSK pursuant to Section 11.2 and 11.3, GSK shall continue to have the rights to research, develop, use, optimize, modify, isolate, engineer, identify, select, make, have made, import and/or export Enzymes and their derivatives under the licenses granted to GSK pursuant to Section 3.2, which 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 68 -

shall remain in effect to the fullest extent possible subject only to the payment by GSK of the applicable amounts set out in Article 7.   
11.7    GSK Termination at Will.  At any time following Completion of Wave 1, GSK may terminate this Agreement in its entirety, or on a country-by-country basis, upon providing ninety (90) days’ written notice to Codexis at any time and for any reason or for no reason at all.  In such event, GSK shall pay to Codexis all reasonable non-cancellable and non-terminable costs incurred by Codexis upon such event of termination.  If GSK terminates this Agreement in its entirety pursuant to this Section 11.7 during the TT Term, GSK shall pay to Codexis the applicable termination payment set forth in this Section 11.7. 

	
		
	Termination at Will During TT Term
	Termination At Will Payment

	During Technology Transfer Project 1, as defined in the Technology Transfer Plan
	$[***]

	During Technology Transfer Project 2, as defined in the Technology Transfer Plan
	$[***]

	During Technology Transfer Project 3, as defined in the Technology Transfer Plan
	$[***]

	During Technology Transfer Project 4, as defined in the Technology Transfer Plan
	$[***]

11.8    Additional Consequence of Certain Terminations.  If Codexis terminates this Agreement pursuant to Section 11.2, or if GSK terminates this Agreement in its entirety, then, in addition to the consequences set forth in Sections 11.5 - 11.7, [***]. 
11.9    Survival.  Notwithstanding anything to the contrary in this Agreement, the following provisions shall survive, as well as any other provision which by its terms or by the context thereof, is intended to survive expiration or termination of this Agreement:  Articles 1 (Definitions), 6 (Intellectual Property), 7 (Financial Terms) (in accordance with Section 7.11), 9 (Confidentiality) (for the period of time set forth in Section 9.1), 12 (Dispute Resolution), and 13 (Miscellaneous), and Sections 3.1.2, 3.1.3, 3.4.1 and 3.4.2 (for the remaining term of the relevant Patents), 3.7.2, 8.6, 8.7, 10.1, 10.2, 10.3, 11.5, 11.8 and 11.9. Except as otherwise expressly 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 69 -

provided, all other rights, licenses and obligations shall terminate upon expiration or termination of this Agreement.  
12.    DISPUTE RESOLUTION.
12.1    Resolution by Executive Officers.  The Parties agree that the procedures set forth in this Article 12 shall be the exclusive mechanism for resolving any dispute, controversy, or claim (each, a “Dispute”) between the Parties that may arise from time to time pursuant to this Agreement relating to any Party’s rights and/or obligations.  Except as otherwise provided in this Agreement, in the event of any Dispute between the Parties in connection with this Agreement, the construction hereof, or the rights, duties or liabilities of either Party hereunder, the Parties shall first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves.  In the event that such Dispute is not resolved on an informal basis within ten (10) Business Days, either Party may, by written notice to the other Party, refer the Dispute to the executive officers designated by the Parties for attempted resolution.  Such officers, or their designees, shall attempt in good faith to promptly resolve such Dispute within thirty (30) Business Days thereafter.  In the event that any matter is not resolved under the foregoing provisions, each Party may, at its sole discretion, seek resolution of such matter in accordance with Section 12.2.  
12.2    Mediation.  If a Dispute arises out of or relating to this Agreement, or the breach thereof, and if said Dispute is not resolved through negotiation by the Parties under Section 12.1, the Parties agree that they shall try in good faith to resolve the Dispute by referring it for confidential mediation under the CPR Mediation Procedure in effect at the start of mediation.  Unless otherwise agreed, the Parties shall select a mediator from the CPR Panels of Distinguished Neutrals.  If the Parties cannot agree, they will defer to the CPR to select a mediator.  The cost of the mediator shall be borne equally by the Parties.  The place of mediation shall be New York, New York, United States of America.  Any Dispute not resolved within forty-five (45) days (or within such other time period as may be agreed to by the Parties in writing) after appointment of the mediator shall be finally resolved by arbitration pursuant to Section 12.3.
12.3    Arbitration.  Subject to Section 12.4, any Dispute referred for arbitration shall be finally resolved by binding arbitration before a panel of three (3) arbitrators in accordance with the rules of the American Arbitration Association (“AAA”) in effect at the time the proceeding is initiated. If the issues in Dispute involve scientific, technical or commercial matters, then any arbitrator chosen under this Agreement shall have educational training and industry experience sufficient to demonstrate a reasonable level of relevant scientific, technical and commercial knowledge relevant to the subject matter of the Dispute.  All proceedings and communications as part of the arbitration shall be in English.  Following selection of the third arbitrator, the arbitrators shall use all reasonable efforts to complete the arbitration proceedings and render an award within six (6) months after the last arbitrator is appointed. In any such arbitration, the following additional procedures shall apply: 

- 70 -

12.3.1    Rules.  The arbitration shall be conducted pursuant to the then-current AAA rules in effect for disputes between U.S. parties on the date of commencement of the arbitration; provided, however, that discovery in any arbitration shall be conducted in accordance with the AAA Commercial Arbitration Rules in effect immediately prior to October 1, 2013, for large complex commercial disputes between U.S. based entities. 
12.3.2    Panel.  Within thirty (30) days after a Party demands arbitration, each Party shall select one (1) arbitrator and the third chosen by the two (2) Party-chosen arbitrators.  If either, or both, of GSK or Codexis fails to choose an arbitrator within thirty (30) days after receiving notice of commencement of arbitration or if the two arbitrators fail to choose a third arbitrator within thirty (30) days after their appointment, then either or both Parties shall immediately request that the AAA select the remaining number of arbitrators to be selected, which arbitrator(s) shall have an appropriate background, experience and expertise in the subject matter at issue in the Dispute.  The place of arbitration shall be San Francisco, California, United States of America.  The seat of arbitration shall be the State of New York, United States of America (for clarity, the Parties intend this to mean that the procedural rules of the State of New York, United States of America, will apply to any arbitration).
12.3.3    Injunctive Relief; Costs and Expenses.  Either Party may apply to the arbitrators for interim injunctive relief until the arbitration decision is rendered or the Dispute is otherwise resolved.  Either Party may, without waiving any right or remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending resolution of the Dispute pursuant to this Article 12.  The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages.  Each Party will share equally the cost and expenses of the panel selected in Section 12.3.2 and any administrative fees unless in each case the arbitrators agree otherwise, which they are hereby empowered, authorized and instructed to do if they determine that to be fair and appropriate.  Each Party shall bear its own costs and expenses and attorneys’ fees in connection with any such arbitration; provided, however, that the prevailing Party in any such arbitration shall be entitled to recover from the other Party the reasonable attorneys’ fees, costs and expenses incurred by such prevailing Party in connection with such arbitration. 
12.3.4    Confidentiality.  Except to the extent necessary to confirm an award or decision or as may be required by Applicable Law, or the requirement of any exchange on which a Party’s shares are traded, neither Party nor any arbitrator may disclose the existence or results of any arbitration without the prior written consent of both Parties. In no event shall any arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the Dispute would be barred by the applicable Delaware statute of limitations.
12.3.5    Breach of the Agreement.  In the event of a Dispute involving the alleged breach of this Agreement (including, without limitation, whether a Party has satisfied its diligence obligations hereunder), (a) neither Party may terminate this Agreement under 

- 71 -

Article 11 until resolution of the Dispute pursuant to this Article 12 and (b) if the arbitrators render a decision that a breach of this Agreement has occurred, the arbitrators shall have no authority to modify the right of the non-breaching Party to terminate this Agreement in accordance with Section 11.2.
12.3.6    Performance. Any disputed performance or suspended performance pending the resolution of a Dispute that the arbitrators determine to be required to be performed by a Party shall be completed within a reasonable time period following the final decision of the arbitrators.
12.3.7    Binding Decision.  The decision of the arbitrators shall be the sole, exclusive and binding remedy between the Parties regarding the determination of all Disputes presented.  The arbitrators shall prepare and deliver to the Parties a written, reasoned opinion conferring their decision.  Judgment on the award so rendered may be entered in any court having competent jurisdiction thereof.  Any monetary payment to be made by a Party pursuant to a decision of the arbitrators shall be made in Dollars, free of any tax or other deduction.
12.4    Confidentiality and Patent Disputes.  Notwithstanding anything in this Agreement to the contrary, any and all issues regarding (a) breach or threatened breach of a Party's confidentiality obligations under this Agreement or (b) the ownership, scope, construction, validity and enforceability of any Patent shall be determined in a court of competent jurisdiction under the local Patent laws of the jurisdictions having issued the Patent in question.
13.    MISCELLANEOUS.
13.1    Non-Solicitation.  During the period beginning on the Effective Date and ending on the date that is [***], (the “Non-Solicitation Period”), GSK and its Affiliates shall not, directly or indirectly, solicit, hire, employ or attempt to solicit, hire or employ any person acting in a scientific role who is or was an employee or contractor of Codexis or any Codexis Affiliate during the Non-Solicitation Period, or in any other way directly or indirectly seek to solicit, induce, bring about, influence, promote, facilitate, or encourage any such individual to work for GSK or any party other than GSK; provided that the foregoing shall not restrict GSK or its Affiliates from advertising employment opportunities in any manner that does not directly target Codexis or its Affiliates or from hiring or employing any person who responds to such generalized public advertisements.
13.2    Severability.  If one or more of the provisions of this Agreement is held to be invalid or unenforceable, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.  The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 72 -

such that the objectives contemplated by the Parties when entering this Agreement may be realized.
13.3    Notices.  Any notice required or permitted to be given by this Agreement shall be in writing and shall be (a) delivered by hand or by overnight courier with tracking capabilities, (b) mailed postage prepaid by first class, registered or certified mail, or (c) delivered by facsimile or e-mail followed by delivery via either of the methods set forth in (a) or (b), in each case, addressed as set forth below unless changed by notice so given:
If to GSK:
GlaxoSmithKline
709 Swedeland Road 
P.O. Box 1539, Mail Code UW2318 
King of Prussia, PA 19406-0939 
United States

Attention:    [***]
Email:    [***]

With a copy to:

GlaxoSmithKline 
2301 Renaissance Boulevard  
Mailcode RN0220 
King of Prussia, PA 19406-2772 
United States

Attention:     [***]
Email:    [***]
If to Codexis:
Codexis, Inc.
200 Penobscot Drive
Redwood City, CA  94063
Attention:  Chief Executive Officer 
Telephone:  [***]
Fax:  [***]
Email:    [***] 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 73 -

With a copy to:

Codexis, Inc.
200 Penobscot Drive
Redwood City, CA  94063
Attention:  General Counsel
Telephone:  [***]
Fax:  [***]
Email:    [***]

Any such notice shall be deemed given on the date received.  A Party may add, delete or change the Person or address to which notices should be sent at any time upon written notice delivered to the Party’s notices in accordance with this Section 13.3. 
13.4    Force Majeure.  Except for the payment of money, neither Party shall be liable for delay or failure in the performance of any of its obligations hereunder if such delay or failure is due to causes beyond its reasonable control, including acts of God, fires, earthquakes, acts of war, terrorism, or civil unrest (“Force Majeure”); provided, however, that the affected Party promptly notifies the other Party; provided further that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and shall continue performance with the utmost dispatch whenever such causes are removed.  When such circumstances arise, the Parties shall negotiate in good faith any modifications of the terms of this Agreement that may be necessary or appropriate in order to arrive at an equitable solution.
13.5    Assignment.  Neither Party may, without the consent of the other Party, assign or transfer any of its rights and obligations hereunder; provided that no such consent is required for an assignment or transfer to an Affiliate of such Party or to a successor in interest to such Party by reason of merger or consolidation or sale of all or substantially all of the business of such Party relating to the subject matter of this Agreement, whether by merger, sale of stock, sale of assets or otherwise.  This Agreement shall inure to the benefit of and be binding on the Parties’ successors and assigns.  Any assignment or transfer in violation of the foregoing shall be null and void. 
13.6    Change of Control [***].  [***] 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 74 -

[***].
13.7    GSK Divestments.  If GSK sells, leases, loans, provides or otherwise transfers to any Third Party any asset, facility, business unit or personnel that practice or otherwise use any Codexis Core Technology, Codexis Core Technology Improvements or Enzyme Technology, GSK shall provide a certification to Codexis and Codexis shall have an audit right as set forth in Section 11.5.3. 
13.8    Waivers and Modifications.  The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation.  Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any succeeding occasion.  No waiver, modification, release or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by both Parties.
13.9    Choice of Law.  This Agreement shall be governed by, enforced and construed in accordance with the laws of the State of Delaware, United States of America, excluding: (a) any conflicts of law principles that would result in the application of the laws of any state other than the State of Delaware; (b) the United Nations Convention on Contracts for the International Sales of Goods; (c) the 1974 Convention on the Limitation Period in the International Sale of Goods (the “1974 Convention”); and (d) the Protocol amending the 1974 Convention, done at Vienna April 11, 1980; provided, however, that with respect to matters involving the enforcement, validity or scope of Intellectual Property rights, the laws of the applicable country shall apply.
13.10    Relationship of the Parties.  Each Party is an independent contractor under this Agreement.  Nothing contained herein is intended or is to be construed so as to constitute Codexis and GSK as partners, agents or joint venturers.  Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party.  
13.11    Entire Agreement.  This Agreement, together with the attached exhibits and schedules, constitutes the entire agreement between the Parties as to the subject matter of this Agreement, and supersedes and merges all prior and contemporaneous negotiations, representations, agreements and understandings regarding the same.
13.12    Counterparts.  This Agreement may be executed in counterparts with the same effect as if both Parties had signed the same document.  All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 75 -

Signatures to this Agreement transmitted by facsimile, by email in “portable document format” (“.pdf”), or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement shall have the same effect as physical delivery of the paper document bearing original signature.  Notwithstanding the aforementioned, the Parties shall as soon as reasonably practicable exchange original signed counterparts to this Agreement. 
13.13    Interpretation.  
13.13.1    Drafting Party.  Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties and their counsel.  Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
13.13.2    Singular and Plural; Gender.  The definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined.  Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms.  The word “will” shall be construed to have the same meaning and effect as the word “shall.”  The word “any” means “any and all” unless otherwise clearly indicated by context.  The word “including” will be construed as “including without limitation.”  The word “or” is disjunctive but not necessarily exclusive.
13.13.3    References.  Unless the context requires otherwise, (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (b) any reference to Applicable Law herein shall be construed as referring to such Applicable Law as from time to time enacted, repealed or amended, (c) any reference herein to any Person shall be construed to include the Person’s successors and assigns, and (d) all references herein to Articles, Sections or Exhibits, unless otherwise specifically provided, shall be construed to refer to Articles, Sections and Exhibits of this Agreement.
13.13.4    Headings and Captions.  Headings and captions are for convenience only and are not be used in the interpretation of this Agreement.

- 76 -

13.14    Anti-Bribery and Corruption.
13.14.1    Codexis acknowledges that it has read GSK’s ‘Prevention of Corruption – Third Party Guidelines’ attached at Exhibit 13.14 and agrees to perform its obligations under the Agreement in accordance with the principles set out therein.
13.14.2    Codexis shall comply fully at all time with all applicable laws and regulations, including but not limited to applicable anti-corruption laws, of the territory in which Codexis conducts business with GSK.
13.14.3    GSK shall be entitled to terminate this Agreement immediately on written notice to Codexis, if Codexis fails to perform its obligations in accordance with this Section 13.14. [***].
13.15    Ethical Standards and Human Rights.  Codexis represents and warrants, to the best of its knowledge, that in connection with this Agreement, it respects the human rights of its staff and does not employ child labor, forced labor, unsafe working conditions, discrimination on the basis of race, religion, disability or gender, or cruel or abusive disciplinary practices in the workplace; and that it pays each employee at least the minimum wage, provides each employee with all legally mandated benefits, and complies with the laws on working hours and employment rights in the countries in which it operates.  Codexis shall encourage compliance with these standards by any supplier of goods or services that it uses in performing its obligations under this Agreement.
13.16    Good Data Management.  During the Technology Transfer or under any Collaborative Project conducted pursuant to this Agreement, each Party shall, and shall cause any Third Party acting for and on behalf of such Party to, carry out its obligations under the Agreement, and collect and record any data generated therefrom, in accordance with the following good data management practices:
13.16.1    Data are being generated using sound scientific techniques and processes;
13.16.2    Data are being accurately recorded in accordance with good scientific practices; 
13.16.3    Data are being analyzed appropriately without bias in accordance with good scientific practices;

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 77 -

13.16.4    Data and results are being stored securely and can be retrieved, and
13.16.5    Data trails exist to demonstrate and/or reconstruct key decisions.

[Signature Page Follows]

- 78 -

IN WITNESS WHEREOF, the Parties have caused this Platform Technology Transfer, Collaboration and License Agreement to be executed by their respective duly authorized officers as of the Effective Date.

	
				
	Codexis, Inc.
	GlaxoSmithKline Intellectual 
Property Development Limited

	By:
	/s/ John J. Nicols   
	By:
	/s/ Paul Williamson   

	Name:
	John J. Nicols   
	Name: 
	Paul Williamson   
For and on behalf of
Edinburgh Pharmaceutical Industries Limited

	Title:
	President & CEO   
	Title:
	Corporate Director   

[Signature Page to Platform Technology Transfer, Collaboration and License Agreement]

Exhibit 1.18

Codexis Core Patents

	
								
	CODEXIS CORE PATENTS

	Country
	Application Title
	Application Status
	Application Number
	Filing Date
	Publication Number
	Patent
Number
	Issue
Date

	US
	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
	Granted
	12/562988
	09/18/2009
	2010/0093560
	8,383,346
	02/26/2013

	CN
	METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS
	Granted
	200980122093.2
	12/13/2010
	102066561
	200980122093.2
	09/25/2013

	CA
	METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS
	Published
	2,726,850
	12/02/2010
	2726850
	 
	 

	EP
	METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS
	Published
	9763625.2
	11/29/2010
	2285958
	 
	 

	IN
	METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS
	Published
	8090/CHEN/2010
	12/13/2010
	8090/CHENP/2010
	 
	 

	SG
	METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS
	Granted
	201009215-3
	12/13/2010
	 
	167342
	05/31/2013

- 1 -

	
								
	CA
	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
	Published
	2763017
	11/21/2011
	2763017
	 
	 

	CN
	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
	Published
	200980159766.1
	12/08/2011
	102803489
	 
	 

	EP
	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
	Published
	9845944.9
	12/05/2011
	2451951
	 
	 

	IN
	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
	Published
	9101/CHENP/2011
	12/07/2011
	9101/CHENP/2011
	 
	 

	US
	COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
	Published
	13/756778
	02/01/2013
	2013/0143767
	 
	 

	US
	METHOD OF SELECTING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS
	Granted
	12/867429
	08/12/2010
	2011/0029468
	8,504,498
	08/06/2013

- 2 -

	
								
	EP
	METHOD OF SELECTING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS
	Published
	9710859.1
	02/12/2009
	2250595
	 
	 

	EP
	METHOD OF GENERATING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS
	Published
	9710490.5
	02/12/2009
	2250594
	 
	 

	US
	METHOD OF GENERATING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS
	Granted
	12/867433
	10/21/2010
	2011/0034342
	8,768,871
	07/01/2014

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	EP
	REDUCED CODON MUTAGENESIS
	Published
	10817881.5
	03/30/2012
	2478137
	 
	 

	US
	PROTEIN VARIANT GENERATION BY REGION SHUFFLING
	Published
	13/577651
	08/07/2012
	2014/0005057
	 
	 

	EP
	PROTEIN VARIANT GENERATION BY REGION SHUFFLING
	Published
	12803889.0
	12/12/2013
	2726651
	 
	 

	WO
	GENE SHUFFLING METHODS
	Published
	PCT/US2013/030526
	03/12/2013
	WO2013138339
	 
	 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 3 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 4 -

Exhibit 1.19 

Codexis Core Technology

The enzyme optimization process starts by identifying genes that code for enzymes known to have the general type of catalytic reactivity for a desired chemical reaction. Typically, we identify gene sequences in published databases and then synthesize candidate genes having those sequences. Using a variety of biotechnology tools, we diversify these genes by introducing mutations, giving rise to changes in the enzymes for which they encode. The methods for diversifying these genes, and types of diversity being tested, often vary over the course of an enzyme optimization program. For finding initial diversity, methods typically include random mutagenesis and site-directed (included structure-guided) mutagenesis. We also test mutational variations that distinguish related enzymes among different organisms. Once we have identified potentially beneficial mutations, we test combinations of these mutations in libraries made using our proprietary gene recombination methodologies, gene shuffling and multiplexed gene SOEing, or Splicing by Overlap Extension.
With our proprietary gene shuffling methodology, we generate libraries of genes that have random combinations of the mutations we are testing. The pool of genes is used to transform host cells, which entails introducing the various genes, one by one, into host cells. These cells are then segregated and grown into colonies. Cells from individual colonies are cultured in high throughput to produce the enzyme encoded by the shuffled gene in those cells. The enzymes are then screened in high throughput using test conditions relevant to the desired process. The screening results identify individual shuffled genes that produce improved enzymes having combinations of beneficial mutations and weed out enzymes having detrimental ones. Using different test conditions and/or different analytical methods, we can identify variant enzymes that exhibit various improved performance characteristics, such as stability, activity and selectivity, under conditions relevant to the desired chemical process.
In the next step in our optimization process, we use our proprietary software tool, ProSARTM, to analyze protein sequence-activity relationships. ProSARTM aids in identifying specific gene and enzyme mutations that are beneficial, neutral or detrimental with respect to the desired performance characteristics. Earlier directed evolution methods did not separately evaluate individual mutations in libraries of variants which carry multiple mutations, where beneficial and detrimental performance characteristics may be mixed in an individual gene or enzyme. Capitalizing on the advent of inexpensive gene sequencing, we are able to determine which particular mutations are present in the genes and proteins we have screened. Our ProSARTM bioinformatics software relates the screening results to the mutations and ranks the individual mutations with regard to their degree of benefit or detriment, relative to whichever process 

- 5 -

parameter(s) the screening tested. Using that information, we can bias the pool of mutational diversity in the next iteration to further the accumulation of beneficial diversity and cancel out detrimental diversity in the individual genes in the resulting shuffled library. The ProSARTM results also help us develop ideas about new diversity to test. ProSARTM, combined with efficient gene synthesis and high quality library generation methods, has led to a significant increase in the efficiency and speed of enzyme improvement and optimization.
In another step of our optimization process, we take the best variants we have identified and prepare enough of each to test in the desired chemical process at laboratory scale, for in-process confirmation. This optimization routine is done iteratively, typically adding new diversity to the pool in each iteration. The gene that codes for the best performing enzyme in one iteration is used as the starting gene for the next iteration of shuffling and screening. As the enzymes improve over these iterations, the screening conditions are made increasingly more stringent. In this way, enzymes are rapidly optimized until all in-process performance requirements have been achieved and the economic objectives for the desired process have been met.
Multiplexed gene SOEing is our proprietary methodology for rapidly generating gene variants. Using multiplexed gene SOEing, we rapidly generate collections of individual gene variants that have predetermined, as opposed to random, combinations of mutations we are testing. It is based on a biotechnology technique, which we refer to as SOEing, generally used to make a hybrid, or spliced, gene from fragments of two genes and/or to introduce a specific mutation into a splice between fragments of one gene. We have automated the process to make robotically, in parallel, one hundred to several hundred variants, each with a predetermined combination of the mutations we are testing. The variants are introduced into host cells, and the encoded enzyme is produced and screened in high throughput, as described above.
Using multiplexed gene SOEing, we can test many mutations and combinations thereof in parallel, and because the mutation incorporation is controlled and predetermined before screening, as opposed to random incorporation and selection after screening, the resulting data set can be more optimal for ProSARTM analysis.
We believe using multiplexed gene SOEing to survey many mutations quickly, followed by ProSARTM-driven shuffling of beneficial mutations, is a particularly effective approach, providing rapid gains in enzyme performance

- 6 -

Exhibit 1.24

Codexis Enzyme Patents

	
								
	CODEXIS ENZYME PATENTS

	Country
	Application Title
	Application Status
	Application
Number
	Filing
Date
	Publication Number
	Patent
Number
	Issue
Date

	US
	TRANSAMINASE POLYPEPTIDES
	Granted
	12/684864
	01/08/2010
	2010/0209981
	8,470,564
	06/25/2013

	EP
	TRANSAMINASE POLYPEPTIDES
	Published
	10729606.3
	01/08/2010
	2385983
	 
	 

	SG
	TRANSAMINASE POLYPEPTIDES
	Published
	201104947-5
	07/06/2011
	172891
	 
	 

	IN
	TRANSAMINASE POLYPEPTIDES
	Published
	5648/CHENP/2011
	08/04/2011
	5648/CHENP/2011
	 
	 

	IL
	TRANSAMINASE POLYPEPTIDES
	Pending
	213950
	07/06/2011
	 
	 
	 

	CN
	TRANSAMINASE POLYPEPTIDES
	Published
	201080010926.9
	01/08/2010
	102341494
	 
	 

	US
	TRANSAMINASE POLYPEPTIDES
	Published
	13/920,902
	06/18/2013
	2013/0266994
	 
	 

	US
	TRANSAMINASE BIOCATALYSTS
	Granted
	12/714397
	02/26/2010
	2010/0285541
	8,293,507
	10/23/2012

	CN
	TRANSAMINASE BIOCATALYSTS
	Published
	201080017312.3
	10/19/2011
	102405281
	 
	 

	EP
	TRANSAMINASE BIOCATALYSTS
	Granted
	10746948.8
	09/26/2011
	2401366
	2401366
	12/18/2013

	IN
	TRANSAMINASE BIOCATALYSTS
	Published
	6857/CHENP/2011
	09/22/2011
	6857/CHENP/2011
	 
	 

- 1 -

	
								
	SG
	TRANSAMINASE BIOCATALYSTS
	Granted
	201106064-7
	02/26/2010
	173815
	173815
	11/15/2013

	JP
	TRANSAMINASE BIOCATALYSTS
	Published
	2011-552209
	08/23/2011
	2012-519004
	 
	 

	US
	TRANSAMINASE BIOCATALYSTS
	Published
	13/604,323
	09/05/2012
	2012/0329108
	 
	 

	DE
	TRANSAMINASE BIOCATALYSTS
	Granted
	10746948.8
	09/26/2011
	2401366
	202010012539.4
	12/18/2013

	FR
	TRANSAMINASE BIOCATALYSTS
	Granted
	10746948.8
	09/26/2011
	2401366
	2401366
	12/18/2013

	ES
	TRANSAMINASE BIOCATALYSTS
	Granted
	10746948.8
	09/26/2011
	2401366
	2401366
	12/18/2013

	CH
	TRANSAMINASE BIOCATALYSTS
	Granted
	10746948.8
	09/26/2011
	2401366
	2401366
	12/18/2013

	GB
	TRANSAMINASE BIOCATALYSTS
	Granted
	10746948.8
	09/26/2011
	2401366
	2401366
	12/18/2013

	IE
	TRANSAMINASE BIOCATALYSTS
	Granted
	10746948.8
	09/26/2011
	2401366
	2401366
	12/18/2013

	IT
	TRANSAMINASE BIOCATALYSTS
	Granted
	10746948.8
	09/26/2011
	2401366
	2401366
	12/18/2013

	NL
	TRANSAMINASE BIOCATALYSTS
	Granted
	10746948.8
	09/26/2011
	2401366
	2401366
	12/18/2013

	CN
	KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
	Published
	201080027481.5
	12/20/2011
	102482648
	 
	 

	EP
	KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
	Published
	10797576.5
	12/22/2011
	2446025
	 
	 

- 2 -

	
								
	IN
	KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
	Pending
	9363/CHENP/2011
	12/21/2011
	 
	 
	 

	SG
	KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
	Allowed
	201109538-7
	12/21/2011
	177331
	 
	 

	US
	KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
	Allowed
	13/378618
	12/15/2011
	2012/0190086
	 
	 

	EP
	KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE
	Published
	10810597.4
	03/15/2012
	2467473
	 
	 

	IN
	KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE
	Published
	 
	03/15/2012
	2372/CHENP/2012
	 
	 

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE
	Published
	13/390677
	02/15/2012
	2012/0149073
	 
	 

	SG
	KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE
	Published
	201201086-4
	02/16/2012
	178456
	 
	 

	CN
	TRANSAMINASE REACTIONS
	Published
	201080027740.4
	12/21/2011
	102597226
	 
	 

	EP
	TRANSAMINASE REACTIONS
	Published
	10797544.3
	12/22/2011
	2446026
	 
	 

	IN
	TRANSAMINASE REACTIONS
	Published
	9683/CHENP/2011
	12/22/2011
	9683/CHENP/2011
	 
	 

- 3 -

	
								
	SG
	TRANSAMINASE REACTIONS
	Published
	201109536-1
	12/21/2011
	177329
	 
	 

	US
	TRANSAMINASE REACTIONS
	Published
	13/378963
	04/09/2012
	2012/0190085
	 
	 

	IL
	TRANSAMINASE REACTIONS
	Pending
	216099
	11/02/2011
	 
	 
	 

	US
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	12/490190
	06/23/2009
	2010/0063300
	8,178,333
	05/15/2012

	CN
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Allowed
	200980133157.9
	06/24/2008
	102131813
	 
	 

	SG
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	201009300-3
	06/23/2009
	 
	167392
	08/15/2013

	EP
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	9798485.0
	06/23/2009
	2307419
	2307419
	11/06/2013

- 4 -

	
								
	IN
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Published
	397/CHENP/2011
	01/19/2011
	397/CHENP/2011
	 
	 

	US
	STEREOMERICALLY PURE FUSED BICYLIC PROLINE COMPOUNDS USEFUL FOR PREPARING HEPATITIS C PROTEASE INHIBITORS
	Allowed
	13/294930
	11/11/2011
	2012/0130087
	 
	 

	US
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	13/436506
	03/30/2012
	2012/0244581
	8,574,876
	11/05/2013

	FR
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	9798485.0
	06/23/2009
	2307419
	2307419
	11/06/2013

	DE
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	9798485.0
	06/23/2009
	2307419
	602009019988.9
	11/06/2013

- 5 -

	
								
	IE
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	9798485.0
	06/23/2009
	2307419
	2307419
	11/06/2013

	IT
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	9798485.0
	06/23/2009
	2307419
	2307419
	11/06/2013

	NL
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	9798485.0
	06/23/2009
	2307419
	2307419
	11/06/2013

	ES
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	9798485.0
	06/23/2009
	2307419
	2307419
	11/06/2013

	CH
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	9798485.0
	06/23/2009
	2307419
	2307419
	11/06/2013

- 6 -

	
								
	GB
	BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
	Granted
	9798485.0
	06/23/2009
	2307419
	2307419
	11/06/2013

	US
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Granted
	12/545761
	08/21/2009
	2010/0055751
	8,288,131
	10/16/2012

	US
	POLYNUCLEOTIEDES ENCODING ENGINEERED KETOREDUCTASE POLYPEPTIDES
	Granted
	13/610723
	09/11/2012
	2013/0005018
	8,455,230
	06/04/2013

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE
	Granted
	12/549154
	08/27/2009
	2010/0151534
	8,426,178
	04/23/2013

	EP
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE
	Published
	9810573.7
	08/27/2009
	2329013
	 
	 

	IN
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE
	Published
	2014/CHENP/2011
	03/22/2011
	2014/CHENP/2011
	 
	 

- 7 -

	
								
	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE
	Granted
	13/796985
	03/12/2013
	2013/0177962
	8,673,607
	03/18/2014

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOLYL]-4PHENYL1,3-OXAZOLIDIN-2-ONE
	Granted
	12/545034
	08/20/2009
	2010/0062499
	8,273,554
	09/25/2012

	CN
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
	Published
	200980141486.8
	04/19/2011
	102186972
	 
	 

	SG
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
	Pending
	201101090-7
	02/16/2011
	 
	 
	 

- 8 -

	
								
	EP
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
	Published
	9810477.1
	03/29/2011
	2329014
	 
	 

	IN
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
	Published
	2000/CHENP/2011
	03/22/2011
	2000/CHENP/2011
	 
	 

	US
	POLYNUCLEOTIDES ENCODING RECOMBINANT KETOREDUCTASE POLYPEPTIDES
	Granted
	13/590882
	08/21/2012
	2012/0322136A1
	8,415,126
	04/09/2013

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOLYL]-4PHENYL1,3-OXAZOLIDIN-2-ONE
	Published
	13/764596
	02/11/2013
	2013/0210098
	 
	 

	US
	ENONE REDUCTASES
	Granted
	12/646907
	12/23/2009
	2010/0190218
	8,329,438
	12/11/2012

	EP
	ENONE REDUCTASES
	Published
	9835878.1
	12/23/2009
	2382308
	 
	 

	IN
	ENONE REDUCTASES
	Published
	4505/CHENP/2011
	12/23/2009
	4505/CHENP/2011
	 
	 

- 9 -

	
								
	SG
	ENONE REDUCTASES
	Published
	201104630-7
	12/23/2009
	172783
	 
	 

	US
	ENONE REDUCTASES
	Published
	13/658582
	10/23/2012
	2013/0115663
	 
	 

	US
	RECOMBINANT HALOHYDRIN DEHALOGENASE POLYPEPTIDES
	Granted
	12/642586
	12/18/2009
	2010/0173372
	8,187,856
	05/29/2012

	IN
	RECOMBINANT HALOHYDRIN DEHALOGENASE POLYPEPTIDES
	Published
	5068/CHENP/2011
	12/18/2009
	5068/CHENP/2011
	 
	 

	US
	RECOMBINANT HALOHYDRIN DEHALOGENASE POLYPEPTIDES
	Granted
	13/452328
	04/20/2012
	2012/0220002
	8,580,555
	11/12/2013

	US
	PENICILLIN G ACYLASES
	Granted
	12/615139
	11/09/2009
	2010/0143968
	8,247,192
	08/21/2012

	US
	PENICILLIN G ACYLASES
	Granted
	13/542835
	07/06/2012
	2012/0270282
	8,569,013
	10/29/2013

	US
	NITRILASE BIOCATALYSTS
	Granted
	13/381155
	12/28/2011
	2012/0142063
	8,614,081
	12/24/2013

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE
	Granted
	12/549293
	08/27/2009
	2010/0173369
	8,288,141
	10/16/2012

	US
	POLYNUCLEOTIDES ENCODING ENGINEERED KETOREDUCTASE POLYPEPTIDES
	Published
	13/610166
	09/11/2012
	2013/0005017
	 
	 

- 10 -

	
								
	CN
	SYNTHESIS OF PRAZOLE COMPOUNDS
	Published
	201080054980.3
	06/04/2012
	102884178
	 
	 

	EP
	SYNTHESIS OF PRAZOLE COMPOUNDS
	Published
	10836590.9
	07/05/2012
	2510089
	 
	 

	IN
	SYNTHESIS OF PRAZOLE COMPOUNDS
	Published
	5934/CHENP/2012
	07/05/2012
	5934/CHENP/2012
	 
	 

	SG
	SYNTHESIS OF PRAZOLE COMPOUNDS
	Published
	201204152-1
	06/06/2012
	181535
	 
	 

	US
	SYNTHESIS OF PRAZOLE COMPOUNDS
	Published
	13/514750
	06/08/2012
	2013/0017580
	 
	 

	EP
	BIOCATALYSTS FOR EZETIMIBE SYNTHESIS
	Published
	11778262.3
	12/03/2012
	2566497
	 
	 

	IN
	BIOCATALYSTS FOR EZETIMIBE SYNTHESIS
	Published
	10077/CHENP/2012
	11/30/2012
	10077/CHENP/2012
	 
	 

	US
	BIOCATALYSTS FOR EZETIMIBE SYNTHESIS
	Published
	13/695856
	11/02/2012
	2013/0052699
	 
	 

	US
	PROCESSES USING AMINO ACID DEHYDROGENASES AND KETOREDUCTASE-BASED COFACTOR REGENERATING SYSTEM
	Published
	13/577772
	10/16/2012
	2013/0029385
	 
	 

- 11 -

	
								
	IN
	PROCESSES USING AMINO ACID DEHYDROGENASES AND KETOREDUCTASE-BASED COFACTOR REGENERATING SYSTEM
	Published
	7740/CHENP/2012
	09/07/2012
	7740/CHENP/2012
	 
	 

	SG
	STRUCTURE-ACTIVITY RELATIONSHIPS
	Published
	201200817-3
	02/12/2001
	178753
	 
	 

	US
	STRUCTURE-ACTIVITY RELATIONSHIPS
	Published
	13/757554
	02/01/2013
	2013/0165341
	 
	 

	US
	STRUCTURE-ACTIVITY RELATIONSHIPS
	Published
	13/764252
	02/11/2013
	2013/0157900
	 
	 

	CN
	KETOREDUCTASES AND USES THEREOF
	Granted
	200880004582.3
	02/08/2008
	CN 101627116A
	ZL2008 8 0004582.3
	07/10/2013

	SG
	KETOREDUCTASES AND USES THEREOF
	Granted
	200904674-9
	02/08/2008
	 
	154045
	03/30/2012

	KR
	KETOREDUCTASES AND USES THEREOF
	Pending
	10-2009-7016084
	02/08/2008
	 
	 
	 

	US
	KETOREDUCTASES AND USES THEREOF
	Granted
	12/028,780
	02/08/2008
	2008/0318295
	7,820,421
	10/26/2010

	EP
	KETOREDUCTASES AND USES THEREOF
	Granted
	8725329.0
	02/08/2008
	2115130
	2115130
	08/03/2011

	IL
	KETOREDUCTASES AND USES THEREOF
	Pending
	199399
	02/08/2008
	 
	 
	 

	JP
	KETOREDUCTASES AND USES THEREOF
	Published
	2009-549110
	02/08/2008
	2010-517574
	 
	 

	US
	KETOREDUCTASES AND USES THEREOF
	Granted
	12/881734
	09/14/2010
	2011/0165670
	8,071,347
	12/06/2011

- 12 -

	
								
	CH
	KETOREDUCTASES AND USES THEREOF
	Granted
	8725329.0
	02/08/2008
	2115130
	2115130
	08/03/2011

	DE
	KETOREDUCTASES AND USES THEREOF
	Granted
	8725329.0
	02/08/2008
	2115130
	2115130
	08/03/2011

	FR
	KETOREDUCTASES AND USES THEREOF
	Granted
	8725329.0
	02/08/2008
	2115130
	2115130
	08/03/2011

	GB
	KETOREDUCTASES AND USES THEREOF
	Granted
	8725329.0
	02/08/2008
	2115130
	2115130
	08/03/2011

	IE
	KETOREDUCTASES AND USES THEREOF
	Granted
	8725329.0
	02/08/2008
	2115130
	2115130
	08/03/2011

	NL
	KETOREDUCTASES AND USES THEREOF
	Granted
	8725329.0
	02/08/2008
	2115130
	2115130
	08/03/2011

	US
	KETOREDUCTASES AND USES THEREOF
	Granted
	13/290773
	11/07/2011
	2012/0178142
	8,415,127
	04/09/2013

	US
	KETOREDUCTASES AND USES THEREOF
	Published
	13/793158
	03/11/2013
	2013/0196408
	 
	 

	JP
	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
	Allowed
	2007-526267
	06/04/2005
	 
	5042831
	 

	DE
	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
	Granted
	102004029112.8
	06/11/2004
	 
	1763577
	10/06/2010

- 13 -

	
								
	EP
	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
	Granted
	5756002.1
	06/04/2005
	1763577
	1763577
	10/06/2010

	US
	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
	Granted
	11/629000
	12/08/2006
	2009/0162893
	7,943,356
	05/17/2011

	GB
	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
	Granted
	5756002.1
	06/04/2005
	1763577
	1763577
	10/06/2010

	IT
	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
	Granted
	5756002.1
	06/04/2005
	1763577
	1763577
	10/06/2010

	AT
	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
	Granted
	5756002.1
	06/04/2005
	1763577
	1763577
	10/06/2010

- 14 -

	
								
	FR
	ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
	Granted
	5756002.1
	06/04/2005
	1763577
	1763577
	10/06/2010

	SG
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
	Granted
	201000745-8
	08/24/2008
	 
	159008
	09/14/2012

	IN
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
	Pending
	1624/CHENP/2010
	08/24/2008
	 
	 
	 

	EP
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
	Published
	8798570.1
	08/24/2008
	2195443
	 
	 

	CN
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
	Published
	200880104011.7
	08/24/2008
	101784669
	 
	 

- 15 -

	
								
	US
	KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
	Granted
	12/197286
	08/24/2008
	2009/0093031
	7,977,078
	07/12/2011

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (r)-3-HYDROXYTHIOLANE
	Granted
	13/110789
	05/18/2011
	2011/0217754
	8,227,229
	07/24/2012

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (r)-3-HYDROXYTHIOLANE
	Published
	13/525048
	06/15/2012
	2012/0276599
	 
	 

	CN
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	200880115770.3
	09/13/2008
	101855342
	ZL 2008 8 0115770.3
	07/10/2013

	JP
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Published
	2010-525057
	09/13/2008
	2010-538657
	 
	 

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	12/210195
	09/13/2008
	2009/0191605
	8,748,143
	06/10/2014

	IN
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Pending
	2039/CHENP/2010
	09/13/2008
	 
	 
	 

	SG
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	201001576-6
	09/13/2008
	 
	159828
	04/13/2012

- 16 -

	
								
	EP
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	8830789.7
	09/13/2008
	2198018
	2198018
	11/20/2013

	KR
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Pending
	10-2010-7007675
	09/13/2008
	 
	 
	 

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	13/682600
	11/20/2012
	2013/0078692
	8,512,973
	08/20/2013

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Allowed
	13/970284
	08/19/2013
	2013/0344552
	 
	 

	DE
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	8830789.7
	09/13/2008
	2198018
	602008028883.8
	11/20/2013

	FR
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	8830789.7
	09/13/2008
	2198018
	2198018
	11/20/2013

	CH
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	8830789.7
	09/13/2008
	2198018
	2198018
	11/20/2013

	GB
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	8830789.7
	09/13/2008
	2198018
	2198018
	11/20/2013

	IE
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	8830789.7
	09/13/2008
	2198018
	2198018
	11/20/2013

- 17 -

	
								
	NL
	KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
	Granted
	8830789.7
	09/13/2008
	2198018
	2198018
	11/20/2013

	SG
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Granted
	201001902-4
	09/28/2008
	 
	160022
	07/31/2013

	US
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Granted
	12/240986
	09/29/2008
	2009/0155863
	8,088,610
	01/03/2012

	CN
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Allowed
	200880118039.6
	09/28/2008
	101889081
	ZL200880118039.6
	06/18/2014

	EP
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Granted
	8833139.2
	09/28/2008
	2203557
	2203557
	02/29/2012

	IN
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Pending
	2378/CHENP/2010
	09/28/2008
	 
	 
	 

	IL
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Granted
	204331
	09/28/2008
	 
	204331
	07/31/2013

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (S,3)-METHYL2-(3-(3-(2(7-CHLOROQUINOLIN-2-YL)VINYL)PHENYL)-3-HYDROXYPROPYL)BENZOATE
	Granted
	13/329986
	12/19/2011
	2012/0184000
	8,617,853
	12/31/2013

	DE
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Granted
	8833139.2
	09/28/2008
	2203557
	2203557
	02/29/2012

- 18 -

	
								
	IE
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Granted
	8833139.2
	09/28/2008
	2203557
	2203557
	02/29/2012

	NL
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Granted
	8833139.2
	09/28/2008
	2203557
	2203557
	02/29/2012

	CH
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Granted
	8833139.2
	09/28/2008
	2203557
	2203557
	02/29/2012

	GB
	KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
	Granted
	8833139.2
	09/28/2008
	2203557
	2203557
	02/29/2012

	EP
	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF ARMODAFINIL
	Published
	EP11846568.1
	06/14/2013
	2649187
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	US
	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF ARMODAFINIL
	Published
	13/992138
	06/06/2013
	2013/0260426
	 
	 

	EP
	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL
	Published
	11796441.1
	12/17/2012
	2582799
	 
	 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 19 -

	
								
	IN
	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL
	Pending
	267/CHENP/2013
	01/11/2013
	 
	 
	 

	US
	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL
	Allowed
	13/704507
	12/14/2012
	2013/0089898
	 
	 

	EP
	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE
	Published
	11818555.2
	04/29/2013
	2606139
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	US
	BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE
	Published
	13/817295
	03/12/2013
	2013/0164794
	 
	 

	SG
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
	Granted
	201001989-1
	10/01/2008
	 
	160517
	05/05/2014

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
	Granted
	12/243,968
	10/01/2008
	2009/0162909
	7,883,879
	02/08/2011

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 20 -

	
								
	EP
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
	Published
	8836133.2
	10/01/2008
	2205727
	 
	 

	IL
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
	Pending
	204379
	10/01/2008
	 
	 
	 

	JP
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
	Pending
	2010-527257
	10/01/2008
	 
	 
	 

	IN
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
	Pending
	2450/CHENP/2010
	10/01/2008
	 
	 
	 

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
	Granted
	12/977,825
	12/23/2010
	2011/0159567
	8,257,952
	09/04/2012

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
	Granted
	13/569900
	08/08/2012
	2013/0034895
	8,470,572
	06/25/2013

	US
	KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
	Published
	13/925096
	06/24/2013
	2014/0057330
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	EP
	BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF
	Published
	12771861.7
	11/06/2013
	2697662
	 
	 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 21 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	WO
	BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS
	Published
	PCT/US13/039874
	05/07/2013
	WO2013/169725
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	WO
	BIOCATALYSTS FOR THE PREPARATION OF HYDROXY SUBSTITUTED CARBAMATES
	Published
	PCT/US2012/065046
	11/14/2012
	WO2013/074650
	 
	 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 22 -

	
								
	[***]
	[***]
	[***]
	 
	 
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	[***] 
	 
	 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 23 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	IN
	IMPROVED KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	514/CHENP/2006
	08/11/2004
	 
	239120
	03/09/2010

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 24 -

	
								
	SG
	IMPROVED KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	200600860-1
	08/11/2004
	 
	119648
	12/31/2008

	US
	KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	10/916311
	08/11/2004
	2006/0195947
	7,629,157
	12/08/2009

	US
	KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	12/576195
	10/08/2009
	2010/0028972
	7,833,767
	11/16/2010

	EP
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	3785237.3
	08/11/2003
	1537222
	1537222
	03/09/2011

	US
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	11/502745
	08/10/2006
	2007/0161094
	7,807,423
	10/05/2010

	US
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES AND VICINAL CYANO, HYDROXY SUBSTITUTED CARBOXYLIC ACID ESTERS
	Granted
	10/782258
	02/18/2004
	2004/0214297 A1
	7,132,267
	11/07/2006

- 25 -

	
								
	US
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	10/639159
	08/11/2003
	2004/0137585
	7,125,693
	10/24/2006

	IN
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYR1C ACID DERIVATIVES
	Granted
	158/CHENP/2005
	08/11/2003
	 
	220964
	06/11/2008

	SG
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	2005007634-8
	08/11/2003
	 
	109875
	08/31/2007

	SG
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-RYDROXYBUTYRIC ACID DERIVATIVES AND VICINAL CYANO, HYDROXY SUBSTITUTED CARBOXYLIC ACID ESTERS
	Granted
	200600847-8
	02/18/2004
	 
	119636
	02/29/2008

	JP
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	2004-528083
	08/11/2003
	2005-535330
	4578240
	09/03/2010

	HK
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	5108017.7
	08/11/2003
	 
	HK1074059
	09/09/2011

- 26 -

	
								
	FR
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	3785237.3
	08/11/2003
	1537222
	1537222
	03/09/2011

	DE
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	3785237.3
	08/11/2003
	1537222
	1537222
	03/09/2011

	IE
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	3785237.3
	08/11/2003
	1537222
	1537222
	03/09/2011

	NL
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	3785237.3
	08/11/2003
	1537222
	1537222
	03/09/2011

	GB
	ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
	Granted
	3785237.3
	08/11/2003
	1537222
	1537222
	03/09/2011

	SG
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	200600859-3
	08/11/2004
	 
	119647
	02/27/2009

	US
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	12/790784
	05/28/2010
	2010/0304459
	7,939,309
	05/10/2011

- 27 -

	
								
	IN
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	521/CHENP/2006
	08/11/2004
	 
	239922
	04/09/2010

	AU
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	2004288134
	08/11/2004
	 
	2004288134
	04/01/2010

	US
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	10/915927
	08/11/2004
	2005/0095619A1
	7,816,111
	10/19/2010

	EP
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	4816807.4
	08/11/2004
	1660648
	1660648
	10/09/2013

	FR
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	4816807.4
	08/11/2004
	1660648
	1660648
	10/09/2013

	DE
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	4816807.4
	08/11/2004
	1660648
	602004043547.3
	10/09/2013

	IE
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	4816807.4
	08/11/2004
	1660648
	1660648
	10/09/2013

- 28 -

	
								
	NL
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	4816807.4
	08/11/2004
	1660648
	1660648
	10/09/2013

	CH
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	4816807.4
	08/11/2004
	1660648
	1660648
	10/09/2013

	GB
	IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
	Granted
	4816807.4
	08/11/2004
	1660648
	1660648
	10/09/2013

	US
	HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
	Granted
	12/573824
	10/05/2009
	2010/0167345
	8,101,395
	01/24/2012

	US
	HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
	Granted
	10/917179
	08/11/2004
	2005/0153417
	7,824,898
	11/02/2010

	IN
	IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
	Granted
	519/CHENP/2006
	08/11/2004
	 
	239852
	04/06/2010

	SG
	IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
	Granted
	200808477-4
	11/14/2008
	148180
	148180
	01/30/2014

	US
	IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
	Granted
	11/266747
	11/02/2005
	2006/0099700
	7,588,928
	09/15/2009

- 29 -

	
								
	US
	IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
	Granted
	11/067323
	02/23/2005
	2005/0272064
	7,541,171
	06/02/2009

	US
	IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
	Granted
	12/505374
	07/17/2009
	2009/0298125
	8,252,554
	08/28/2012

	US
	HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
	Granted
	13/349514
	01/12/2012
	2012/0208259
	8,535,910
	09/17/2013

	US
	ALANINE 2,3-AMINOMUTASES AND RELATED POLYNUCLEOTIDES
	Granted
	11/919271
	03/20/2009
	2010/0099143
	7,790,432
	09/07/2010

	IN
	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
	Pending
	2322/CHENP/2009
	10/01/2007
	 
	 
	 

	SG
	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
	Granted
	200901677-5
	10/01/2010
	 
	150849
	01/30/2014

- 30 -

	
								
	EP
	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
	Allowed
	7843631.8
	10/01/2007
	2066788
	 
	 

	CN
	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
	Published
	200780036841.6
	10/01/2007
	101528917
	 
	 

	US
	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
	Granted
	11/865696
	10/01/2007
	2004/0248539
	7,879,585
	02/01/2011

	US
	COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
	Granted
	12/978022
	12/23/2010
	2011/0195465
	8,273,547
	09/25/2012

	US
	POLYNUCLEOTIDES ENCODING KETOREDUCTASES FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
	Granted
	13/571,248
	08/09/2012
	2013/0040364
	8,617,864
	12/31/2013

- 31 -

	
								
	EP
	ENZYMATIC CONVERSION OF EPOXIDES
	Granted
	1934641.0
	05/23/2001
	1287155
	1287155
	08/23/2006

	CH
	ENZYMATIC CONVERSION OF EPOXIDES
	Granted
	1934641.0
	05/23/2001
	1287155
	1287155
	08/23/2006

	US
	ENZYMATIC CONVERSION OF EPDXIDES
	Granted
	11/833933
	08/03/2007
	2008/0220485
	7,695,942
	04/13/2010

	FR
	ENZYMATIC CONVERSION OF EPOXIDES
	Granted
	1934641.0
	05/23/2001
	1287155
	1287155
	08/23/2006

	DE
	ENZYMATIC CONVERSION OF EPOXIDES
	Granted
	1934641.0
	05/23/2001
	1287155
	60122505.8
	08/23/2006

	GB
	ENZYMATIC CONVERSION OF EPOXIDES
	Granted
	1934641.0
	05/23/2001
	1287155
	1287155
	08/23/2006

	IE
	ENZYMATIC CONVERSION OF EPOXIDES
	Granted
	1934641.0
	05/23/2001
	1287155
	1287155
	08/23/2006

	NL
	ENZYMATIC CONVERSION OF EPOXIDES
	Granted
	1934641.0
	05/23/2001
	1287155
	1287155
	08/23/2006

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 32 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 33 -

Exhibit 1.30

Codexis Mayflower Patents

	
								
	CODEXIS MAYFLOWER PATENTS

	Country
	Application Title
	Application Status
	Application Number
	Filing Date
	Publication Number
	Patent Number
	Issue
Date

	GB
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	96940934.1
	12/02/1996
	876509
	876509
	09/19/2001

	US
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	09/075511
	05/08/1998
	 
	6,165,793
	12/26/2000

	AU
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	2005202165
	12/02/1996
	 
	2005202165
	06/26/2008

	CA
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	2239099
	12/02/1996
	2239099
	2239099
	11/30/2004

	EP
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	96940934.1
	12/02/1996
	876509
	876509
	09/19/2001

	BE
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	96940934.1
	12/02/1996
	876509
	876509
	09/19/2001

	NL
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	96940934.1
	12/02/1996
	876509
	876509
	09/19/2001

	DK
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	96940934.1
	12/02/1996
	876509
	876509
	09/19/2001

- 1 -

	
								
	FR
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	96940934.1
	12/02/1996
	876509
	876509
	09/19/2001

	DE
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	96940934.1
	12/02/1996
	876509
	876509
	09/19/2001

	KR
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	96-0704465
	02/17/1995
	 
	491810
	05/19/2005

	CH
	METHOD FOR IN VITRO RECOMBINATION
	Granted
	96940934.1
	12/02/1996
	876509
	876509
	09/19/2001

	US
	END-COMPLEMENTARY POLYMERASE REACTION
	Granted
	08/425684
	04/18/1995
	 
	5,834,252
	11/10/1998

	US
	END-COMPLEMENTARY POLYMERASE REACTION
	Granted
	08/675502
	07/03/1996
	 
	5,928,905
	07/27/1999

	US
	END-COMPLEMENTARY POLYMERASE REACTION
	Granted
	09/245802
	02/05/1999
	 
	6,489,146
	12/03/2002

	US
	EVOLVING CELLULAR DNA UPTAKE BY RECURSIVE SEQUENCE RECOMBINATION
	Granted
	09/724067
	11/28/2000
	 
	6,482,647
	11/19/2002

	US
	EVOLVING CELLULAR DNA UPTAKE BY RECURSIVE SEQUENCE RECOMBINATION
	Granted
	08/792409
	02/03/1997
	 
	6,096,548
	08/01/2000

- 2 -

	
								
	US
	EVOLVING CELLULAR DNA UPTAKE BY RECURSIVE SEQUENCE RECOMBINATION
	Granted
	09/430927
	11/01/1999
	 
	6,358,742
	03/19/2002

	US
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	10/646221
	08/22/2003
	 
	7,534,564
	05/19/2009

	US
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	09/954692
	09/12/2001
	 
	6,946,296
	09/20/2005

	US
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	08/769062
	12/18/1996
	 
	6,335,160
	01/01/2002

	GB
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

	US
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	09/693389
	10/20/2000
	 
	6,586,182
	07/01/2003

	US
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	09/693350
	10/20/2000
	 
	6,579,678
	06/17/2003

	US
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	09/339913
	06/24/1999
	 
	6,303,344
	10/16/2001

	US
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	09/339926
	06/24/1999
	 
	6,653,072
	11/25/2003

- 3 -

	
								
	US
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	12/069011
	02/05/2008
	 
	7,776,598
	08/17/2010

	CA
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	2274319
	12/17/1997
	 
	2274319
	04/09/2013

	BE
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

	CA
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Published
	2589337
	12/17/1997
	2589337
	 
	 

	MC
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

	CH
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

	EP
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	10075154.4
	12/17/1997
	 
	2202308
	02/13/2013

	EP
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

	DK
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

- 4 -

	
								
	JP
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	10-528054
	12/17/1997
	 
	5008784
	06/08/2012

	FR
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

	LU
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

	FI
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

	DE
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	1149905
	69739996.6-08
	09/15/2010

	GR
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

	NL
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	1202350.3
	12/17/1997
	 
	1149905
	09/15/2010

	BE
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	10075154.4
	12/17/1997
	 
	2202308
	02/13/2013

	DE
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	10075154.4
	12/17/1997
	 
	2202308
	02/13/2013

- 5 -

	
								
	GB
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	10075154.4
	12/17/1997
	 
	2202308
	02/13/2013

	CH
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	10075154.4
	12/17/1997
	 
	2202308
	02/13/2013

	DK
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	10075154.4
	12/17/1997
	 
	2202308
	02/13/2013

	FR
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	10075154.4
	12/17/1997
	 
	2202308
	02/13/2013

	NL
	METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING
	Granted
	10075154.4
	12/17/1997
	 
	2202308
	02/13/2013

	US
	METHOD FOR PRODUCING POLYNUCLEOTIDES WITH DESIRED PROPERTIES
	Granted
	09/333762
	06/15/1999
	 
	6,337,186
	01/08/2002

	US
	OPTIMIZATION OF INSECT RESISTANCE GENES USING DNA SHUFFLING
	Granted
	09/296886
	04/22/1999
	 
	6500617
	12/31/2002

	US
	DNA SHUFFLING OF MONOOXYENASE GENES FOR PRODUCTION OF INDUSTRIAL CHEMICALS
	Granted
	09/373,928
	08/12/1999
	 
	6,605,430
	08/12/2003

- 6 -

	
								
	US
	HIGH THROUGHPUT MASS SPECTROMETRY
	Granted
	09/502,283
	02/11/2000
	 
	7,384,387
	06/10/2008

	US
	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
	Granted
	11/339090
	01/24/2006
	 
	7,620,502
	11/17/2009

	US
	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
	Granted
	11/975638
	10/18/2007
	 
	7,853,410
	12/14/2010

	US
	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
	Granted
	12/557463
	09/10/2009
	 
	7,957,912
	06/07/2011

	US
	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
	Granted
	11/982405
	10/31/2007
	 
	7,904,249
	03/08/2011

- 7 -

	
								
	US
	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
	Granted
	09/618579
	07/18/2000
	 
	7,024,312
	04/04/2006

	US
	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
	Granted
	09/539486
	03/30/2000
	 
	7,058,515
	06/06/2006

	US
	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
	Granted
	09/494282
	01/18/2000
	 
	6,917,882
	07/12/2005

	US
	METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
	Granted
	11/075231
	03/07/2005
	 
	7,421,347
	09/02/2008

	US
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	09/626929
	07/27/2000
	 
	6,319,714
	11/20/2001

	GB
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	909923.5
	01/18/2000
	 
	1072010
	04/21/2010

- 8 -

	
								
	US
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	09/694863
	10/23/2000
	 
	6,521,453
	02/18/2003

	US
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	11/987555
	11/30/2007
	 
	8,029,988
	10/04/2011

	US
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	12/557829
	09/11/2009
	 
	8,058,001
	11/15/2011

	CA
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Published
	2320697
	01/18/2000
	2320697
	 
	 

	CH
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	909923.5
	01/18/2000
	 
	1072010
	04/21/2010

	EP
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	909923.5
	01/18/2000
	 
	1072010
	04/21/2010

	EP
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Published
	10075153.6
	01/18/2000
	2253704
	 
	 

	BE
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	909923.5
	01/18/2000
	 
	1072010
	04/21/2010

	DK
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	909923.5
	01/18/2000
	 
	1072010
	04/21/2010

- 9 -

	
								
	FR
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	909923.5
	01/18/2000
	 
	1072010
	04/21/2010

	DE
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	909923.5
	01/18/2000
	 
	1072010
	04/21/2010

	NL
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	909923.5
	01/18/2000
	 
	1072010
	04/21/2010

	US
	OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
	Granted
	09/626595
	07/27/2000
	 
	6,479,652
	11/12/2002

	US
	RECOMBINATION OF INSERTION MODIFIED NUCLEIC ACIDS
	Granted
	09/723520
	11/27/2000
	 
	6,413,745
	07/02/2002

	US
	RECOMBINATION OF INSERTION MODIFIED NUCLEIC ACIDS
	Granted
	09/723473
	11/27/2000
	 
	6,358,740
	03/19/2002

	US
	RECOMBINATION OF INSERTION MODIFIED NUCLEIC ACIDS
	Granted
	09/517933
	03/03/2000
	 
	6,365,377
	04/02/2002

	US
	OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION
	Granted
	12/557434
	09/10/2009
	 
	8,108,150
	01/31/2012

	US
	OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION
	Granted
	11/818237
	06/12/2007
	 
	8,224,580
	07/17/2012

- 10 -

	
								
	US
	OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION
	Granted
	10/386903
	03/10/2003
	198988
	7620500
	11/17/2009

	JP
	OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION
	Granted
	2003-576577
	03/10/2003
	 
	4851687
	 

	EP
	OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION
	Published
	3711540.9
	03/10/2003
	1488335
	 
	 

	US
	INTEGRATED SYSTEMS AND METHODS FOR DIVERSITY GENERATION AND SCREENING
	Granted
	11/677505
	02/21/2007
	 
	8,014,961
	09/06/2011

	US
	INTEGRATED SYSTEMS AND METHODS FOR DIVERSITY GENERATION AND SCREENING
	Granted
	10/154936
	05/23/2002
	 
	7,462,469
	12/09/2008

	US
	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
	Granted
	12/557746
	09/11/2009
	 
	8,170,806
	05/01/2012

	US
	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
	Granted
	11/973805
	10/09/2007
	 
	7,873,499
	01/18/2011

- 11 -

	
								
	US
	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
	Granted
	11/210239
	08/22/2005
	 
	7,430,477
	09/30/2008

	US
	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
	Granted
	13/434261
	03/29/2012
	 
	8,589,085
	11/19/2013

	US
	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
	Granted
	09/495668
	02/01/2000
	 
	6,961,664
	11/01/2005

	CA
	METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
	Granted
	2337949
	01/18/2000
	 
	2337949
	03/15/2011

	US
	METHOD AND SYSTEM USING SYSTEMATICALLY VARIED DATA LIBRARIES
	Granted
	10/225564
	08/20/2002
	 
	7,873,477
	01/18/2011

	US
	METHOD AND APPARATUS FOR PREFERREED CODON DETERMINING SIMULATIONS
	Granted
	10/232770
	08/30/2002
	 
	7,702,464
	04/20/2010

- 12 -

	
								
	US
	METHOD AND APPARATUS FOR PREFERREED CODON DETERMINING SIMULATIONS
	Granted
	13/229228
	09/09/2011
	 
	8,457,903
	06/04/2013

	EP
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	10181057.0
	09/28/2010
	 
	2390803
	11/20/2013

	US
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Published
	12/979,637
	12/28/2010
	2011/0161265
	 
	 

	BE
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	5779687.2
	06/21/2005
	 
	1761879
	08/14/2013

	FR
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	5779687.2
	06/21/2005
	 
	1761879
	08/14/2013

	GB
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	5779687.2
	06/21/2005
	 
	1761879
	08/14/2013

- 13 -

	
								
	DE
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	5779687.2
	06/21/2005
	 
	1761879
	08/14/2013

	DK
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	5779687.2
	06/21/2005
	 
	1761879
	08/14/2013

	BE
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	10181057.0
	09/28/2010
	 
	2390803
	11/20/2013

	GB
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	10181057.0
	09/28/2010
	 
	2390803
	11/20/2013

	DE
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	10181057.0
	09/28/2010
	 
	2390803
	11/20/2013

	NL
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	10181057.0
	09/28/2010
	 
	2390803
	11/20/2013

- 14 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	FR
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	10181057.0
	09/28/2010
	 
	2390803
	11/20/2013

	CH
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	10181057.0
	09/28/2010
	 
	2390803
	11/20/2013

	DK
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	10181057.0
	09/28/2010
	 
	2390803
	11/20/2013

	CH
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	5779687.2
	06/21/2005
	 
	1761879
	08/14/2013

	NL
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	5779687.2
	06/21/2005
	 
	1761879
	08/14/2013

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 15 -

	
								
	JP
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	2003-573522
	03/03/2003
	 
	5,319,865
	07/19/2013

	US
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	11/981577
	10/30/2007
	 
	7,751,986
	07/06/2010

	US
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	11/706034
	02/12/2007
	 
	7,747,393
	06/29/2010

	US
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Allowed
	11/429628
	05/05/2006
	2006/0205003
	 
	 

	US
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	10/629351
	07/29/2003
	 
	7,747,391
	06/29/2010

	US
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	10/379378
	03/03/2003
	 
	7,783,428
	08/24/2010

- 16 -

	
								
	EP
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	5779687.2
	06/21/2005
	 
	1761879
	08/14/2013

	EP
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Allowed
	3743748.0
	03/03/2003
	1493027
	 
	 

	EP
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Published
	10181000.0
	09/28/2010
	2278509
	 
	 

	US
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Granted
	11/981578
	10/30/2007
	 
	8,762,066
	06/24/2014

	EP
	METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
	Published
	10181159.4
	09/28/2010
	2315145
	 
	 

- 17 -

Exhibit 1.74

In-License Agreements
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 1 -

Exhibit 1.77

In-Licensed Patents

	
								
	Country
	Application Title
	Application Status
	Application No.
	Filing Date
	Publication No.
	Pat. No.
	Issue Date

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 1 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 2 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 3 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	 
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 4 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 5 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 6 -

	
								
	[***]
	[***]
	[***]
	[***]
[***]
	[***]
	[***]
[***]
	 
	 

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	 
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 7 -

	
								
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 8 -

Exhibit 1.80

Invoice Requirements

All payments subsequent to the Upfront Payment to Codexis due under this Agreement shall be paid within [***] days after the date of receipt of the relevant Invoice by GSK, and as according to Article 7 of this Agreement. The Upfront Payment to Codexis shall be paid within [***] after receipt of the relevant Invoice from Codexis by GSK in accordance with Section 7.1.
The invoice should include the following details:
(a)    “INVOICE” stated at the top and addressed to 
GlaxoSmithKline Intellectual Property Development Limited 
980 Great West Road,  
Brentford,  
Middlesex,  
TW8 9GS  
United Kingdom
(b)    Bank details
(c)    Codexis letterhead. 
(d)    Invoice Number, Currency and Date
(e)    Complete Name, Address, Contact name and number
(f)    Amount being invoiced
(g)    VAT Registration number where VAT is being charged
(i)    Following GSK Information: 
• GSK Contact for Invoices : [***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 1 -

Exhibit 1.112

Restricted Enzymes

To be provided in accordance with Section 3.7.1

- 1 -

Exhibit 1.117

Technology Transfer Plan

- 1 -

Technology Transfer Plan
Establishment of Codexis CodeEvolver® 
Directed Evolution Technology 
at GSK’s site in Upper Merion, PA

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 2

		
	1.
	EXECUTIVE SUMMARY

The scope of this Plan is the full implementation of Codexis’ biocatalyst screening and CodeEvolver® directed evolution technology within GlaxoSmithKline (GSK), in order to augment GSK’s capabilities in cost efficient development and manufacture of pharmaceutical compounds (also referred to within the plan as API’s). The complete transfer of Codexis technology to one GSK site (Upper Merion, PA (UM)) will be accomplished across the following three Waves:

		
	1)
	Transfer of the Codexis [***]. 

		
	2)
	Enabling GSK to practice CodeEvolver® comprising: 

a. GSK laboratory set-up; including transfer of the Codexis informatics [***].
b. Training in Codexis labs with Technology Transfer Evolution [***]
c. Training in GSK labs with Technology Transfer Evolution [***]
		
	3)
	Demonstration of proficiency of the GSK team with Technology Transfer Evolution [***]. 

Codexis and GSK will establish dedicated Training Teams to facilitate the Technology Transfer.  Codexis Team (as defined in Section 2.2.5 (b) in the Platform Technology Transfer, Collaboration, and License Agreement) will include personnel for [***]. Based on the work plan, [***]. 
Likewise, dedicated GSK personnel will shadow Codexis Team and then conduct evolution programs at GSK, to set up and deploy equipment, and provide general program management support.  [***].

2.  TECHNOLOGY TRANSFER PROGRAM SCOPE
2.1  WAVE 1: TRANSFER OF CODEXIS SCREENING CAPABILITIES TO GSK
[***]
[***] 
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 3

[***] 
[***]  

[***]

	
				
	Step
	Inputs
	Process
	Output

	Materials

	 
	[***] 
[***]
	[***]
	[***]

	 
	[***]

	[***]
	[***]

	 
	[***]
	[***] 
	[***]

	 
	[***]
	[***] 
	[***]

	Methods

	 
	[***]
	 
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 4

	
				
	 
	[***]
	[***]
	[***]

	 
	[***]
[***]
	[***] 
	[***]

	 
	[***]  
[***]
	[***]
	[***] 

		
	•
	Wave 1 Milestone Success Criteria

		
	1.
	[***]

		
	2.
	[***]

		
	3.
	[***]

		
	4.
	[***]

[***]

2.2  WAVE 2: ENABLING GSK TO PRACTICE CODEEVOLVER®
[***]
[***]
		
	1)
	[***]

		
	2)
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 5

		
	3)
	[***]

[***]
[***]

	
				
	Step
	Inputs
	Process
	Output

	Materials

	 
	[***]
	[***] 
	[***]

	Methods

	 
	[***]
	•   [***]
	[***]

	 
	[***]
	•   [***]
	[***]

	 
	[***]
	•   [***]
•   [***]
•   [***]
•   [***]
•   [***]
•   [***]
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 6

	
				
	 
	[***]
	•   [***]
•   [***]
	[***]

	 
	[***]
	•   [***] 
•   [***]
	[***]

	 
	[***]
	•   [***]
•   [***]
	[***]

	 
	[***]
	•   [***]
•   [***]
	[***]

	 
	[***]
	•   [***]
•   [***]
•   [***]
•   [***]
•   [***]
•   [***]

	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 7

	
				
	 
	[***]
	•   [***]
•   [***]
	[***]

	 
	[***]
	•   [***] 
•   [***] 
	[***]

	 
	[***]
	•   [***]
•   [***]
	[***]

	 
	[***]
	•   [***]
•   [***]
	[***]

	 
	[***]
	[***]
	[***]
•   [***]
•   [***]

	 
	[***]
	[***]
	[***]
•   [***]
•   [***]

[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 8

[***]

[***]

		
	•
	Wave 2 Milestone Success Criteria

		
	1.
	[***]

		
	2.
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	3.
	[***]

2.3  WAVE 3: DEMONSTRATED PROFICIENCY OF GSK TEAM ACROSS TWO INDEPENDENT PROJECTS
[***]
[***]
[***]
		
	•
	[***]

		
	•
	[***]

		
	•
	[***] 

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

[***]

		
	•
	Wave 3 Milestone Success Criteria

		
	4.
	[***]

		
	•
	[***]

		
	•
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 9

		
	•
	[***]

		
	•
	[***]

		
	5.
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]  

2.4 INDICATIVE GANTT CHART
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 10

3.  PERSONNEL COMPETENCY REQUIREMENTS
Codexis will provide the following competencies to support successful technology transfer:
		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 11

APPENDIX I - TRANSFER OF MATERIALS (WAVE 1)

[***]
		
	1)
	[***]

		
	A)
	[***]

	
						
	Platform
	Short
Name
	# of 96-well
Plates
per Panel
	# of Enzymes
per Kit
	Format
	Quantity
Provided

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]

[***]
[***]
[***]
[***] [***]

B) [***]
		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 12

		
	2)
	[***]

	
					
	Platform
	Short Name
	Format
	Number of Enzymes
	Quantity
Provided

	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]

	[***]
	 
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]
	[***]
	[***]

		
	3)
	[***]

	
			
	Platform
	Short
Name
	Format

	[***]
	[***]
	[***]

[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 13

APPENDIX II – EQUIPMENT LIST
	
	
	Principal Equipment

	[***]

	[***]

	[***]  

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***] 

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***]

	[***] 

	[***]

	[***]

	[***] 

	[***]

	[***] 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 14

APPENDIX III - SOFTWARE LIST

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

		
	•
	[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 15

APPENDIX IV- PROTOCOLS AND SOP LIST

[***]

    
[***]
[***] 
[***]
[***]
[***]

************************************************************************

[***]

[***] 
[***]
[***]
[***] 
    
************************************************************************

[***]

[***]
[***]
[***]

************************************************************************

[***]

[***]
[***]
[***]
[***]

************************************************************************

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

GSK-Codexis Technology Transfer
Page 16

[***]
[***]
[***]
[***]

************************************************************************

[***]

[***]
[***]
[***]

************************************************************************

[***]

[***]
[***]
[***]
[***]

************************************************************************

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

CODEXIS CONFIDENTIAL INFORMATION

Exhibit 2.5

Material Transfer Record Form

GSK and Codexis

Capitalized terms used herein that are not defined herein shall have the meanings set forth in the Platform Technology Transfer and License Agreement dated 10 July 2014 made between GSK and Codexis.

In connection with the performance of the Agreement and pursuant to the terms of the Agreement: 

(i) GSK will transfer to Codexis the Materials set forth below;
 and/or 
(ii) Codexis will transfer to GSK the Materials set forth below. 

This Material Transfer Record Form shall be used as the record of all such Material transfers, whether from GSK to Codexis or from Codexis to GSK. 

Transfer Date: 

Description of Materials 

Description of Research for which the Material(s) will be Used

Signature – GSK Scientific Lead ...............................

Date

Signature – Codexis Scientific Lead ................................

Date

- 1 -

Note:  This MTR is to be completed and signed by the Codexis and the GSK Scientific Lead for each transfer.  A copy of each completed MTR is to be timely provided to Alliance Manager (for GSK) and to the Alliance Manager (for Codexis).  This MTR should not be used to transfer any materials in which the Transferor believes that Third Parties have rights, or which the Transferor believes infringe or misappropriate any Intellectual Property rights held by any Third Party. If there are any questions about the appropriateness of a transfer, please contact the GSK Scientific Lead or the Codexis Scientific Lead, as appropriate, identified herein before making the transfer. 

- 2 -

Exhibit 3.3.1

Codexis Strain-Related Protocols

[***]

[***]

[***]

[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 1 -

Exhibit 8.5.4

Third Party In-License Agreements

[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

- 1 -

Exhibit 9.6

Press Release

- 1 -

Exhibit 13.14

Prevention of Corruption – Third Party Guidelines

PREVENTION OF CORRUPTION – THIRD PARTY GUIDELINES
The GSK Anti-Bribery and Corruption Policy (POL-GSK-007) requires compliance with the highest ethical standards and all anti-corruption laws applicable in the countries in which GSK (whether through a third party or otherwise) conducts business.  POL-GSK-007 requires all GSK employees and any third party acting for or on behalf of GSK to ensure that all dealings with third parties, both in the private and government sectors, are carried out in compliance with all relevant laws and regulations and with the standards of integrity required for all GSK business.  GSK values integrity and transparency and has zero tolerance for corrupt activities of any kind, whether committed by GSK employees, officers, or third-parties acting for or on behalf of the GSK. 
Corrupt Payments – GSK employees and any third party acting for or on behalf of GSK, shall not, directly or indirectly, promise, authorize, ratify or offer to make or make any “payments” of “anything of value” (as defined in the glossary section) to any individual (or at the request of any individual) including a “government official” (as defined in the glossary section) for the improper purpose of influencing or inducing or as a reward for any act, omission or decision to secure an improper advantage or to improperly assist the company in obtaining or retaining business.  
Government Officials – Although GSK ́s policy prohibits payments by GSK or third parties acting for or on its behalf to any individual, private or public, as a “quid pro quo” for business, due to the existence of specific anticorruption laws in the countries where we operate, this policy is particularly applicable to “payments” of “anything of value” (as defined in the glossary section), or at the request of, “government officials” (as defined in the glossary section).
Facilitating Payments – For the avoidance of doubt, facilitating payments (otherwise known as “greasing payments” and defined as payments to an individual to secure or expedite the performance of a routine government action by government officials) are no exception to the general rule and therefore prohibited.
GLOSSARY
The terms defined herein should be construed broadly to give effect to the letter and spirit of the ABAC Policy.  GSK is committed to the highest ethical standards of business dealings and any 

- 1 -

acts that create the appearance of promising, offering, giving or authorizing payments prohibited by this policy will not be tolerated.  
Anything of Value: this term includes cash or cash equivalents, gifts, services, employment offers, loans, travel expenses, entertainment, political contributions, charitable donations, subsidies, per diem payments, sponsorships, honoraria or provision of any other asset, even if nominal in value.  
Payments: this term refers to and includes any direct or indirect offers to pay, promises to pay, authorizations of or payments of anything of value.  
Government Official shall mean:
		
	•
	Any officer or employee of a government or any department, agency or instrument of a government;

		
	•
	Any person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government;

		
	•
	Any officer or employee of a company or business owned in whole or part by a government;

		
	•
	Any officer or employee of a public international organization such as the World Bank or United Nations;

		
	•
	Any officer or employee of a political party or any person acting in an official capacity on behalf of a political party; and/or

		
	•
	Any candidate for political office

- 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]